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CIRCUL ATING HUMAN BLOOD DENDRITIC CELLS 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) and have the ability 
to initiate an immune response by activating T cells in the lymph node. Upon encountering 
an antigen, DCs are able to take it up, process it and present it via major histocompatibility 
complexes (MHC) to T cells [1]. In addition to the presentation of antigen via the MHC 
class II to CD4+ T cells, DCs can also cross-present their antigen via MHC class I to CD8+ 
T cells, which allows them to present extracellular antigen to T cells. T cells can recognize 
these antigens via their T cell receptors (TCR).
In human blood, two main subsets have been described: myeloid dendritic cells (mDCs) 
and  plasmacytoid dendritic cells (pDCs) [2, 3]. mDCs can then be further subdivided into 
CD1c+ mDCs and BDCA3+ (CD141+) mDCs. In addition, a DC like-inflammatory CD16+ 
monocyte can be found in peripheral blood [4]. Among peripheral blood human DC-like 
cells, CD16+ inflammatory monocytes represent the highest abundant subset (1-2%), but 
these cells are, as a result of their heterogenic and poor immunogenic potential, of less 
interest for immunotherapy [5]. The population size of CD1c+ mDCs varies between 0.5-
1%, pDCs is around 0,1% and BDCA3+ mDCs are the least frequent, representing only 
0.03% of peripheral blood mononuclear cells (PBMCs). Despite these low frequencies the 
different DC subsets harbor very specific characteristics, suggesting each to have distinct 
roles within the immune system [6, 7].
mDCs and pDCs differ from each other by their ability to recognize and respond to different 
pathogens, expressing a subset specific repertoire of  toll-like receptors (TLRs) and secreting 
specific sets of cytokines in response to TLR stimulation [6, 8]. From the reported 10 TLRs, 
pDCs express the intracellular TLR7 and TLR9, that recognize single stranded RNA and 
unmethylated CpG DNA, respectively [6]. Myeloid DCs on the other hand lack the 
expression of these two TLRs, but express a wide range of the other TLRs. CD1c+ mDC and 
BDCA3+ mDCs also show slight differences in TLR expression. BDCA3+ mDCs, for 
example, more abundantly express TLR3 which senses retroviral double-stranded RNA, 
while CD1c+ mDC express more TLR8 [9].  Myeloid DCs are key players in anti-fungal 
and anti-bacterial immune response, sense injuries and have a high phagocytotic potential 
[4, 10, 11]. More specifically, CD1c+ mDCs are known to secrete IL-12 and have been shown 
to induce Th1 cell and cytotoxic T lymphocyte CTL responses upon TLR8 stimulation, 
while BDCA3+ mDCs have a similar effect on T cells upon TLR3 stimulation [6, 9, 12-14]. 
BDCA3+ mDCs form the smallest population of DC subsets and uniquely express CLEC9A 
that enables them to sense and ingest necrotic cells and subsequently cross-present antigens 
derived from this material to the T cells [15, 16]. Consistent with this function, BDCA3+ 
mDCs have been suggested by several studies to be the most potent cross-presenting DC 
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subset [9, 17]. Additionally, BDCA3+ DCs uniquely produce high amounts of IL-29 upon 
TLR3 stimulation [18]. Recent studies have been shown that the admission of FLT3L in 
vivo, leads to a systemic increase of the precursor of mDCs and therefore increased numbers 
of mDCs [19, 20].
Plasmacytoid dendritic cells (pDCs) express BDCA2 and BDCA4, but lack the myeloid 
marker CD11c found on mDCs [2]. pDCs release of high amounts of type I IFNs in response 
to TLR activation and for this reason play an important role in anti-viral immune responses 
[22]. Furthermore, pDCs express ILT-7 and CD123, but lack the expression of CD1d to 
interact with certain T cells, like the invariant natural killer T (iNKT) cells, which only 
Figure 1. DC subsets and their characteristics. This overview illustrates the differences and similarities of mDCs, 
pDC, the CD16+ DC-like inflammatory monocyte and the monocyte-derived DCs (moDCs). To the very left, 
moDC and CD16+ DC-like inflammatory monocyte are known for their IL-12p70 release upon stimulation with 
LPS or endogenous inflammatory cytokines (TNF-α, IL-4 and GM-CSF) [21]. Additionally, CD1c+ mDCs react 
against fungal and bacterial pathogens with the release of IL-12p70. BDCA3+ mDCs, however, are known for 
their high release of IFN-λ upon encountering double-stranded RNA via their TLR3. pDCs sense viral pathogens 
and respond with the high production of IFN-α, which effectively activates NK cells and T cells.
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recognize antigens presented to them by CD1d [23, 24]. Interestingly, immature pDCs have 
tolerogenic potential [25]. Studies have demonstrated the presence of pDCs exhibiting 
reduced type I IFN production in tumors, which points towards inhibition of an anti-tumor 
response [26, 27]. Additionally, pDCs found in the tumor draining lymph nodes have been 
linked to the generation of regulatory T cells (T-regs) based on the expression of indoleamine 
2,3-dioxygenase (IDO) [28, 29]. Furthermore, the activation of the tryptophan pathway 
can have a cytotoxic effect on T cells and therefore leads to cell cycle arrest or apoptosis of 
T cells [30]. More recently, Bakdash et al. has characterized a double positive CD14+/CD1c+ 
population within the CD1c+ mDCs, which showed inhibiting effects on the immune 
response [31]. This lead to a change of the isolation protocol and thus and depletion of this 
subpopulation from the CD1c+ mDC subset. 
Altogether, these  findings highlight the importance of a sufficient DC stimulation but also 
the correct choice of DC subsets to induce an efficient ant-tumor response instead of 
promoting an tolerogenic environment [32]. Through extensive studies by our department 
and others, the use of CD1c+ mDCs and pDCs is the most promising choice; since CD1c+ 
mDCs and pDCs have complementary characteristics regarding sensitivity, cytokine release 
and TLRs, the combination of both subsets suggests to lead to a better clinical response 
than using only one subset alone. Despite their low frequencies and therefore practical 
issues, BDCA3+ mDCs might be used in a clinical setting in the near future, since this subset 
shows the most promising cross-presenting abilities.  
DC MATURATION
To reach the lymph nodes and to effectively evoke a T cell response, DCs need to go through 
a maturation process and increase their migratory potential and to upregulate cell surface 
receptors and synthesize cytokines needed for T cell activation. Through a range of pattern-
recognition receptors (PPRs) and pathogen-associated molecular patterns (PAMPs), like 
the previously mentioned TLRs, DCs sense pathogens and become activated [33]. 
Additionally, pro-inflammatory cytokines such as IL-6, or members of the IL-1 family, can 
promote DC maturation. 
For migration to the lymph node upon DC maturation, upregulation of CCR7, the 
chemokine receptor for CCL19 and CCL21, is crucial. Having reached the T cell area in 
the lymph node T cells are activated by the presentation of peptide-MHC complexes (Signal 
I) and the simultaneous engagement of costimulatory molecules such as CD40, CD80, 
ICAM1, OX40L present on the surface of activated DC (Signal II). The third signal DCs 
send out to T cells is the release of cytokines. The composition of cytokines secreted by the 
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DC determines the polarization of the T cells and their differentiation into either cytotoxic 
T cells, T helper cells or a tolerogenic cells. For example, IL-12, which is highly released by 
mDCs, and IFN-α/β, which is highly released by pDCs, have been demonstrated to enhance 
cytotoxic CD8+ T cell proliferation and promote a TH1 phenotype [34-38]. Interestingly, 
the presence of IFN-γ, produced by APCs and NK cells prevent the TH2 differentiation 
[38]. However, the release of IL-10 by DCs polarizes T cells to a more tolerogenic phenotype, 
such as T regulatory cells [39].
Besides the aforementioned co-stimulatory molecules, co-inhibitory molecules (PD-L1, 
PD-L2) which exhibit tolerogenic or proliferation dampening effect on T cell proliferation 
can be upregulated on DC [40-43]. This is especially relevant in the context of cancer since 
tumor cells can upregulate PD-L1 which results in immune escape [44]. Furthermore, the 
tumor microenvironment can lead to an upregulation of PD-L1 on tumor infiltrating 
immune cells, which then inhibit the T cell activity [45-47]. On T cells, the predominant 
co-inhibitory receptors are PD-1, the receptor for PD-L1 and PD-L2, and CTLA-4; both 
pathways have a crucial role for the T cell regulation and therefore have been targeted for 
checkpoint inhibitor therapies (for example, ipilimumab, pembrolizumab) [48, 49]. The 
CTLA-4 pathway is thought to play a role during the initiation phase of naive T cell priming, 
mostly in the lymph node [50, 51]. In contrast to that, the PD-L1 pathway has been suggested 
to execute its suppressive and tolerogenic effect in a later stage of the T cell regulation [50].
Previous studies have demonstrated how important efficient maturation of DCs is for the 
efficacy of DC vaccination [52]. As such, not only is the choice of DC subset, but also the 
choice of the DC activation stimulus during an immunotherapy approach is likely detrimental 
for the effect on the patient’s immune response. Choice of a DC maturation stimulus not 
only depends on its in vitro ability to mature DCs but also on its availability in a clinical 
grade quality; in the past, for moDC-based vaccination, different cytokine maturation 
cocktails have been used in clinical trial settings including TNF-α combined with IL-1β, 
IL-6 and prostaglandin E2 and/ or monocyte-conditioned medium [53-55]. In more recent 
settings, where naturally occurring DC subsets were used for vaccination, alternative 
strategies have been used to mature DCs. In our initial clinical studies using primary DC 
subsets, we used FSME, an off-the shelve prophylactic vaccine for tick borne encephalitisvirus 
and a presumed TLR7/8 ligand, to mature pDCs and the cytokine GM-CSF to mature CD1c+ 
mDCs [56, 57]. Although very effective in maturing these DC subsets, the compounds cannot 
be exchanged, and FSME might even toxic to mDCs; this is obviously problematic for 
strategies combining DC subsets in one vaccine. Through extensive research and in vitro 
studies, we proceeded with the later clinical studies using a new stimulus, protamine-RNA 
complex (pRNA). pRNA stimulation leads to a strong type I IFN release by pDCs and a 
IL-12 by CD1c+mDCs, combined by a favorable low IL-10 release [58, 59].
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DC IMMUNOTHERAPY
As a better tolerated alternative to the commonly used cancer therapies, DC-
immunotherapies have become as a promising treatment option aiming to evoke anti-tumor 
adaptive immune responses. A significant part of immunotherapies is based on the 
important role of DCs in initiating adaptive immune responses.  DC immunotherapy has 
been proven to have a positive effect on the survival of patients suffering from melanoma 
[56, 57]. This approach is based on the principle to support and strengthen the immune 
system to find and eliminate cancerous cells. To this end, DCs are isolated from the patient, 
stimulated and loaded with tumor antigens ex vivo and given back to the patient. These 
activated and tumor-antigen-presenting DCs are then anticipated to activate and prime 
tumor-recognizing cytotoxic T cells, which after proliferation will swarm out to eliminate 
the tumor cells.
Figure 2. DC-based immunotherapy. This overview illustrates the previous monocyte-derived DC vaccination 
model and the current primary DC vaccination approach. Monocytes are isolated and go through an extensive 
ex-vivo culturing process of six days, followed by a maturation process and the tumor antigen loading. The matured 
moDCs are subsequently given back to the patient. The primary DC vaccination approach starts directly with the 
maturation stimulus, followed by the tumor antigen loading. The duration of the current approach is one day.
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The complex fight of the immune system against tumors has been summarized in three key 
phases that constitute cancer immuno-editing: “elimination, equilibrium, and escape” [60, 
61]. Firstly, the adaptive and innate immune response aims to eliminate the tumor: 
elimination. The equilibrium phase is described as a phase that the tumor withold the 
pressure the immune system puts on it. Once the tumor forms a resistance towards that 
immune response, it enters the third phase: escape. During this phase, the tumor grows 
and may become more malignant. Due to their central role for the initiation of an immune 
response, DCs have become a key player for immunotherapy. In the natural course of cancer 
disease progression, a bottle neck in the induction of anti-tumor immune responses is the 
DCs’ ability to find and identify tumor cells among other healthy cells in the body. By 
activating and loading DCs with tumor antigens ex vivo this bottle neck is overcome. 
Furthermore, ex vivo DCs can be activated optimally to induce the most potent immune 
response. In 1996, the first DC clinical trial was performed using autologous, antigen-loaded 
DC and clinical responses could be detected [62].  Three years later, Dhodapkar et al. 
demonstrated for the first time that a single injection of tumor antigen-loaded DCs lead to 
an “antigen-specific immune response in vivo” [63]. Additional clinical trials using ex vivo 
generated monocyte-derived DCs (moDCs) further demonstrated the possibility to induce 
a tumor response by DCs and therefore boosting the anti-tumor response [64]. These results 
have laid the foundation for further developments in the field of DC vaccination of cancer 
patients. However, these studies also highlighted the importance of gaining more insight 
into the factors that determine clinical success, such as providing the DC with sufficient 
maturation stimuli, since the immature phenotype was linked to a high potential of antigen 
uptake but low T cell activation [65-67]. In line with this, we demonstrated in a phase I/II 
clinical trial with stage IV melanoma patients, that tumor antigen-loaded moDCs lead to 
the generation of an increased number of specific T cells in patients receiving activated 
DCs compared to those treated with immature DCs [68]. Overall however, only in a 
minority of the treated melanoma patients could a beneficial effect of the DC vaccination 
be observed [69-71].  The lack of a clinical success could be explained by a possible 
exhaustion of the moDCs, due to their long ex vivo culturing protocol [72, 73]. To avoid 
the extensive in vitro culture, the possibility of using naturally occurring blood DCs was 
suggested [74]; this process has   now resulted in the first FDA-approved cell-based therapy 
of prostate cancer, Provenge® [75]. In accordance with these findings, our research groups 
initiated clinical trials using natural occurring blood DC subsets, beginning with pDCs 
[56], and subsequently with mDCs [57]. With these trials, we demonstrated for the first 
time that it is the possible to isolate and stimulate primary DCs for use in a melanoma 
immunotherapy approach. Despite the low numbers of both DC subsets used for 
vaccination, the results suggest a survival benefit for the vaccinated patients compared to 
matched chemotherapy controls. Side effects using pDCs and mDCs were lower compared 
to the clinical trial using moDCs [56]. Although more elaborate clinical testing is required, 
these first studies highlight the strong potential of primary dendritic cell subset. 
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All things considered, a very important part of optimizing the DC based immunotherapy 
is a better understanding of the diverse functional capacities of each DC subsets and how 
these subsets can be effectively matured during vaccine preparation. In line with that, my 
PhD project has aimed to obtain data and answer open questions regarding the DC subsets 
and their functions, but also evaluating different adjuvants and study their effect on different 
DC subsets. Furthermore, we studied their crosstalk based on their cytokine release and 
how this affects their functional characteristics. To do so, we performed transcriptomic and 
proteomic approaches, to cover not only the gene expression levels, but also the resultant 
proteins expression in all DC subsets. We characterized the surfaceome of the cells by 
studying the expressed receptors, which includes maturation and subset specific identification 
markers. And finally, we analyzed released signal molecules by the DCs, like cytokines and 
chemokines. Those signals can be used as an indication for the maturation state, stress level 
and functional state of the cell. The combined information of transcriptome, proteome, 
secretome and surfaceome delivers an important contribution to improve our understanding 
of the DC subsets in vitro but also to translate those finding into clinical use. 
Figure 3 PhD project overview. This figure summarizes the rational of my PhD project by demonstrating how 
we aim to characterize the properties of the DC subsets in steady state and after stimulation. We covered the fields 
of transcriptomics and proteomics, and combine those results with studies concentrating on the secretomics, the 
released proteins like cytokines and chemokines, and surfaceome.
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SCOPE OF THE THESIS
All studies in this thesis aim to improve the understanding of human blood DC subsets 
and translate results into the clinic to optimize dendritic cell immunotherapy for cancer. 
Chapter 1 serves as general introduction about immunotherapy, human DC subsets, and 
their maturation. Followed by a more detailed characterization of pDCs and their role in 
the immune system in Chapter 2. This chapter illustrates the central role of pDCs and their 
high potential interacting with a high number of different immune cells. It summarizes the 
confirmed interactions and points out possible interesting possible molecules to study in 
the future.
Chapter 3 presents a mass spectrometry-based study comparing protein expression in the 
4 different DC-like subsets. This proteomics dataset provides a unique overview of 
expression differences between DC subsets and discusses their functional implications. 
Furthermore, this study lead to the identification of 5 uniquely expressed receptors and 
exposed a lack of Caspase-1 in pDCs rendering them unable to secrete IL-1β in response 
to inflammasome activation.  Chapter 4 continues on this topic and describes differences 
between pDCs and CD1c mDCs in sensing the inflammatory cytokine IL-1β. 
In Chapter 5 we describe a RNA-sequencing (RNA-seq) based approach to evaluate the 
efficiency of clinical grade stimuli for immunotherapies by using an analyzing the whole 
transcriptomic dataset. Therefore, the previously used and potential new stimuli were 
compared. These results confirmed the strong potential of the new stimulus pRNA in the 
currently running clinical trials. 
Chapter 6 concentrates on the interplay between IFN-α and IL-12. It describes the effect 
of type I IFNs, predominantly produced by pDCs, on the maturation and phenotype of 
mDCs. Furthermore, it points out the effect this interaction has on immune cells of the 
innate and adaptive immune system.
Chapter 7 presents the results of a RNA-seq study of clinical grade BDCA3+ mDCs upon 
two different clinical grade stimuli. Both stimuli show a high efficacy stimulating BDCA3+ 
mDCs. Despite targeting different TLRs, they both show a similar effect on the maturation 
of this DC subset. 
Chapter 8 serves as a summarizing discussion and an outlook of the future perspectives 
of the studied research field. 
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Plasmacytoid Dendritic Cells (pDCs) are a specific subset of naturally occurring dendritic 
cells, that secrete large amounts of Type I interferon and play an  important role in the 
immune response against viral infection. Several studies have highlighted that they are also 
effective antigen presenting cells (APCs), making them an interesting target for 
immunotherapy. However, the modes of action of pDCs are not restricted to antigen 
presentation and IFN secretion alone. In this review we will highlight a selection of cell 
surface proteins expressed by human pDCs that may facilitate communication with other 
immune cells, and we will discuss the implications of these molecules for pDC-driven 
immune responses.
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INTRODUCTION
Within the heterogeneous dendritic cell (DC) family, two main subsets of naturally 
occurring blood DCs can be discriminated based on their phenotype and functional 
characteristics: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). In recent years, 
numerous studies have been performed to characterize the expression of pathogen 
recognition receptors (PRRs), toll-like receptors (TLRs), Fc receptors, C-type lectin (CTL) 
receptors and other surface receptors on these cells [1-9]. Furthermore, these studies have 
emphasized both similarities and differences between DC subtypes in their cytokine release 
profiles, and their ability to acquire, process and present antigens [10-13].
The characteristics of the different DC subtypes have recently been reviewed extensively 
elsewhere [14]. Here, we will focus our attention specifically on pDCs, their role in 
immunity and, more specifically, their (potential) direct interactions with cells of the innate 
and adaptive immune system. Although studies on murine pDCs are numerous, and 
commonalities between human and murine pDCs certainly exist, major differences between 
pDC of both species have also been reported. Therefore, in order to prevent confusion we 
limited ourselves to human pDCs unless stated otherwise. 
pDC FUNCTION
A perturbation of the homeostatic condition that sets off the immune system can trigger 
either an immunogenic (immunostimulatory) or a tolerogenic (immunosuppressive) 
response, depending on the local circumstances and type of disease. By default, immature 
pDCs are tolerogenic, whereas activated (mature) pDCs can have both immunogenic and 
tolerogenic capacities depending on the local environment in which they are activated 
[15-17]. pDCs are characterized as Lin- MHC-II+ CD123+ CD4+ CD303(BDCA2)+ 
CD304(BDCA4)+ and are mostly known for their ability to quickly produce large amounts 
of the Type I interferons (IFNs), IFN-α and IFN-β, following viral infection, implicating 
pDCs as an important contributor during the early phase of antiviral response [14, 18, 19].
The most important documented enveloped viruses known to stimulate Type I IFN release 
by pDCs are human immunodeficiency virus type 1 (HIV-1), herpes simplex virus (HSV) 
and influenza virus [20-23]. Furthermore, parasites and bacteria containing DNA with 
unmethylated CpG sequences can trigger pDC activation [24-27]. In addition to the anti-
viral capacity, type I IFN release by pDCs has also been reported to be important for pDC 
survival, (m)DC-mediated CD4+ and CD8+ T cell responses, mDC differentiation, cross 
presentation, upregulation of costimulatory major histocampatibility complexes (MHC) 
molecules and activation of natural killer (NK) and B cells [28-30].
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Because of their expression of the endosomal TLRs TLR7 and TLR9, pDCs, in contrast to 
other (immune) cells, do not need to become infected to respond to viruses or intracellular 
bacteria [31, 32]. TLR7 recognizes guanosine or uridine-rich, single-stranded RNA from 
viruses or synthetic products like guanosine analogs. TLR9 is sensitive for single-stranded 
DNA containing unmethylated CpG motifs, which are usually found in bacterial and viral 
genomes, and additionally for synthetic oligonucleotides, such as CpG-ODN [33, 34]. pDCs 
show differential responses based on the type of virus/ bacteria that is recognized, which 
has been suggested to be attributed to a different site of TLR activation within the endosomal 
system [35]. For example, depending on the subtype of CpG recognized (CpG-A, CpG-B, 
CpG-C) the outcome of the response can be different. While CpG-A, that triggers TLR-9 
in early endosomes, induces IFN-α release, CpG-B, signaling from late endosomes, leads 
to TNF-α and IL-6 production by pDCs [36]. In addition, the interplay of the various PRRs 
tailors the pDC response to a specific pathogenic threat. In addition to TLRs, pDCs express 
several CLRs, including BDCA-2, DEC-205, dectin-1 and DCIR, and Fc receptor CD32, 
but they lack for instance DC-SIGN [18, 37-41]. Although the full repertoire of receptors 
is still under investigation, most of these receptors drive antigen uptake, and in concert 
with TLR 7 & TLR9, coordinate pDC-mediated immune responses.
pDC LOC ALIZATION
Immature pDCs circulate in the blood but have been equipped with migratory capacities 
as they are found within lymph nodes, tumors and near sites of viral/bacterial infection 
[42, 43]. At all these sites pDCs are able to promote inflammatory responses by attracting 
other immune cells through chemokine release, and the subsequent modulation of these 
cells via cytokines or direct cell-cell interactions [44-47]. However, in contrast to human 
myeloid mDCs or murine pDCs studies, reports addressing which inflammatory 
chemokines and adhesion receptors specifically drive migration of human pDCs are scarce 
[48]. Similar to mice, human pDCs express chemotactic receptors CCR7, CXCR3, CXCR4 
and ChemR23 (CMKLR1) that likely mediate migration of pDCs into lymphoid organs 
and/or into inflamed tissue [44, 48-51]. However, due to conflicting reports the role of 
classical lymphoid tissue CCR7-CCL21/CCL19 pathways in resting human pDCs,is not 
conclusive yet [49, 52]. Several studies show a high expression of CCR7 on “resting” blood 
DCs while others have reported a very low or a lack of expression on resting pDCs [49, 
53-56]. Similar to mDCs and murine pDCs, human pDCs upregulate expression of CCR7 
upon TLR stimulation and migrate towards CCL21 molecules, suggesting an important 
role of CCR7 at least for the migration of mature pDCs to the lymph node [51]. In contrast 
to mDCs, which migrate from peripheral tissue to secondary lymphoid organs via afferent 
lymphatic vessels, pDCs have been described to migrate to the LN mostly directly from 
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the blood via high endothelial venules (HEVs) [57, 58]. Since pDCs first need to engage 
and traverse the endothelial cells lining of the blood vessels, endothelial cells likely represent 
the first cellular contact pDCs will engage in after leaving the blood stream. pDC would 
require a similar migration capacity to enter into inflamed or tumor tissue, which also 
requires interaction with endothelial cells and extravasation.
Next, within the LN, or at the site of infectious or cancerous lesions, pDCs may encounter 
various immune cells. In the LN, pDC have been found in close contact with T lymphocytes, 
Invariant Natural Killer T cells (iNKT) cells, B lymphocytes and NK cells [17, 20, 38, 59-
61]. At sites of infection pDCs might activate or get activated by mDCs and NK cells, 
whereas within the tumor microenvironment pDCs are known to interact predominantly 
with tumor cells and regulatory T (Treg) cells [62, 63]. Below we have summarized the 
evidence reported thus far for each of these (potential) interactions, and the circumstances 
under which they occur (figure 1).
Figure 1. pDC have the capacity to interact with various immune cells through an array of surface molecules. 
The expressed surface molecules of each cell type are divided into confirmed and potential interactions. The 
“confirmed” molecules have been reported to have a functional effect. Molecules listed in the “potential” column 
are molecules that have been found on human pDC but without functional data reported in literature. Molecules 
playing a potential role in humans, but already confirmed with functional studies in mouse are depicted in red.
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ENDOTHELIAL CELL
Intriguingly, and in contrast to murine pDCs, both resting and matured human pDCs 
(stimulated by influenza virus) uniquely express the receptor for chemerin, ChemR23 [44]. 
Chemerin is present on the surface of endothelial cells in the lumen of HEVs as well as in 
blood vessels of inflamed tissue. The interaction between endothelial cell-bound chemerin 
and pDC ChemR23 seems to play a crucial role in the migration of pDC both into LNs and 
into inflamed tissue (figure 2) [44, 64, 65]. 
Like pDCs, T cells also migrate from the blood to the LN via HEVs and thus pDCs may 
exploit a similar set of molecules as used by T cells. Indeed, pDCs express adhesion 
molecules CD31, CD43, CD44, CD47, CD62L, CD99 and CD162 (SELPLG, CLA) that may 
play an important role in the tethering and rolling of pDCs on endothelial cells, but for 
most of these molecules, functional data for a role on pDCs is lacking [50, 66, 67]. The 
LFA-1 and VLA-1 (CD49a/CD29) molecules might play an important role in subsequent 
firm adhesion and transmigration of pDCs [66]. Although the expression of all these 
molecules was initially only detected by microarray, with the exception of CD44, most were 
confirmed by flow cytometry [68]. Furthermore, flow cytometry demonstrated that 
expression of both CD62L (moderately) and CD99 was downregulated upon exposure to 
IL-3 and HSV, indicating that activated pDCs may take different migratory routes compared 
to their immature counterparts [68]. While immature pDCs express CD62L and use HEVs 
to migrate into the lymph nodes, downregulation of CD62L on mature pDCs suggests that 
these cells enter LN without passing HEV, but rather through the lymphatic vessels. 
Furthermore, another study identified a cleavage of CD62L after entering the HEV 
Figure 2. Ligand/receptor paring of a pDC with an endothelial cell and the maturation state/ activation stimuli 
associated with ligand or receptor expression on the pDC surface. 
201751 proefschrift_Till Mathan_titel_kleur.indd   30 23-02-18   19:49
shor t  t i t le
31
2
suggesting this molecule may have become obsolete for pDCs following this pathway [69]. 
In skin, in contrast, after transversing the vessel wall expression of CD162 on pDC remains 
high, indicating that in this case it may still have a function at a later stage [50]. 
Although there is evidence for ICAM-1/LFA, CD31/CD38 and CD34/CD62L interaction 
between pDCs and endothelial cells, until now, only the chemerin/ChemR23 interaction 
has been conclusively demonstrated to play a role during the migration process. The 
migratory function of the other adhesion molecules reportedly expressed by human pDC 
are currently only hypothetical.
INTERACTION WITH T CELLS
During infection, immature DCs located in the inflamed tissue get activated through 
pathogenic interaction and pro-inflammatory cytokines. Mature (activated) DCs 
subsequently translocate to the lymph nodes and induce naïve T cells to differentiate into 
effector T cells. Based on the repertoire of danger signals, effector T cells will have different 
characteristics and will evoke a different immune response. pDCs have an important role 
in coordinating such an immune response, since the molecules involved in the interaction 
between DCs and T cells determine T cell polarization (Th1, Th2, Th17). Numerous studies 
have established that pDCs are bona fide APCs, capable of presenting exogenous antigens 
on both MHC class I and MHC class II molecules and thus can trigger both CD4+ T helper 
cells and CD8+ cytotoxic T cells [13, 22, 70-72]. The nuances of pDCs antigen processing 
and presentation have recently been reviewed by Guery et al and Nierkens et al [38, 73]. 
Here, we focus our attention on how pDC cell surface receptors may skew T cell function 
(figure 3). Freshly isolated (immature) pDCs are known to induce CD4+ T cell anergy 
presumably because they lack co-stimulatory molecules; conversely, activated pDC clearly 
induce a broad spectrum of T cell differentiation, for example, Th1, Th2, Th17 and Treg, 
based on the cytokines secreted and cell surface proteins expressed [17, 74-78]. Like mDCs, 
activated pDC express high levels of MHC molecules and the costimulatory molecules 
CD80 (B7-1), CD86 (B7-2) and CD83 to present antigens and fully license and activate T 
cells [13, 79]. Several studies have demonstrated that (virally-) matured pDCs, through the 
release of cytokines, mostly induce a Th1 phenotype (IFN-γ/Il-12 in response to CpG, 
virus) but Th2 (IL-4) and Th17 (IL-17) skewing has also been reported when pDC are 
activated with IL-3 or CD40 and TLR7 ligands, respectively [76, 80-82]. This shows how 
pDCs may regulate immune responses. Apart from cytokines released by pDCs, several 
pDC surface receptors may directly affect T cell skewing and function, including the 
inducible T-cell co-stimulator ligand (ICOSL). pDCs express ICOSLG when activated by 
CpG-(A, B &C) IL-3/CD40L or virus (Flu/HSV) [77]. ICOSLG is the ligand for the T-cell-
201751 proefschrift_Till Mathan_titel_kleur.indd   31 23-02-18   19:49
CHAPTE R 2
32
specific cell surface receptor (ICOS) and has been shown to trigger naive CD4+ T cells to 
produce IL-10 during both pDC Th1 or Th2 skewing in response to CpG/virally or IL-3/
CD40L-matured pDCs, respectively [77, 78]. It has been suggested that ICOSL-activated 
pDCs generate IL-10 producing Tregs to dampen immune responses, preventing excessive 
inflammation [77]. Furthermore TLR-activated, but not resting pDCs and mDCs, express 
programmed death receptor-ligand 1 (PD-L1), which may induce T cells anergy/suppresses 
T cell activation by binding to its receptor, program death ligand 1 (PD1), which is expressed 
by T cells [83, 84]. The immunosuppressive effect of PD-L1 has been confirmed by using 
blocking antibodies on DCs, and additionally in follow-up studies where blocking the PD-
L1/PD1 interaction lead to “enhanced tumor-specific T cell expansion and activation” [79, 
85, 86]. The surface receptor OX40, which is expressed on IL-3 activated pDCs, can induce 
a Th2 T cell response resulting in IL-4, IL-5 and IL-13 release by CD4+ T cells [87, 88]. 
Furthermore, after stimulation either with synthetic TLR7 and TLR9 agonists or with the 
natural TLR7 agonists, like influenza virus or UV-inactivated herpes simplex virus type 
1(HSVUV) pDCs can induce programmed cell death/apoptosis, by expressing tumor necrosis 
factor–related apoptosis-inducing ligand (TRAIL) [68, 89, 90]. TRAIL expression on pDCs 
uniquely correlates with individual viral load, and the capacity to kill HIV-infected CD4+ 
T cells, by binding to the TRAIL receptor, a process described as “TRAIL-dependent pDC-
Figure 3. Ligand/receptor paring of a pDC with a T cell and the maturation state/ activation stimuli associated 
with ligand or receptor expression on the pDC surface.
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mediated killing” [91]. However, given the very limited cell numbers, it remains to be seen 
how important TRAIL+ pDCs are in clearing a viral infection via the direct killing of infected 
cells [91, 92].
Another surface molecule expressed on TLR-activated pDCs that may affect T cell function 
is the lectin-like transcript 1 (LLT1), which in addition to activated pDCs, is expressed by 
most activated lymphocytes (including B cells, T cells and NK cells) and mature monocyte-
derived DCs [93]. LLT1 is a ligand of CD161 (NKR-P1A), which is expressed by subsets of 
T cells (e.g. Th1, Th17 and a subpopulation of CD8+ T cells) and NK cells. When ligated 
LLT1 triggers T cell proliferation and IFN-γ secretion as well as inhibition of NK-cell 
cytotoxicity [93-96]. Thus, LLT1 on pDCs may serve as a co-stimulatory molecule, and after 
binding to CD161 expressing T cells, could drive proliferation and IFN-γ secretion [47]. 
So far, we discussed how pDC receptors may affect T cell function but of course, conversely, 
T cells may also influence pDC function. In a multicellular immune cell signaling cascade 
the presentation of viral antigens by pDCs brings about IL-2 release by T cells as well as 
CD40L expression. T cell CD40L upon binding to CD40 on pDCs, triggers IL-6 release by 
pDC, which in turn enables B cell plasma blasts to become antibody-secreting plasma cells 
(figure 8) [17, 59].
In summary, while immature pDCs predominantly induce T cell anergy, their activated 
counterparts may have either inhibitory or activating effects on T cells. Which of the latter 
in the case depends on stimuli that trigger pDC maturation and which cytokines and surface 
molecules are expressed as a result. Thus pDCs play pivotal role in T cell activation and 
fine tuning of the adaptive immune response. 
INTERACTION WITH INKT CELLS
Natural Killer T (NKT) cells form a specialized T cell subset expressing a semi-invariant 
T cell receptor (TCR alpha beta) and surface antigens traditionally associated with NK cells. 
The unique TCR on their cell surface enables NKT cells to recognize glycolipid antigens 
rather than peptides, presented in the context of the MHC class I-like molecule, CD1d[97]. 
The most well characterized subset of NKT cells are called invariant NKT (iNKT) cells, 
since they express an invariant TCR alpha chain, and are reactive to the potent NKT cell 
agonists alpha-galactosylceramide (α-GalCer) [97].
Studies have shown that pDCs interact with iNKT cells directly, both via cell-cell interactions 
and by cytokines release [98]. In contrast to the mDCs, pDCs lack the expression of CD1d, 
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which is an important molecule for cross-talk with iNKT cells [99]. Nonetheless, over the 
past few years the ability of iNKT cell to ‘sense’ subtle changes within their microenvironment 
in a CD1d-independent mechanism, uncovered that cytokines released by pDCs are 
essential [100, 101]. Indeed, CpG activated pDCs upregulate activation markers on iNKT 
cells via TNF-α and IFN-α release, and selectively enhance double-negative iNKT cell 
survival but not that of other NKT cell populations [98]. However, the interplay of iNKT 
cells with pDCs alone is not sufficient for iNKT expansion and does not lead to a cytokine 
release by iNKT cells. Rather, the CpG activated pDCs enables the iNKT cells to productively 
interact with CD1d expressing mDCs, thus initiating an immune response (61). Both iNKT 
cells and mDCs lack expression of TLR9 and are therefore unresponsive to CpG; hence, 
cytokines released upon ligation of TLR9 on pDCs modulate the tissue microenvironment. 
Not only cytokines, but also a direct interaction between pDCs and iNKT cells may be of 
importance; CpG-stimulated pDCs express the ligand CD252 (OX40L), which binds CD134 
(OX40) present on the surface of NKT cells, and augments IFN-γ release by iNKT cells in 
response to lipid antigen presentation by mDCs (figure 4) [61]. Further support for such 
a direct interaction between pDCs and iNKT cells via OX40L/OX40 comes from murine 
studies [102, 103].
INTERACTION WITH B CELLS
B cells are the only cells that produce antibodies, and therefore, have a critical role in the 
humoral immune response. Release of type I IFNs by pDCs leads to an increase of TLR7 
and several activation markers on B cells [104, 105]. Moreover, as outlined above, pDCs, 
in concert with T cells, control B cell differentiation into plasma cells via the secretion of 
IFN-α and IL-6 [59]. In addition, pDCs can affect B cells via direct cell-cell contact. Several 
studies have shown the importance of CD40-CD40L interactions between B cells and pDCs 
Figure 4. Ligand/receptor paring of a pDC with an iNKT cell and the maturation state/ activation stimuli 
associated with ligand or receptor expression on the pDC surface.
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(figure 5) [20, 59, 60]. In addition, upon activation with CpG, pDCs were demonstrated to 
interact with B cells via CD70/CD27 molecules. This interaction results in B cell growth, 
differentiation and immunoglobulin secretion [106].
Furthermore, recent in vitro studies have shown that activated B cells are able to stimulate 
matured pDC to produce IFN-α by direct cell-cell contact [107]. Blocking the surface 
molecules OX40L, CD27, CD40 or CD40L with monoclonal antibodies did not influence the 
effect of B cells on pDC-derived IFN-α production. However, the IFN-α production by pDCs 
was significantly reduced when blocking LFA-1 or PECAM-1 (CD31) by 50% and 80%, 
respectively, indicating that these molecules are at least partially responsible for B cell mediated 
pDCs activation [107]. Taken together, pDCs and B cells are able to induce reciprocal cytokine 
release and activation by both soluble mediators and direct cell-cell interaction, and so far 
have been found to be predominantly stimulatory in nature [59, 106, 107].
pDC /  mDC SYNERGY
Synergism of mDCs and pDCs are not restricted to the activation of NKT cells. pDCs and 
mDCs have been demonstrated to be in close contact in vivo at steady state as well as under 
inflammatory conditions, and it has been suggested that they act synergistically to induce 
more potent immune responses[108-110]. Upon stimulation both mDCs and pDCs 
function as APCs, and express the costimulatory markers CD40, CD80, CD83 and CD86 
to interact with T cells [111]. However, there are complementary differences especially in 
the expression of PRRs (e.g. TLRs, CLRs) and thus in their response to pathogenic triggers. 
Figure 5. Ligand/receptor paring of a pDC with a B cell and the maturation state/ activation stimuli associated 
with ligand or receptor expression on the pDC surface.
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Whereas mDC subtypes express TLR1, 2, 3, 4, 5, 6, 8 and 10, but no TLR7 and 9, the 
expression of these TLRs on pDCs is the exactly opposite except from TLR2 and TLR10, 
which are shared [3, 4, 31, 112-115]. pDCs respond to TLR7 and TLR9 ligands with large 
amounts of IFN-α and tumor necrosis factor α (TNF-α) [116]. In contrast, mDCs release 
very different cytokines, primarily IL-1β, IL-8, IL-6, IL-10, IL-12p70, TNF-α to variable 
extents, upon triggering of their TLRs [3, 111, 115]. Upon viral infection pDCs are known 
to respond quicker and with larger amounts of cytokines than mDCs [117]. Thus pDCs 
and mDCs have non-overlapping sensitivities to invading pathogens, and accumulating 
reports suggest that pDC and mDC may cross-activate each other for a more effective 
immune response. Cross-talk may occur in a paracrine fashion through cytokines like Type 
I IFNs and TNF-α but also via direct cell contact [111]. Although there is clear evidence to 
suggest that mDCs and pDCs require close contact for some parts of this crosstalk, until 
now it is unclear what molecules are involved [111]. Recent studies by Picciolini et al. 
implies that several members of the TNF family, CD40L/CD40, OX40L, HEVML, RANKL, 
CD27, CD30L, GITRL and 4-1BB are redundant in the mDC/pDC cross talk [5]. 
Experimental evidence for the absence of a role for any of these interactions however was 
so far not reported but only came from unpublished blocking experiments mentioned in 
these studies, making it extremely hard to deduce whether these interactions can and should 
be excluded completely [5, 111]. Interestingly, murine models do suggest that the TNF 
member CD40/CD40L may have a crucial role in the pDC-mDC cross talk, yet this result 
needs to be recapitulated in human pDC-mDC assays [5].
So far only for the NOTCH receptor-ligand interaction evidence is provided for a role in 
the communication between pDCs and mDCs but again experimental evidence is scant 
(figure 6) [110]. With coculture experiments they demonstrated that LPS-activated mDCs 
caused an upregulation of maturation marker (CD25, CD86) on the pDC surface and 
increased IL-6 and CCL19 release in the supernatant. To confirm the involvement of 
NOTCH pathway, experiments with γ-secretase/NOTCH inhibitor DAPT and soluble 
NOTCH ligands were preformed and showed a reduced effect on Notch target genes. 
Activation of the NOTCH pathway upon pDC-mDC interaction suggests that this 
intercellular contact promotes an immune stimulatory response, however, further 
experiments are needed to unravel the exact mechanism and other molecules potentially 
involved in this pDC-mDC cross talk  [110]. 
Another possible candidate for the interaction between pDC-mDC is ICAM-1, expressed 
on both, pDCs and mDCs, and known as an widespread adhesion molecule with 
costimulatory activity on other immune cells [118]. ICAM-1 was found to be strongly 
upregulated on pDC upon stimulation with TLR 9 ligand CpG, while its matching receptor 
LFA-1 (CD11a/CD18)  is constitutively expressed on mDCs [5]. 
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Taken together, there is clear evidence that direct cellular interactions are indeed important 
for pDC-mDC cross-talk in humans, similar to what was observed in murine studies. 
However, besides NOTCH receptor-ligand interactions, any experimental evidence that 
argues in favor of or against the involvement of other specific receptor-ligand interactions 
is so far lacking [5, 111]. 
INTERACTION WITH NK CELLS
NK cells belong to the innate immune system and are able to respond rapidly to virally 
infected cells and to tumor formation. This is due to their unique ability to recognize 
stressed cells or the absence of MHC on the surface of infected or malignantly transformed 
cells, and their subsequent ability to lyse these cells. The bidirectional pDC-NK cell 
interaction is known to play an important role in host defense, and again is mediated both 
by cytokines and via direct cell contact [119, 120]. Type I IFNs secreted by pDCs have long 
been known to enhance the cytolytic potential of NK cells, and NK cells co-cultured with 
pDCs are more activated, and have increased cytolytic activity [45, 46, 121-124]. pDCs and 
NK cells have been found in close proximity in the T cells areas of human tonsils [46]. In 
addition, during infection or in case of a malignancy, pDCs and NK cells may migrate 
simultaneously to the site of the lesion, for example during Herpes simplex infection [21]. 
These reports demonstrate the ample opportunities for these cells to engage in direct 
interactions, which is further supported by the findings that, when co-cultured, pDCs and 
NKs cells readily interact [125]. Upon stimulation by a virus or CpG, pDCs express 
glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) that can bind GITR 
expressed by NK cells (figure 7). Via the (GITRL)-GITR interaction mature pDCs enhance 
Figure 6. Ligand/receptor paring of a pDC with a mDC and the maturation state/ activation stimuli associated 
with ligand or receptor expression on the pDC surface.
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NK cell mediated killing as well as IFN-γ production. To affect NK cells, however, pDCs 
expressing GITRL do require the simultaneous presence of IFN-α [46]. Furthermore, while 
the upregulation of CD69 on the surface of NK cells depends on the release of IFN-α and 
TNF-α by mature pDCs, upregulation of HLA-DR on the surface of a subpopulation of NK 
cells depends on direct pDC-NK cells contact [45]. HLA-DR expressed on NK cells is 
thought to play an important role in handling bacterial infections such as Mycobacterium 
bovis (BCG) [126]. Although the interaction responsible for HLA-DR upregulation remains 
to be elucidated, it is known that the maturation state of the pDC is not important for the 
induction of HLA-DR expression on NK cells, indicating the HLA-DR inducing factor is 
not affected by pDC maturation [45, 121, 123, 127]
The bi-directional crosstalk between pDCs and NK cells also affects pDC function; IL-2, 
immune complex or IL12/IL18 –stimulated NK cells induce pDCs to release IFN-α which 
was shown to depend largely on LFA-1-mediated interactions between NK cells and pDCs, 
and to a lesser extent on NK cell secreted MIP1α [123, 125]. LFA-1 and FcγRIIIA on the 
pDC also increase cytokine release by NK cells [128]. Furthermore, IL-2 stimulated NK 
cells induced pDCs to express the maturation marker CD83, but not CD80 and CD86, in 
a contact dependent manner, which also indicates the existence of different stimulatory 
pathways that can induce expression of different maturation markers on pDCs [123].
Contact with NK cells potentially puts pDCs in danger of becoming lysed. However, 
immature pDCs are protected from NK cell mediated lysis, and this is at least partly due 
to the high expression of HLA class I, and the absence of nectin-2, the ligand for NK cell 
activating receptors DNAM-1 [123, 129]. Culture of pDCs with IL-3 however causes the 
upregulation of Nectin-2 on pDCs, and makes them more susceptible to DNAM-1 and 
NKp30-mediated killing [129]. Activation of pDCs by TLR7- and TLR9 may help to 
Figure 7. Ligand/receptor paring of a pDC with an NK cell and the maturation state/ activation stimuli associated 
with ligand or receptor expression on the pDC surface.
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prevent NK cells lysis as they express the lectin-like transcript 1 (LLT1 or CLEC2D; above), 
which is a ligand of natural killer cell surface protein P1A (NKR-P1A; CD161). P1A is 
expressed by both NK and NKT cells and when ligated inhibits NK cell cytolytic function 
and IFN-γ release [47, 93, 95, 130]. Taken together, pDCs in various modes of action, 
seem to be differentially susceptible to NK cell- mediated lysis through the absence of 
activating NK cell receptor ligands, as well as the regulated expression of ligands for NK 
cell inhibitory receptors. Also, high MHC expression is protective. Therefore, non-lethal 
pDC/NK cell interactions seem to play an important role in enhancing the early immune 
response to a viral or bacterial infection as pDCs activate the NK cell by producing IFN-α 
and via GITRL. This feed-forward system likely promotes NK cells to rapidly lyse infected 
cells [123]. NK cell activity in turn induces a further increase of IFN-α by pDCs and 
promotes their maturation, which may in turn increase the recruitment and survival of 
myeloid DCs (figure 8).
TUMOR CELLS
Several early studies have reported decreased numbers of pDCs and mDCs in the blood of 
patients suffering from various types of cancers [131-134]. However, a recent study with 
melanoma patients detected no significant difference between the levels of immature pDCs 
in healthy donors and patients [135]. Compared to healthy volunteers, pDCs derived from 
melanoma patients did, however, show a higher expression of Chemokine receptor 6 
(CCR6), and increased ability to migrate towards Chemokine (C-C motif) ligand 20 
Figure 8.  Direct cell interaction dependent on GITR/GITRL or CD40/CD40L binding and their effect on a certain 
cell type.
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(CCL20), a ligand for CCR6 [135]. CCL20 is expressed by keratinocytes in the skin and by 
melanoma cells, suggesting that the CCL20/CCR6 interaction is involved in the pDC 
migration process from the blood to the tumor [136-138]. Indeed, high pDC infiltration 
have been observed in many types of cancer including melanoma, head and neck cancer, 
ovarian and prostate cancer, and these infiltrates mostly negatively correlate with patient 
survival. On the other hand, an increase of pDCs in tumor draining lymph nodes may be 
beneficial (Reviewed: Demoulin et al. 2013) [134, 139]. pDCs infiltrated in tumor 
microenvironment are mainly immature, and therefore seem to be predominantly 
immunosuppressive/ tolerogenic [139]. In recent years, evidence has accumulated that 
tumors may block pDC’s anti-tumor response by maintaining pDCs in an inactive/
tolerogenic state. Mechanisms responsible for keeping the pDC in this state include the 
secretion of prostaglandin 2 (PGE2) and TGF-β, which, in a synergistic manner inhibit 
pDC-derived IFN-α and TNF-α production in response to TLR7 and TL9 ligands, as well 
as inhibiting CCR7 expression, thereby impairing the migration of pDCs to the tumor-
draining LN to prime T cells with tumor antigens [139-141]. In addition, there is evidence 
that PGE2-stimulated pDCs indirectly support tumor cell proliferation, migration and 
invasion, as well as tumor angiogenesis, via the release of IL-6 and IL-8 [142-149]. 
Furthermore, tumor resident pDCs may also influence tumor growth indirectly through 
the induction of Tregs. In epithelial ovarian cancer the majority of Foxp3+ Treg cells 
accumulating in the tumor microenvironment expressed the inducible costimulator (ICOS), 
and tumor pDCs expressing the ICOS-L were shown to be essential for the expansion and 
suppressive function of these regulatory Foxp3+ Tregs [62, 63].
Figure 9. Ligand/receptor paring of a pDC with a tumor cell and the maturation state/ activation stimuli associated 
with ligand or receptor expression on the pDC surface.
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On their surface, unstimulated pDCs (uniquely with respect to all other leukocytes) express 
the immunoglobulin-like transcript 7 (ILT7) protein, which is activated by binding to bone 
marrow stromal cell antigen 2 (BST2, CD317; Reviewed Cao et al 2010) [150]. BST2 is 
expressed on human cancer cells, monocytes and vascular endothelium in response to 
IFN-α (figure 8) [151-153]. Similar to BDCA-2, ILT7 forms a complex with FcεRIγ, which, 
when ligated activates an immunoreceptor tyrosine-based activation motif (ITAM)–
mediated signaling pathway that dampens TLR-7 & TLR-9-induced IFN-α and TNF-α 
production [154, 155]. ILT7 is downregulated upon stimulation of the pDCs by CpG, HSV 
or IL-3, suggesting that pDC maturation prior to entering the tumor site may partly protect 
it from this suppressive mechanism [150, 155, 156]. In addition to ILT7, immature pDCs 
also express the ITIM motif containing receptors ILT2 and ILT3 that bind to MHC class I 
molecules, and an unknown ligand, respectively. Both receptors are associated with immune 
tolerance, probably through the suppression of T cell responses, and in agreement with this 
notion, these receptors are downregulated upon pDC activation [157-159]. Whether these 
molecules may also have an active role in the pDC-tumor cell interaction, or rather regulate 
pDC-T cell activation, remains to be investigated. Likewise, there may be a yet unappreciated 
role for pDC expression of NKp44, which has been demonstrated to down modulate pDC 
IFN-α responses upon ligation, and may be utilized by the tumor to dampen pDC mediated 
immune responses [160]. Indeed, an inhibitory NKp44 ligand complex containing HLA I 
and PCNA was recently reported to be expressed by several tumor cells [150, 156, 161].
So far, most studies point out an immune suppressive role for pDCs favoring tumor 
progression, however several other studies demonstrate that the situation may be very 
different if pDCs are properly activated. In this case pDCs may trigger anti-tumor T cell-
mediated immune responses (above) or even actively kill tumor cells [162, 163]. As 
previously discussed, in relation to the T cell/pDC interaction, activated pDCs express 
TRAIL, which induces an apoptotic process by binding to the TRAIL receptors. Tumor 
cells are known to be sensitive to TRAIL, and via this interaction could directly induce 
tumor cell apoptosis [162]. Avoiding this apoptotic pathway by downregulation of TRAIL 
has been reported for several cancers by numerous studies [164].
Taken together, the suppressive tumor microenvironment decreases the immune stimulatory 
functions of pDCs resulting in tumor progression. Preventing these processes, while at the 
same time activating pDCs, forms a promising target for anti-tumor therapies. Moreover, 
in a recent clinical feasibility study in our department, we demonstrated that the 
administration of autologous ex vivo-matured tumor antigen loaded pDC-s proved to be 
successful and induced objective clinical responses in several patients [56].
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LESS E XPLORED IN pDC CELLUL AR INTERACTION S: THE SL AM FAMILY
Above we have provided an overview of the interactions pDCs likely engage in during their 
lifecycle, as based on experimental evidence and in vivo proximity. In addition we discussed 
the molecules likely to participate in these interactions. There is, however, a poorly 
understood family of proteins which are highly expressed pDCs, and which deserve more 
attention. This is the SLAM family of receptors, for which a role in a diverse range of cellular 
interactions is highly suspected, yet currently unexplored. It is comprised of five members 
which are all expressed on the pDC surface (largely) independent of its activation state: 
SLAMF2 (CD48; BLAST1), SLAMF5 (CD84), SLAMF3 (CD229; Ly9), SLAM7 (CD319, 
CRACC) and NTBA (CD352) [68, 96]. Except for SLAMF2 (below), these proteins have 
in common that they engage mostly in homotypic interactions; such interactions may occur 
between homotypic cells, but also between different cell types, opening up the possibility 
that these molecules mediated direct cell interactions of pDCs with each other, or with 
others cells also expressing these receptors [165]. Homotypic SLAM family interactions 
have the ability to regulate cell activation and proliferation as well as cytolytic activity [165]. 
SLAMF5 is highly expressed by many immune cells, and has been shown to play a role in 
T cell-B cell adhesion, and for optimal germinal center formation [166, 167]. Furthermore 
SLAMF5 was detected on leukemic pDCs, and can work as an inhibitor for FcεRI-mediated 
signaling in mast cells [168, 169]. SLAMF3 is also expressed on T cells. Here it reduces 
IFN-γ production and ERK activation upon stimulation, and thus via this molecule pDCs 
might trigger a similar response [166, 170]. SLAM7, in contrast, is widely expressed on 
activated B lymphocytes, NK cells and CD8+ T lymphocytes [68, 171-173] and has been 
shown to promote B cell proliferation, activate NK cell cytotoxicity (but not NK cell 
proliferation) [171, 173, 174]. Finally, NTBA in addition to pDCs, is present on NK, T and 
B cells where it may affect cytotoxity as well as the IFN-γ and TNF-α release [165, 175, 
176]. Interactions between NTBA on pDCs and NK cells may therefore have the potential 
to positively regulate both NK cells and pDCs.
In contrast to the other family members, SLAMF2 which is also present on the surface of 
pDCs, engages in a heterotypic interaction with family member 2B4 (CD244), and could 
thus play a role in the interaction of pDCs with 2B4-expressing NK or T cells [68, 166, 177]. 
SLAMF2 via 2B4 can activate NK cells [177].
Overall, although experiments are largely lacking, the presence of such a high number of 
SLAM family members on pDCs, their homotypic interactions, as well as the known effects 
of their triggering on other immune cells makes us speculate that pDCs may very well 
exploit these receptors to communicate with other immune cells.
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CONCLUSION AND OUTLOOK
In this review we summarized the existing data which supports the idea that during their 
life cycle, human pDCs interact with numerous immune cells. Additionally, we have 
attempted to provide a contemporary overview of the molecules that drive these interactions, 
and the consequences of their expression on pDCs. It is clear that pDCs play a pivotal role 
in ensuring a rapid immune response, especially upon viral infection, by strong IFN-α 
release, but also via direct cell-cell interaction. Depending on the pDC activation state, 
cytokines released by pDCs and direct pDCs surface receptors may inhibit or activate other 
immune cells. This large influential capacity of pDCs suggest that they are master regulators 
of both innate and adaptive immune responses. Besides secretion of the highly potent yet 
broadly acting IFN-α, pDCs have a highly versatile repertoire of cell surface molecules to 
further fine tune immune responses. These characteristics make them an interesting and 
potential highly valuable therapeutic target to be exploited or targeted in cancer therapy, 
infectious or autoimmune disease. Importantly, controlling cytokine secretion and the 
surface expression of specific receptors is essential to steer the immune response into the 
desired direction. In cancer therapy, lifting the suppressive actions of tumor-resident pDCs 
may greatly enhance existing/endogenous antitumor immune response [2]. In addition, 
anti-cancer immune responses may be initiated or boosted by vaccination with autologous 
tumor antigen loaded pDCs [56]. A preliminary clinical trial using pDCs in melanoma 
vaccination therapy, carried out by our department, has demonstrated the use of thick born 
virus vaccine (FSME)-matured pDCS in cancer vaccination is safe and feasible, and despite 
low patients numbers, showed an improved survival of pDCs vaccinated patients [56]. In 
particular, the extremely low doses ranging from 0.5-3 million pDC per patient demonstrate 
the potency of these cells. The exact reason for the success of pDCs however is not yet 
completely understood, but in addition to IFN-α production and the induction of tumor 
specific T cells, we envision there may also be a significant role for the effective combination 
of surface receptors expressed by the pDCs and their resulting interaction with other 
immune cells. 
In conclusion, research over the past few years has greatly increased our knowledge of the 
repertoire of pDC-expressed surface receptors and cellular interaction partners, and has 
emphasized that there is more to the pDCs than IFN-α alone. Importantly, however, further 
studies are required to identify the role of these molecules and interactions in pDC function 
and immune responses in general. 
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SUMMARY
Dendritic cells (DCs) play a key role in orchestrating adaptive immune responses. In human 
blood three distinct subsets exist: plasmacytoid DCs (pDCs) and BDCA3+ and CD1c+ 
myeloid DCs. In addition, a DC-like CD16+ monocyte has been reported. Although RNA-
expression profiles have been previously compared, protein expression may provide a 
different picture. Here, we exploited label-free quantitative mass spectrometry to compare 
primary human DC subset protein expression and identify many differences in protein 
expression. Moreover, we integrated obtained proteome data with existing mRNA data to 
derive robust protein-based cell-specific expression signatures, containing more than 400 
differentially expressed proteins between subsets, which now form a solid base to investigate 
subset specific functions. This, we illustrated by extracting subset identification markers 
and by demonstrating that pDCs completely lack Caspase-1 and also only express low levels 
of other inflammasome-related proteins. Concordantly, pDCs were incapable of IL-1β 
secretion in response to ATP. 
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INTRODUCTION
Dendritic cells (DCs) play a critical role in the initiation of antigen-specific adaptive 
immune responses to foreign antigens and the maintenance of tolerance to self-antigens 
(reviewed by [1-3]). DCs harbor the unique capacity to process and present antigens 
complexed to either major histocompatibility complex (MHC) class I or II and thereby can 
activate naïve T cells. It is because of this ability that DCs have become of interest as tools 
or targets for cancer immunotherapy to initiate or boost tumor immunity.
Several DC subsets can be distinguished that differ in their ability to sense and respond to 
pathogens and in the type of immune response they initiate. Two main types of naturally 
occurring blood DCs have been characterized: Plasmacytoid DCs (pDCs) and myeloid 
DCs (mDCs) (reviewed by [3]). pDCs play a key role in anti-viral immunity, by their ability 
to produce large amounts of type I IFNs. Myeloid DCs represent the ‘traditional’ antigen 
presenting DC that can be further subdivided based on the expression of BDCA3 (CD141) 
and CD1c (BDCA1). Each can be defined through the expression of different pattern 
recognition receptors (PRR; e.g. toll like receptors (TLR) and C-type lectin receptors (CLR)) 
and secretion of a distinct set of cytokines upon stimulation (reviewed by [1-3]). Whereas 
CD1c+ mDCs express most TLRs except TLR9, BDCA3+ mDCs express mainly TLR3. 
Furthermore, BDCA3+ mDCs express the CLR CLEC9a, which facilitates uptake of dying 
cells and subsequent cross presentation of derived antigens to T cells [4-6]. Finally, although 
not considered a genuine DC, a CD16+ subset of monocytes coined “non-classical 
monocytes” can be found in blood with DC-like properties [7]. So far, these DCs subsets 
have been mostly characterized and isolated based on cell specific (surface) markers and 
functionally compared for abilities such as antigen presentation, cytokine secretion and 
migration [1-3]. These functional assays however can be biased as they provide information 
on only a few a priori determined functional responses to a limited set of activation stimuli 
and antigens. Although highly valuable to investigate the abilities of each subset under 
specific circumstances, these assays may leave more untraditional unique characteristics 
of each subset undetected. To overcome this, unbiased analysis of mRNA expression of 
human and mouse DC subsets have been performed and proved to be highly informative 
[8-11]. Comparative transcriptome analysis delivered the most compelling evidence for 
the current thought that the human BDCA3+ mDC is the counterpart of the murine CD8a+ 
DC, despite the lack of conservation of identification markers [10]. In addition, the same 
study demonstrated that the CD16+ DC-like cell, based on its full transcriptional program, 
resembles a monocyte more than a DC. Although these studies have provided valuable new 
insight into the relation between DC subsets in mice and humans, RNA expression does 
not always reflect protein expression. Since, not all RNA is translated, RNA and proteins 
may have dissimilar half-lives and kinetics, and protein levels are also regulated by post-
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transcriptional modifications. Furthermore transcriptomics does not take into account 
pre-existing protein levels, alterations in translation efficiency, or protein stability. Therefore, 
transcriptome expression data may have limited predictive power on which proteins really 
define each DC subset, and may have left important phenotypical and functional differences 
unnoticed. To confirm and supplement the existing transcriptome analysis, we have 
performed a comprehensive mass spectrometry (MS) based quantitative proteome 
comparison of rare blood DCs subsets. Furthermore, we integrated protein and RNA data 
to derive expression signatures that give a more reliable and comprehensive account of 
expression differences than could be achieved from using either technique alone. The 
expression signatures represent an easily accessible resource to derive hypotheses on subset 
specific functions. To illustrate this, we validated 5 of the identified differentially expressed 
surface markers and showed that Caspase-1 is completely lacking in pDCs, which is 
accompanied by restricted expression of other inflammasome components and affects the 
function of these cells.
RESULTS
Quantitative proteomics of primary human DC subsets 
For proteome characterization, 4 DC-(like) subsets (i.e. pDCs, CD1c+ mDC, BDCA3+ 
mDC and CD16+ monocytes) were isolated from apheresis products obtained from healthy 
volunteers by magnetic bead-based cell separation. The purity of the isolated cells and 
presence of cross-contamination was assessed by flow cytometry (Figure S1). For pDCs, 
CD1c+ mDCs and CD16+ monocytes, high purity (≥ 95%) was obtained for all subsets 
without major cross contamination or presence of B or T cells in 2 out of 3 donors. For a 
third donor medium high purity was obtained (78-92%). For BDCA3+ mDCs samples, 
most cells were BDCA3+CD11c+ (87-95%). We observed however, a variable number of 
CD11c+ cells expressing intermediate levels of BDCA3 (BDCA3int) in the isolate together 
with cells positive for CD1c+, indicating cross contamination of this sample with 
CD11c+CD1c+BDCA3int cells. Therefore, we consider these samples BDCA3+ mDC-
enriched rather than pure. Nevertheless, we reasoned that this sample is still of use to derive 
BDCA3+ mDC-specific protein expression, which may be achieved by relating the BDCA3+ 
mDC-enriched samples to the (BDCA3+-depleted) CD1c+ mDC samples. All 12 (3 donors 
x 4 subsets) samples were first separated using SDS-PAGE, fractionated into 20 fractions 
and subjected to in-gel trypsin digestion (yielding 240 fractions in total). Fractions were 
measured in triplicate using highly sensitive Liquid Chromatography- tandem Mass 
Spectrometry (LC-MS/MS) for maximal protein coverage. After peptide identification and 
sequence alignment, proteins were quantified using the LFQ algorithm in Maxquant [12]. 
The Pearson correlation was very high (r=0.97 ± 0.02) between technical replicates and 
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high (r= 0.93 ± 0.02) between biological replicates (e.g. the same subsets from different 
donors), indicating good reproducibility across measurements and donors (Table S1). In 
total we identified 42723 non-redundant peptide sequences corresponding to 4196 protein 
groups (Table S2 and S3). Requiring a protein to be expressed in at least 2 donors for each 
subsets, we identified 2351, 2197, 2009, 1883 proteins in pDCs, BDCA3+ mDCs, CD1c+ 
mDCs and CD16+ cells respectively and 2823 proteins overall (Figure S2A-D and Tables 
S2 and S3). Next, using the corum database of protein complexes, we inspected the 
identification of components of protein complexes essential for cell homeostasis (e.g. 
mitochondrial complexes, proteasome), to assess completeness of the proteome in each 
cell type [13]. We recovered most components indicating our proteome covered the majority 
of DC proteins (Figure S2E). Coverage was best in pDCs and BDCA3+ mDCs, yielding 
70-100 % of essential protein complexes, and least in CD16+ cells (40-100 %; Figure S2E). 
We then evaluated the assignment of key identification markers for each subset. No markers 
specific for other major leukocyte populations (e.g. T, B or NK cells) were identified, 
suggesting a lack of substantial contamination with other leukocytes. In contrast, we readily 
identified unique expression of at least one previously reported subset specific protein for 
each subset, including TLR7, TLR9, CLEC4C, NRP1 and IL3RA for pDCs, IDO and HLA-
DO for BDCA3+ mDCs, and CD16 (FCGR3A) for CD16+ monocytes (Table 1). 
Table 1. Subset identification markers uniquely identified.
Peptides D1 Peptides D2 Peptides D3 
pDCs  
TLR9 5 10 11 
IL3RA (CD123) 2 3 7 
CLEC4C (BDCA2) 0 2 4 
TLR7  0 4 7 
NRP1 (BDCA4) 1 0 1 
CD1c+    
CD1C 2 2 2 
BDCA3+    
IDO1 8 5 10 
TLR3 3 0 0 
THBDa  (BDCA3) 1 0 2 
CLEC9Aa 0 1 0 
CD16+    
FCGR3A (CD16) 3 3 3 
The numbers of peptide identified and quantified for each marker protein for each subsets. Shown markers 
were uniquely identified in the indicated subset. aPeptides were detected by releasing the FDR threshold of 
0.01 and spectra were manually validated.
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Importantly, CD1c was uniquely detected in CD1c+ mDCs but not in BDCA3+ mDCs. 
For BDCA3+ DCs we did not immediately identify more traditional markers such as 
BDCA3 (CD141, THBD), CLEC9a, TLR3, NECL2 and XCR1 using the default peptide 
identification threshold (FDR=0.01). Possibly this was due to a low expression, high 
hydrophobicity or heavy glycosylation of these molecules. Nevertheless, we found a unique 
expression of IDO and HLA-DO in BDCA3+ mDCs, that have previously been reported 
to be highly expressed in especially this subset [14, 15]. Upon more close inspection of 
peptides however, TLR3 was found in one BDCA3+ mDC sample, and CLEC9A and 
BDCA3 (CD141, THBD) in two samples. Because these peptides were detected with low 
confidence (FDR =1), we generated MS/MS-spectra and manually verified this result (data 
not shown). Together, the expression patterns of established marker proteins demonstrate 
the ability of our approach to discern the distinct identity of each subset. 
We also obtained quantitative information using the LFQ algorithm in MaxQuant [12]. 
First, we used this information to compare protein expression in the three main populations 
of blood DC-like cells (i.e. pDCs, CD1c+ mDCs and CD16+ monocytes), excluding the 
BDCA3+ mDC samples. We calculated average expression differences between any two 
subsets and visualized these in volcano plots (Figure 1A; Table S4 for complete statistical 
analysis). It should be noted that here, and in the remainder of the manuscript, only proteins 
expressed in at least 2 donors in one of the cell types being compared are included. Pairwise 
comparisons further highlighted subset identity, showing specific expression of CD11c 
(ITGAX/ ITGB2) in myeloid cells, and overexpression in pDCs of several proteins with a 
reported pDC-specific expression and function (e.g. PACSIN1, SLC14A4, IRF7, TCF4, 
BCL11A, BLNK, CD2AP; [10, 14, 16-21]. 
Next, we determined the relation between cell types by hierarchical clustering (Figure 1B). 
Based on all proteins, subsets clustered together mostly on cell type rather than on donor. 
Furthermore, CD16+ monocytes and CD1c+ mDCs that share a myeloid origin were closer 
to each other than to pDCs. Hierarchical clustering of samples based on 1218 differentially 
expressed proteins (DEPs) between the 3 subsets showed a similar separation as when using 
all proteins and indicated 6 main groups of DEPs higher or lower expressed in one of the 
three subsets (Figure 1C). Next, we assessed how our protein data related to mRNA data. 
We merged our protein data with a previously published and publicly available microarray 
dataset of the same subsets [8]. For one the donor that was used for MS analysis we also 
acquired sufficient material to perform RNA sequencing on the same sample (Table S5). 
We first assessed the overall correlation between microarray derived RNA data and 
proteome data for each cell type and found this to be low, similar to our previous 
observations (Figure 1D; r=0.28-0.31; [22]). The correlation between RNA sequencing data 
and proteome data for the matched donor was slightly better (0.37-0.45). Cross correlation 
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Figure 1. Comparison of protein expression between 3 main blood DC-like subsets and integration with RNA 
data. (A) Volcano plots depicting protein expression differences (x-axis: 2log fold change) and the significance 
level (y-axis: -10log (t-test p-value)). Coloured dots represent proteins with a fold change of >2 and p<0.05, 
proteins in grey did not meet these criteria. Proteins specific to one of the 2 subsets compared were assigned a 
fold change of infinity. (See also Table S4) (B) Unsupervised hierarchical clustering of DC subsets using all proteins 
(1-Pearson correlation) (C) Clustering of subsets based on 1218 DEPs (based on 3-group one-way ANOVA 
(p<0.05)) or specific expression) (D) Pearson correlation between protein and RNA (microarray) expression 
levels. (E) Hierarchical clustering of merged transcriptome and proteome data (DEPs only). (See also Figures S1, 
S2 and Tables S1- S6)
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of this RNA sequencing dataset to the protein data of the 2 other donors however, produced 
a similar correlation, indicating the different RNA analysis method was mostly responsible 
for the improved correlation (Table S6). To make a more in debt comparison of the RNA 
data to our proteome dataset possible, we transformed both microarray-derived RNA and 
protein expression data to relative expression levels for each dataset separately (z-scores; 
mean to 0, variance to 1). From the merged dataset we yielded 742 DEPs for which also 
RNA data was available. The merged RNA and protein data for these 742 DEPs we again 
used as input for hierarchical clustering (Figure 1E; Table S6). The combined protein and 
RNA samples grouped the distinct subsets from the two datasets together, indicating that 
despite moderate correlation between absolute expression levels, there was a good 
correlation between RNA and protein expression patterns (Figure 1E). Importantly, the 
clustering was neither determined by biological variation between donors nor by technical 
variation between omics technologies. 
Generation of protein based expression signatures and networks
Protein and RNA data were not consistent in all cases and proteome analysis put forward 
DEPs for which differences at the RNA level were only minor, or for which no probes had 
been present on the microarray chips. We next set out to visualize were exactly proteome 
analysis pointed to not previously appreciated differences between DC subsets and in which 
cases RNA and protein were in agreement. For the 6 groups of DEPs associated with the 3 
subsets (Figure 1C) we generated protein expression signatures based on 4 different evidence 
levels: I) subset specific protein expression/absence, supported by RNA data, II) differential 
protein expression between subsets, supported by RNA data III) subset specific protein 
expression/absence, not supported by RNA data, and IV) differential protein expression 
between subset, not supported by RNA data (Figure 2; supplemental methods). Proteins 
included in signatures based on level I and level II evidence behaved consistently in RNA and 
protein datasets. These proteins are thus likely mostly regulated at the transcriptional level. 
t  Figure 2. Cell specific gene signatures derived from proteomics and transcriptomics. (A-F) Protein based 
gene signatures for higher or lower expression in the three main subsets derived from merged proteome and 
transcriptome data based on 4 evidence levels: I) Specific protein expression/ absence with RNA support II), 
differential protein expression with RNA support III), specific protein expression without RNA support and IV) 
differential protein expression without RNA support. Proteins marked by asterisks were specifically identified by 
MS in two donors only but were included because of RNA support (e.g. “rescued”). The heat map colors represent 
relative protein expression (LFQ) in each DC subset and donor. (See also Table S7)
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Importantly, for these proteins proteomics data confirmed RNA-identified differences 
between subsets. Many stablished markers were present in these 2 groups (e.g. IL3RA, 
CLEC4C, TLR9, CD1c and FCGR3B (CD16)). Supported by two lines of evidence, other 
proteins in these groups now represent high potential subset identification markers and 
include CD163 for CD1c+ mDCs and SIGLEC10 for CD16+ monocytes (Figure 2; Table 
S7). In contrast, proteins included in signatures based on level III and level IV evidence, 
reflect less consistence between protein and RNA expression patterns, or a lack of 
transcriptional information/ CHIP annotation. Proteins in these evidence groups represent 
the added value of the proteome analysis (Figure 2). Finally, proteins put forward as 
differentially expressed by RNA data (DEGs) that were also present in our protein dataset 
but were not confirmed as differentially expressed by proteomics are listed in Table S8. 
Together, we confirmed differential or unique expression of 253 proteins between the 3 
subsets previously observed by RNA expression (pDCs, 109 higher/ 65 lower; CD1c+ 
mDCs, 17 higher/ 1 lower; CD16+ monocytes,34 higher/ 27 lower) that could also be 
derived from the transcriptome data (Level I and II; Figure 3; Table S7 including lower 
confidence DEPs). In addition, 143 proteins were found to be differently/ uniquely expressed 
between subsets based on proteomics data only (Level III and IV) which hold yet 
unappreciated differences between DC subsets (pDCs, 75 higher/ 14 lower; CD1c+ mDCs, 
10 higher/ 8 lower; CD16+ monocytes, 10 higher/ 26 lower) 
To obtain insight into the overall function of signature proteins, we performed a protein-
protein interaction (PPI) and functional annotation (FA) analysis (Figure 3; Table S9). PPI 
analysis demonstrated good connectivity between proteins high in pDCs (0.73 connection/ 
protein) or low in pDCs (1 connection/ protein), high in CD1c+ mDCs (0.85 connection/ 
protein) and those low in CD16+ monocytes (0.64 connection/ protein; Figure 3 and Table 
S9). Much less connectivity was found between proteins high in CD16+ monocytes (0.25 
connection/ protein) or low in CD1c+ mDCs (no connections identified). 
In the CD1c+ mDCs high signature, the MCM family and accessory proteins that regulate 
the cell cycle, were found by proteome analysis only and were highly connected, suggesting 
a unique role for this complex in CD1c+ mDCs (Figure 3 and Table S9). This complex was 
completely absent from CD16+ monocytes. Proteome analysis but not RNA analysis also 
pointed out CD1c+ mDCs higher expressed both the alpha- and beta-chain of HLA-DQ, 
which may thus be of specific importance in this DC subset. The largest gene signatures 
were obtained for pDCs and mostly mapped to expected pDC functions including TLR 
and IFN signaling (e.g. TLR9, IRF7, IRF8, SMAD3), but also to endoplasmic reticulum 
(ER), Golgi and vesicular transport, indicating high protein biosynthesis in this cell type 
(e.g. SEC24A, SEC31A, SEC11C, PDIA5, PDIA4, ERGIC3, LMAN1; Figure 3 and Table 
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Figure 3.Signature protein-protein interaction networks highlight functional differences between subsets. 
(A-E) Signatures were used as input for STRING PPI analysis (confidence level 0.4) to visualize possible 
connections between proteins. (See also Table S9.) Proteins indicated in blue were included based on protein 
and RNA data and red protein were pointed out by protein data only (see also methods and table S7). Important 
biological functions of sections of each network are indicated (based on functional annotation; see Table S9).    
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S9). Intriguingly, IFN and TLR signaling pathway constituents were highly expressed in 
pDCs by both RNA and protein analyses, while proteins involved in protein biosynthesis 
and vesicular transport were in many cases highly expressed at the protein level only (Figure 
3). The proteins absent from pDCs (e.g. shared by CD1c+ mDCs and CD16+ monocytes) 
were also highly connected and related to cell adhesion and protrusion formation (e.g. 
ZYX, MSN, PAK1, VASP, FSCN1; Table S9), in line with the rounder non-adhesive 
phenotype of pDCs. Furthermore, pDCs hardly expressed or even lacked TLR2, that detects 
bacterial lipoproteins, several proteins connected to bactericidal endo/phagosomes (e.g. 
HMOX1, NCF2, RAB27a) and CASP1 (Caspase-1), a crucial enzyme in the inflammasome 
induced cleavage of IL-1β in macrophages and DCs (Figure 3 and Table S9).
BDCA3+ versus CD1c+ mDCs
We next investigated the difference between the two myeloid DC subsets. Despite the 
presence of CD1c+ mDCs in the BDCA3+ mDCs samples, mDC samples were largely 
devoid of other blood cells (Figure S1). Importantly, CD1c+ mDCs samples were devoid 
of BDCA3+ mDCs. A direct comparison between the two sets of samples could thus still 
reveal important expression differences between mDC subsets (Figure 4; Table S4). As 
expected, the number of DEPs between BDCA3+ mDCs and CD1c+ mDCs was much less 
than between other subsets, reflecting the presence of CD1c+ cells in both samples and/ 
or their more common origin. Similar to what we found before, protein only moderately 
correlated to RNA expression (r=0.31 for microarray or r=0.38 for RNA sequencing; Figure 
4B, Table S6). Despite the contamination with CD1c+ mDCs, the BDCA3+ mDC protein 
samples clustered with the microarray RNA samples of BDCA3+ mDCs, indicating the 
cross contamination did not mask BDCA3+ mDC subset identity (Figure 4C). Finally, we 
derived DEPs between BDCA3+ mDCs and CD1c+ mDCs, using integration of protein 
and RNA data (Figure 4D-E). DEPs included IDO1, FUCA1, CD93, HLA-DOB and TAP2, 
(high in BDCA3 mDCs) and SIRPA, SIGLEC9 and CASP1 (high in CD1c+ mDCs). Several 
more DEGs by microarray showed a similar trend at the protein level but did not meet our 
stringent criteria (e.g. IRF8, CAMK2D, TAP1; Table S8). Others were not found differentially 
expressed by proteomics or even showed an opposite trend. 
Validation of differentially expressed proteins.
To demonstrate the resource value of our integrated proteome and RNA analysis, we 
selected 5 cell surface receptors for validation. We chose cell surface receptors because these 
may reflect the ability of each subset to recognize dangerous agents, and could aid subset 
identification by flow cytometry. Using the latter technique, we confirmed differential 
expression of all 5 receptors: SIRPα and Siglec-9 were found on CD16+ monocytes and 
CD1c+ mDCs only, CD93 was especially high on BDCA3+ mDCs, Siglec-10 was unique 
to CD16+ monocytes and finally CD163 was high on CD1c+ mDCs (Figure 5). 
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Absence of Caspase-1 in pDCs reflects low inflammasome activity
Previous transcriptome analysis already indicated pDCs express lower levels of transcripts 
for proteins involved in anti-bacterial innate immune responses [23]. It was not clear 
whether this also translated to protein expression and functionality. Our proteome data 
now confirms pDCs express lower levels of or lack TLR2, NAIP, HMOX, RAB27A, NCF2 
and CASP1 (Figure 2, Table S7). Caspase-1, a crucial player in inflammasome function, 
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Figure 4. Pairwise comparisons of BDCA3+ mDCs and CD1c+ mDCs. (A) Volcano plot depicting protein 
expression differences (x-axis: 2log fold change) and the significance level (y-axis: -10log (t-test p-value) as in 
figure 1. (B) Pearson correlation between protein and RNA (microarray) expression levels. (C) Hierarchical 
clustering of merged z-scored transcriptome and proteome data of DEPs. (D-E) Heat maps of the relative protein 
expression (LFQ) of proteins identified to be specifically (Level I and III) or differentially expressed in either mDC 
subset (Level II or IV; by t-test), based on protein and RNA evidence (Level I and II) or protein evidence only 
(Level III and IV). (See also Figures S1, S2 and Tables S1- S6)
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was abundantly present in CD1c+ mDCs and CD16+ cells but was lacking in pDCs (Figure 
6A). In the BDCA3+ mDC-enriched sample caspase-1 was present but at much lower levels 
than in CD1c+ mDCs. Importantly, protein quantification was based on 6, 11 or even 13 
peptides for BDCA3+ mDC, CD1c+ mDCs or CD16+ monocytes respectively, while in 
pDCs only a single peptide was mapped to Caspase-1 that was not adequate for 
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Figure 5. Confirmation of differentially expressed surface markers. (A) Representative histogram of the 
expression of indicated surface markers by specific antibodies (lines) or isotype controls (grey area) on the 4 
subsets. (B) Bar diagrams summarizing the fluorescence level measured by flow cytometry (FC) in 4 independent 
healthy donors (isotype control antibody signal subtracted; Mean ± SEM).  All markers were found differentially 
expressed by one-way ANOVA (p<0.05), and between pairs of subsets with indicated significance by post-hoc 
Tukey’s Multiple Comparison Test *p<0.05, **p<0.01, *** <0.001. (C) Bar diagrams of mean LFQ values as obtained 
by MS analysis (3 donors).   
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quantification, suggesting absence or very low expression of this protein (Table S3). To 
further substantiate these MS data we analyzed protein expression by Western blot (WB). 
Caspase-1 was readily detected in CD1c+ mDCs and CD16+ monocytes but was present 
only at very low levels in pure BDCA3+ mDCs and not at all detected in pDCs (Figure 6B 
and figure S4). It should be noted that we did detect low levels of Caspase-1 in pDCs isolated 
by magnetic beads but protein expression was completely absent when cells were sorted to 
high purity (>99 %) by flow cytometry (Figures 6 and S4). We next wondered whether 
pDCs would upregulate Caspase-1 when activated. To test this we incubated cells with the 
TLR7/8 ligand R848. Cell activation by TLR stimulation upregulated Caspase-1 in CD1c+ 
mDCs but did not in pDCs (Figure 6C Figure S4). CD16+ monocytes also did not further 
increase Caspase-1 expression upon TLR stimulation. Upregulation of Caspase-1 in 
BDCA3+ DCs could not be tested because we did not manage to isolate sufficient cells to 
test both resting and stimulated conditions by WB. 
Next, we were interested in the expression of other components of the inflammasome 
pathway. Only very few other proteins of this pathway were identified by MS: NAIP was 
also detected in all subsets except for pDCs, while the inflammasome-component NLRC4 
was identified in CD16+ monocytes only (Figure 2; Table S7). Exploration of the publicly 
available RNA expression data however, indicated that low expression in pDCs was not 
restricted to Caspase-1 but also included most other inflammasome components, as stated 
before [23]. CD16+ monocytes in contrast, expressed high levels of inflammasome 
constituents, CD1c+ mDCs more moderate levels, and BDCA3+ mDCs low levels (Figure 
6D). Together, these data strongly suggest an overall low presence of inflammasome-related 
proteins in pDCs. Consequently, pDCs may not be equipped to recognize inflammasome-
activating stimuli and to synthesize and secrete IL-1β in response. All components of the 
pathway downstream of ATP recognition were low in pDCs compared to the other subsets 
(P2XR7, PANX, NLRP3, CARD8, PYCARD and CASP1; Figure 6D) indicating that pDCs 
may not be equipped to respond to this danger-associated molecule. ATP can trigger the 
cleavage and secretion of IL-1β, provided NFkB signaling is present at the same time to 
induce pro-IL-1β expression. As a proof of principle, we tested the ability of subsets to 
secrete IL-1β in response to ATP, preceded by 4 hours or overnight R848 stimulation to 
trigger NFκB signaling via TLR7/8. Upregulation of activation marker CD83 and/ or 
production of TNFα were observed in all DC subsets, demonstrating functional NFkB 
signaling (Figure 6E-G). IL-1β secretion was restricted to especially CD1c+ mDCs and 
CD16+ mDCs. These data thus confirm that pDCs indeed lack IL-1β secretion in response 
to ATP. Of note, IL-18 that also requires Caspase-1 for secretion, was readily secreted by 
ATP/ R848 stimulated CD1c+ mDCs but not by pDCs (Figure S4). BDCA3+ mDC were 
clearly activated by R848 judged by the increased expression of CD83, yet hardly produced 
any cytokines (including IL-1β) under these circumstances (Figure 6E-G). 
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These experiments together demonstrate that the inflammasome/ caspase-1 pathway is 
present and functional in CD1c+ mDCs and CD16+ monocytes but not in pDCs. 
Concordantly, pDCs do not secrete IL1β in response to ATP.
DISCUSSION
This study describes an elaborate proteome analysis of human blood derived DC subsets 
and provides DC subset-specific protein signatures. This dataset holds unique information 
on the differences between DC subsets and reveals which differences previously identified 
using mRNA are really present at the protein level. Previously, Luber and colleagues 
analyzed the proteome of murine DC subsets [13] but large scale proteomics of human DC 
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Figure 6. Absence of Caspase and inflammasome activity in pDCs. (A) Bar diagrams of LFQ values for Caspase-1 
as obtained by MS analysis (3 donors). (B &C) Western blot analysis of DC subsets isolated by flow sorting from 
two independent donors lysed directly after isolation or (C) also after overnight stimulation with R848. Shown 
is the signal for Caspase-1 and actin probed sequentially on one membrane. (D) Heat map of 2log intensity values 
by microarray of probes mapping to inflammasome components (3 donors). (E) Flow cytometry evaluation of 
surface expression of CD83 on immature or R848/ATP stimulated (4 hours 45 min) subsets. Results of a 
representative donor are shown. (E & F) Secretion of indicated cytokines by pDCs and CD1c mDC after stimulation 
for 4 hours (E) or overnight (F) with R848 followed by 45 min with ATP by ELISA. Mean values ± SEM from at 
least 4 donors. Significance was evaluated by a two-tailed Mann-Whitney test. *p<0.05, **p<0.01, *** <0.001, 
ns=non-significant. See also figures S3 and S4.
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was thus far restricted to in vitro generated monocyte derived DCs (moDCs) and CD1c+ 
mDCs [22, 24]. The latter study reported 725 proteins expressed in resting and TLR-
stimulated CD1c+ mDCs together, of which the majority (75%) was also identified in the 
here described analysis in resting CD1c+ mDC, along with a further 1500 other proteins. 
The here presented dataset thus represents, to the best of our knowledge, the most complete 
quantitative proteome analysis of human DC subsets and provides a unique side-by-side 
comparison of these cells from the same donors. 
We report on nearly 400 differentially expressed proteins between the three main blood 
DC-like subsets. In addition, despite the presence of CD1c+ mDCs in the BDCA3+ mDC 
sample we identify over sixty proteins differentially expressed between mDC subsets, of 
which we subsequently validated four by flow cytometry. The protein-based signatures we 
derived provide insight into possible functional differences between subsets. Although we 
cannot discuss in detail all the functional implications of the expression differences we have 
identified, several warrant further discussion. Firstly, we demonstrate abundant expression 
of the MCM-family of proteins in CD1c+mDCs, but not in CD16+ monocytes or in pDCs. 
This protein family is essential for cell division. Thus, our data supports previous findings 
that, in contrast to pDCs, a fraction of the blood mDCs population may still be able to 
expand, possibly reflecting an incomplete differentiation state [25]. Our data suggest that 
like pDCs, CD16+ cells may completely lack the potential to expand. The remaining capacity 
of mDCs to divide is interesting from a clinical perspective, as it implies that mDCs after 
isolation may have the potential to be further expanded. This concept may be of interest 
for the development of immunotherapies for cancer or chronic inflammatory diseases 
where obtaining sufficient cell numbers is still a major hurdle.
Secondly, HLA molecule expression demonstrated some marked differences between subset 
suggesting subset-specific antigen presentation. CD1c+ mDCs not only highly express 
antigen presenting CD1c but also highly expressed HLA-DQ as compared to pDCs and 
CD16+ monocytes (but not HLA-DR). In agreement with a previous report, BDCA3+ cells 
uniquely expressed HLA-DO [15]. For these HLA types either a clear (HLA-DO), or a 
unique (HLA-DQ versus HLA-DR) biological function remains to be defined. The 
consequence of this subset specific expression thus remains elusive.
Thirdly, many ER and Golgi located proteins were expressed at higher levels specifically in 
pDCs. Previously it has been shown that in mice, pDCs and to a lesser extend CD8α+ DCs 
(the supposed murine equivalent of BDCA3+ DCs), were reported to display a constitutive 
activation of the unfolded protein response (UPR) as was indicated by the alternative 
splicing of XBP1 [26]. The increase in UPR was required for ER expansion to facilitate rapid 
IFN-α biosynthesis and is reminiscent of plasma cell differentiation [26]. The high levels 
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of ER and glycoprotein biosynthesis and transport proteins that we describe in pDCs 
support the paradigm that immature pDCs are already prepared for rapid IFNα synthesis. 
Proteins related to intracellular protein transport machinery are also overtly expressed in 
immature pDCs, and these may provide important clues to unravel the largely unknown 
IFN-α secretory route. 
From the identified DEPs we confirmed five cell surface receptors by flow cytometry: SIRPα 
and Siglec-9 that bind to CD47 and sialic acids respectively were found to be highly 
expressed on both CD16+ monocytes and CD1c+ mDCs. These receptors share a capacity 
to limit DC function and inflammation and are exploited by bacteria and malignant cells 
to evade immune responses (Läubli et al., PNAS 2016; Ohta at la., BBRC 2010; Barclay et 
al., Ann Rev Imm, 2014). Lack of these receptors may render cells insensitive to this evasion. 
CD1c+ mDC uniquely expressed CD163, a scavenger receptor and PRR for bacteria 
(Kristiansen Nature 2001; Fabriek et al., blood 2009). Siglec-10, which we found selectively 
expressed on CD16+ monocytes, is a putative adhesion receptor and PRR that has been 
reported to be expressed CD16+ but not CD16- monocytes, as well as on moDCs [27-30]. 
Finally, BDCA3+ mDC highly expressed CD93, which was reported to mediate phagocytosis 
and clearance of apoptotic cells and as such may act as an accessory to CLEC9A [31, 32]. 
Our proteome data provided strong evidence for a lack of Caspase-1 in pDC. We validated 
this by Western blotting and show data to suggest that pDCs have a diminished presence 
of inflammasome pathway constituents. Concordantly, pDCs did not respond to 
inflammasome activator ATP, while CD1c+ mDC and CD16+ monocytes did. Our data 
contradicts several previous studies reporting on IL1-β secretion by pDCs [33, 34]. These 
studies show pDCs to secrete picograms of IL1β per ml culture supernatant in response to 
TLR stimulation alone (without inflammasome activation). However this level of IL1β is 
extremely low compared to production by CD16+ monocytes, which we find can secrete 
over a 100-fold more (nanograms) of IL1β/ ml upon TLR and inflammasome stimulation. 
Furthermore it is conceivable that traces (e.g. ±1%) of high IL1β producing cells may be 
present in these pDC preparations isolated by magnetic beads and such cells can contribute 
to the low amount of IL1β found to be secreted. 
Interestingly our proteome data also indicated that although expression of Caspase-1 was 
readily detected in the BDCA3+ enriched samples by proteomics it was lower than in CD1+ 
mDCs and CD16+ DCs, a result we also verified using highly pure cells. Indeed, BDCA3+ 
mDCs responded less to inflammasome activation in the presence of TLR7/8 ligand. This 
stimulus matured BDCA3+ mDCs but did not induce cytokine secretion. However, low 
IL1-β production by BDCA3+ mDC relative to CD1c+ mDCs, in response to the potent 
BDCA3+ mDC-activating stimulus Poly I:C has also been reported [4]. 
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Several recent publications demonstrate that the pDC hallmarks, type I IFN and IRF7 may 
directly inhibit IL-1β and inflammasome activity [35, 36]. In pDCs TLR7 activation by 
Hepatitis C Virus induced type I IFN secretion but neither IL-1β nor IL-18. TLR7 activation 
in monocytes in contrast, induced IL-1β and IL-18 rather than type I IFN [37, 38]. The 
differentiation program involving IRF7 that allows pDCs to secrete large amounts of type 
I IFN may thus downregulate inflammasome pathway constituents, including Caspase-1. 
Although this causal relation still awaits further experimental confirmation, this could 
switch the pDC response to TLR stimulation/ NF-kB activation away from IL-1β and 
towards type I IFNs.  A switch between Type I IFNs and IL-1β could serve to prevent 
excessive damaging inflammation during anti-viral responses. 
Taken together the proteome dataset we describe provides a rich resource to solidly establish 
the phenotypic and functional capacities of human DC subsets and to decipher the 
contribution of each subset to the initiation of immune responses. 
METHODS
Cells
DCs were isolated from aphaeresis products or buffy coats obtained from healthy volunteers 
after written informed consent and according to institutional guidelines. Peripheral Blood 
Mononuclear Cells (PBMCs) were purified via ficoll density gradient centrifugation (Lucron 
Bioproducts, Sint Martens-Latem, Belgium), followed by magnetic bead (Miltenyi Biotec, 
Bergisch Gladback, Germany) or flow cytometric isolation and directly lysed for MS or 
Western blot analysis or used in in vitro experiments (see below and supplementary 
methods for details) 
LC-MS/MS
In brief: Tryptic peptides were analyzed using liquid chromatography (Easy n-LC; Thermo 
Fisher scientific) coupled to a 7-T linear ion trap Fourier-Transform ion cyclotron resonance 
mass spectrometer model (LTQ FT Ultra, Thermo Fisher Scientific). See supplemental 
methods for details. 
MS data processing 
Proteins were identified and quantified from raw mass spectrometric files using MaxQuant 
software version 1.3.0.5 [39]. Database search was performed in Andromeda search engine 
[40] against Human Uniprot database (86,749 entries, June 2012) The protein abundance 
was determined by MaxLFQ as described by [12]. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository 
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with the dataset identifier PXD004678 [41]. (http://proteomecentral.proteomexchange.
org). See supplemental methods for details.
Statistical analysis of protein and RNA data 
See supplemental methods for details. Statistical analysis was performed in the R programing 
environment. Data was visualized using GENE-E software (http://www.broadinstitute.org/
cancer/software/GENE-E) and Biolayout express 3D (version 3.3)   [42]. For protein-protein 
interaction (PPI) analysis we used the STRING PPI web tool (http://string-db.org/; version 
10) and functional annotation was done using DAVID web tool (https://david.ncifcrf.gov/). 
Western blotting and ELISA
According to standard procedures, see supplemental methods for details and antibodies 
used. 
In vitro DC activation
Isolated and pDCs and CD1c+ mDCs were resuspended in X-VIVO 15 (Cambrex) 
containing 2% pooled human serum (Sanquin), pDCs were supplemented with 10 ng/mL 
recombinant human interleukin-3 (rhIL-3; Cellgenix). Both cell types were stimulated 
4hours or overnight with 4 μg/mL R848 followed by 45-minute stimulation with 5mM ATP 
(Sigma). Culture supernatant was taken for ELISA. 
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ABSTRACT
Interleukin-1β (IL-1β) plays a crucial role in inflammation and works as a danger signal 
to activate immune cells, which cannot sense the danger signal themselves. It matures 
dendritic cells (DCs) and initiates their migration towards the lymph node by the 
upregulation of chemokine receptors. Previously we showed that pDCs do not produce 
this cytokine themselves and lack the caspase-1-dependent inflammasome pathway. We 
here demonstrate that at steady state or upon activation, pDCs, in contrast to mDCs, do 
also not express the IL-1β receptor (IL-1R1) and important downstream signaling elements 
and consequently, are insensitive for IL-1β induced maturation. Altogether, these results 
highlight the unique role of pDCs in the inflammatory response that is independent of 
IL-1β. 
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INTRODUCTION
Dendritic cells (DCs) play an important role in sensing bacterial and viral pathogens. Upon 
inflammation or infection, DCs mature and change their phenotype, which enables them 
to migrate to the lymph node and to stimulate T cells [1, 2].  Among the primary blood 
DCs, there are two main subsets, the plasmacytoid dendritic cells (pDCs) and the myeloid 
dendritic cell (mDCs). pDCs respond to viral infections and produce high amounts of type 
I interferons (IFNs), while mDCs known to respond to bacterial pathogens [3-6]. During 
maturation pDCs upregulate markers that interact with T cells and act as costimulatory or 
co-inhibitory molecules (e.g. CD80, CD86, CD40 or PD-L1) [1, 7, 8]. Furthermore, during 
maturation DCs upregulate cytokine and chemokine receptors that alters their sensitivity 
to environmental cues that can further steers and amplify the response and drives their 
migration to the lymph node. The latter is mediated by CCL21 and its receptor CCR7, 
which is upregulated on plasmacytoid dendritic cells (pDCs) and CD1c+ myeloid dendritic 
cells (CD1c+ mDCs) upon stimulation.
Interleukin-1β (IL-1β) is an inflammatory cytokine which belongs to the IL-1 family and 
is mainly produced by monocytes, macrophages and DCs with wide-spread effects on both 
innate and adaptive immune cells [9, 10]. It acts as a danger signal amplifier, in particular 
for cells that cannot sense microbiological pathogens themselves [11]. The release of the 
biological active form of IL-1β by DCs is depending on two signals. The first signal is 
activation of the NF-κB-pathway after the binding to a toll-like receptor to its ligand, which 
leads to the transcription of pro-IL-1β [12]. The second signal is activation of the Caspase-1 
or Caspase-8 containing inflammasome pathway by bacterial metabolites or ATP. Upon 
activation of the inflammasome caspase-1 or caspase-8 gets activated and cleaves pro-IL-1β 
into the active IL-1β form that is subsequently secreted [12]. However, Netea et al. 
demonstrated that freshly isolated human monocytes do only need a single stimulus, since 
they express the active Caspase-1 constitutively [13]. 
Secreted IL-1β is sensed by surrounding cells through the receptor IL-1R1, and for these 
cells the presence IL-1β constitutes a danger signal. In addition IL-1β can act cell-
autonomously and feedforward and induces IL-12 release by DCs [14]. Furthermore, the 
activation of caspase-1 and IL-1β promotes the cell-survival through triggering of the lipid 
metabolic pathways [15] and have a stimulatory effect on TH17 T cells itself [16, 17]. 
However, an overexpression of Caspase-1 and the strong release of IL-1β are known to 
induce apoptosis and are linked to neuronal and endothelial programmed cell death [18-
20]. This illustrates clearly, that the balance of the IL-1β release but also the sensitivity of 
IL-1β is very crucial for the survival and the homeostasis of the cell. 
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Previously, we demonstrated the absence of Caspase-1 in pDCs and a lack of IL-1β release 
by pDCs in response to combined TLR and inflammasome activation. This was in sharp 
contrast to the CD1c+ mDCs, they produced a high amount of IL-1β [21]. Here we follow 
up on this study and investigated how pDCs react on IL-1β. We show that, even upon 
maturation, pDCs hardly express IL-1R1 and related signaling molecules and consistent 
with this low expression are insensitive to IL-1β stimulation. 
RESULTS
The IL-1β receptor gene is differently expressed between pDCs and CD1c+ mDCs
To get insight in the expression of IL-1β receptor on different DC subsets we studied both 
gene- and protein expression on CD1c+ mDCs and pDCs. First, we interrogated an extensive 
database of gene expression profiles of two dendritic cell subsets, CD1c+ mDCs and pDCs, 
in steady state condition and after stimulation [21, 22]. Strikingly, the IL-1β receptor, IL-
1R1 was not or very low expressed on resting pDCs in contrast to resting CD1c+ mDCs. 
Upon stimulation with either GM-CSF and protamine-RNA complexes (pRNA), mDCs 
increased IL-1R1 transcription almost 8-fold. In pDCs, however, the IL-1R1 expression 
levels remained low also upon stimulation with various TLR ligand containing stimuli 
known to activate pDCs (e.g. FSME, pRNA and CpG-P).
 
No Maturation marker upregulation of pDCs upon IL-1β stimulation
The lack of expression of IL-1R1 transcription in pDCs suggest these cells may be 
unresponsive to IL-1β.  To compare the responsiveness of pDCs and CD1c+ mDCs to IL-1β, 
both cell types were stimulated with IL-1β and a cell type specific maturation stimulus as 
a positive control for full stimulation. For CD1c+ mDCs we used R848, for pDCs CpG-P. 
Upon stimulation with IL-1β, CD1c+ mDCs significantly upregulated CD80 expression but 
to a lesser extent than with R848. Consistent with the absence of IL-1R1 mRNA in, pDCs 
showed no significant upregulation of CD80 expression upon IL-1β stimulation.  CpG-P 
readily induced a significant upregulation of CD80 expression on the pDC surface. This 
result indicates that pDCs in contrast to CD1c+ mDCs, are refractory to IL-1β as a 
maturation stimulus to upregulate CD80.
Besides CD80, pDCs also upregulate the chemokine receptor CCR7 during maturation to 
facilitate their migration to the lymph node. To test whether the lack of response to IL-1β 
also applied to this maturation marker, we investigated the expression of CCR7 in both DC 
subsets in response to IL-1β. Again, upon IL-1β stimulation, CD1c+ mDCs significantly 
upregulated CCR7 and now to an even higher extend than R848. Similar to what we 
observed for CD80, pDCs showed no changes in CCR7 expression upon IL-1β stimulation 
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but CpG-P did upregulate CCR7 expression significantly. Taken together, IL-1β potently 
induces the upregulation of CCR7 on CD1c+ mDCs but not on pDCs.
IL1-R1 signaling pathway
Having demonstrated that pDCs lack mRNA transcripts for IL-1R1 and are insensitive to 
IL-1β stimulation we extended our analyses to the signaling cascade downstream of the 
IL-1R1 and proteins that are linked to this receptor (Figure 4). For this we made use of the 
RNA-seq database we previously generated [22]. First, we used string analysis to retrieve 
proteins functionally connected to IL-1β or its receptor. We studied the expression levels 
of these genes in resting and TLR-stimulated pDCs and CD1c+ mDCs. IRAK2, IL-1RN and 
IL-1α gene expression levels were similar as the IL-1R1 gene expression being upregulated 
in CD1c+ mDC upon stimulation with either GM-CSF or pRNA. Low to absent expression 
of these genes was observed in pDC, either in steady state or after stimulation.
Figure 1. IL-1R1 expression on RNA and protein level of pDCs and CD1c+ mDCs upon different stimuli. A) 
RNA-seq data illustrated the different gene expression levels of IL-1R1 upon different clinical grade stimuli (n=3). 
B) IL-1R1 expression measured by flow cytometry. C) Representative figure of IL-1R1 on unstimulated (light 
grey) and pRNA stimulated (dark grey) pDCs, and also unstimulated (light red) and GM-CSF stimulated (dark 
red) CD1c+ mDCs. 
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The genes of TRAF6 and IRAK1 however remain unchanged in all samples irrespective of 
maturation. Remarkably, the expression levels of these genes between the two DC subsets 
were almost identical. Interestingly, IL-36, a recently identified inflammatory cytokine 
belonging to the IL-1 family was highly upregulated in pDCs and also, albeit to a lesser 
extent, in CD1c+ mDCs. 
Figure 2 pDCs showed a significant lower responsiveness to IL-1β than CD1c+ mDCs. pDCs and CD1c+ mDCs 
were incubated overnight with IL-1β and a positive control. R848 was chosen as the positive control for CD1c+ 
mDCs and CPG-P for pDCs. Representative FACS plots show upregulation of the maturation marker CD80 in 
CD1c+ mDCs (A) and pDCs (B). Unstimulated cells are represented in red, IL-1β stimulated cells in blue and the 
positive control is represented in orange. Quantified results are depicted in (C) for CD1c+ mDCs (n=11) and (D) 
for pDCs (n=11). 
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Figure 3. pDCs do not upregulate CCR7 upon IL-1β stimulation in contrast to CD1c+ mDCs. pDCs and CD1c+ 
mDCs were incubated overnight with IL-1β and a positive control. R848 was chosen as the positive control for 
CD1c+ mDCs and CPG-P for pDCs. Representative FACS plots show upregulation of the chemokine receptor 
CCR7 in CD1c+ mDCs (A) and pDCs (B). Unstimulated cells are represented in red, IL-1β stimulated cells in 
blue and the positive control is represented in orange. Quantified results are depicted in (C) for CD1c+ mDCs 
(n=6) and (D) for pDCs (n=6).
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Figure 4. CD1c+ mDCs have a significant higher expression of proteins related to the IL-1R1 signaling pathway. 
A) String network to point out the related genes. B) Schematic overview about the IL-1R1 signaling cascade. C-G) 
Gene levels of proteins that are involved in the IL-1R1 signaling cascade (IRAK2, IL-1A, TRAF6, IRAK1, IL-1RN). 
H) The RNA expression level of IL-36.   
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DISCUSSION
In this study, the expression of the IL-1R1 and its downstream signaling molecules as well 
as the effect of IL-1β on two DC subsets, CD1c+ mDCs and pDCs, was investigated. We 
identified that pDCs lack IL-1β responsiveness and linked that to a lower gene- and protein 
expression of IL-1R1 and related components on pDCs. Since IL-1β is an important 
maturation stimulus and can initiate migration of DCs to the lymph nodes by upregulation 
of CCR7 expression, this insensitivity of pDCs could be of high interest [23-26]. Additionally, 
the stimulation of CCR7 by its ligand CCL19 leads to a stronger immune reaction, by 
inducing several immune-stimulatory cytokines like TNFα, IL-1β, IL-12 [27].
To which extend inflammatory signal can replace direct DC activation induced by pathogen-
associated molecular pattern (PAMP) stimulation in mice has been extensively reviewed 
by Joffre et al. [28]. They concluded that the source of the inflammatory cytokines defines 
if the DC stays quiescent or matures, but only the additional PAMP recognition leads to a 
fully activated DC, which can efficiently activate T cells [28]. In this context, the importance 
between epithelial cells and pDCs was emphasized, since epithelial cells release a number 
of inflammatory cytokines like GM-CSF, IL-33, IL-1β, osteopontin and IL-25 [29]. Most 
likely, pDCs have been specialized to act independent from this caspase-1 dependent 
inflammasomal pathway and have downregulated this pathway. In line with that, we could 
demonstrate that members of the pathway downstream of IL-1R1 are downregulated and 
therefore support this hypothesis.
 Furthermore, during an ongoing allergic reaction, mDCs but not pDCs have been affected. 
In the airways of asthmatic patients mDCs are found, probably recruited from the 
bloodstream, in contrast to pDCs [30]. Most likely, pDCs have been specialized to act 
independent from this caspase-1 dependent inflammasomal pathway and have 
downregulated this pathway. Our data suggest that pDCs are primed to respond to a more 
specialized signal than the other DCs subsets. Interestingly, we here show that pDCs express 
a newly discovered member of the IL-1 family, the IL-36 cytokine. IL-36 is an inflammasomal 
cytokine with T cell activating capacities and contains no predomains or caspase cleavage 
sites [31]. This means, that the release of IL-36 is caspase-1 independent. IL-36 plays in 
several skin diseases an important role, such as psoriasis [32, 33]. The upregulation of IL-36 
suggests the possibility that pDCs switch its inflammatory capacity and sensitivity towards 
a IL-36-dependent mechanism, in contrast to CD1c+ mDC.  However, more studies have 
to be performed to confirm this hypothesis.
Taken together, we demonstrated that pDCs express IL-1R1 to a much lower extent than 
CD1c+ mDCs and therefore lack the sensitivity for IL-1β. These findings are in line with 
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the previously published article that described the downregulation or lack of inflammasome 
dependent proteins in pDCs. As mentioned earlier, this could be explained by a protective 
mechanism such as avoiding the induction of apoptosis. If IL-36 is taking over 
inflammasomal functions in pDCs has to be studied in follow up experiments. 
MATERIAL AND METHODS
Cell isolation and culture. For functional assays, DCs were isolated from buffy coats of 
healthy volunteers (Sanquin, Nijmegen, the Netherlands). Peripheral blood mononuclear 
cells (PBMCs) were isolated by using Ficoll density centrifugation (Lymphoprep; Axis-
Shield PoC AS, Oslo, Norway). CD1c isolation kit of Miltenyi Biotec (Bergisch-Gladbach, 
Germany) was used to obtain CD1c+ mDCs, by following manufacturer’s instructions. 
Monocytes were depleted by the use of CD14 microbeads (Miltenyi Biotec). Next, pDCs 
were purified by positive selection using anti–BDCA-4–conjugated magnetic microbeads 
(Miltenyi Biotec). DCs were cultured in X-VIVO-15 medium (Lonza, Basel, Switzerland) 
supplemented with 2% human serum (Sanquin). DCs were stimulated with: FSME (5%; 
Baxter AG, Vienna), pRNA (15µg/ml), CpG-P (5µg/ml; Miltenyi Biotech, Germany), GM-
CSF (800 U/ml; (Cellgenix, Freiburg, Germany), R848 (4μg/ml, Enzo Life Sciences, 
Farmingdale, NY). pRNA complexes were prepared fresh 5-10 minutes before adding to 
the cell culture. pDCs were cultured with 10 ng/mL IL-3 (Cellgenix, Freiburg, Germany) 
as a survival factor in addition to the stimuli.
Protamine-RNA complexes. pRNA complexes were made freshly before adding to the cells. 
Protamine (protaminehydrochloride MPH 5000 IE/ml; Meda Pharma BV Amstelveen, the 
Netherlands) was diluted to 0.5 mg/ml in RNase free water and mixed with 2-kbp-long 
single-stranded mRNA (coding for gp100). It was extensively mixed and incubated for 5-10 
minutes at room temperature, before added to the cells.
FACS phenotyping. The phenotype of pDC and CD1c+ mDC populations was determined 
by flow cytometry. DC purity was assessed by double staining CD11c+/CD1c+ for CD1c+mDCs 
(above 95%) and BDCA2/CD123 for pDCs (above 95%; all Miltenyi Biotec) [34]. The 
following primary monoclonal antibodies (mAbs) were used to determine the maturation 
state of the DCs: anti–CD80-APC, anti-CCR7-PE (both BD Bioscience Pharmingen, San 
Jose, CA). Anti-IL1-R1-APC (R&D Systems, Minneapolis, MN) was used to stain for the 
IL-1R1 receptor. Measurements were performed on FACSVerse flowcytometer (BD).
RNA sequencing data. The RNA sequencing data we refer to is deposited at the Gene 
Expression Omnibus (GEO; accession number: GSE89442).
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String network. The evaluation is performed with the network provided by the STRING 
database version 10.5 [35]. Edges are calculated based on the confidence score above 0.700. 
The thickness of the line indicates the strength of the data support. The maximum number 
of interaction to be displayed was limited to 10.
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ABSTRACT
Effective stimulation of immune cells is crucial for the success of cancer immunotherapies. 
Current approaches to evaluate the efficiency of stimuli are mainly defined by known flow 
cytometry-based cell activation or cell maturation markers. This method however does not 
give a complete overview of the achieved activation state and may leave important side 
effects unnoticed. Here, we used an unbiased RNA sequencing (RNA-seq)-based approach 
to compare the capacity of four clinical-grade dendritic cell (DC) activation stimuli used 
to prepare DC-vaccines composed of various types of DC subsets; the already clinically 
applied GM-CSF and Frühsommer meningoencephalitis (FSME) prophylactic vaccine and 
the novel clinical grade adjuvants protamine-RNA complexes (pRNA) and CpG-P. We 
found that GM-CSF and pRNA had similar effects on their target cells, whereas pRNA and 
CpG-P induced stronger type I interferon (IFN) expression than FSME. In general, the 
pathways most affected by all stimuli were related to immune activity and cell migration. 
GM-CSF stimulation, however, also induced a significant increase of genes related to 
nonsense-mediated decay, indicating a possible deleterious effect of this stimulus. Taken 
together, the two novel stimuli appear to be promising alternatives. Our study demonstrates 
how RNA-seq based investigation of changes in a large number of genes and gene groups 
can be exploited for fast and unbiased, global evaluation of clinical-grade stimuli, as 
opposed to the general limited evaluation of a pre-specified set of genes, by which one 
might miss important biological effects that are detrimental for vaccine efficacy.
201751 proefschrift_Till Mathan_titel_kleur.indd   92 23-02-18   19:49
Unbiased evaluat ion of  adjuvants  for  cancer  immunotherapy
93
5
INTRODUCTION
Antigen presenting cells, such as Dendritic cells (DCs), play a central role in many 
immunotherapies because of their ability to induce immune responses or to promote 
immune tolerance by interacting with CD4+ and CD8+ T cells. For T cell activation to occur, 
DCs need to mature and migrate to the lymph nodes. DC immunotherapies aim to 
strengthen antitumoral immune responses by boosting T cell activation [1, 2]. In such 
therapies, DCs are isolated, activated and loaded with tumor antigen and then given back 
to the patient. Vaccine DCs are anticipated to promote antitumor responses by presenting 
tumor antigen in the context of costimulatory molecules and immune-stimulatory cytokines 
[3-7]. Upon activation, DCs upregulate costimulatory markers like CD40 and CD80, but 
also co-inhibitory markers, such as PD-L1, PD-L2, IL-10 and TGF-β, which are essential 
for the termination of an immune response. Expression of the right maturation markers 
and secretion of the right cytokines is thus important for vaccine success and these therefore 
need to be taken into account when selecting the optimal adjuvant for the activation of 
vaccine DCs.
We perform immunotherapies with naturally occurring DCs, namely CD1c+ myeloid 
dendritic cells (mDCs) and plasmacytoid dendritic cells (pDC) [8, 9]. These two subsets 
possess complementary phenotypes: they secrete different cytokines, express different 
pattern recognition receptors (PPR), and even take different, incompletely understood, 
migratory routes [10-14]. Mature plasmacytoid DCs respond to viruses and are known to 
produce large amounts of type I IFNs upon activation and may also induce T cell responses 
[15-20]. Their counterparts, the CD1c+ mDCs, respond to various microbial and fungal 
stimuli and induce Th1 responses via the production of IL-12 upon maturation [11, 21-23]. 
Successful activation of naïve CD8+ T cells to cytotoxic CD8+ lymphocytes (CTLs) is of high 
interest for immunotherapies, since CTLs specifically target the cancerous cells [24, 25]. In 
several clinical studies, the presence of CTLs was associated with a higher survival or 
increased clinical response [26-28]. Taken together, because both DC subsets are able to 
provoke a Th1 response, combining them may increase the efficacy of the antitumor 
immune response. Our clinical trials with either pDCs, stimulated by FSME (an inactivated 
tick borne encephalitis virus that most likely binds to TLR7/8), or with CD1c+ mDCs using 
GM-CSF (a growth factor that promotes myeloid cell maturation), highlighted the anti-
tumor potential and positive clinical outcome in melanoma patients [8, 9].
The only available good manufacturing practice (GMP) grade TLR7/8 ligand is pRNA, a 
complex of protamine and mRNA, which most likely triggers TLR7/8, similar to FSME 
[29]. Sköld et al. have recently shown that pRNA activates CD1c+ mDCs and pDCs and 
induces them to release IL-12 and IFN-α, respectively, making it a promising candidate to 
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use for vaccines containing both subsets [30]. These findings prompted us to further inspect 
the effect of pRNA on DC activation. Furthermore, we investigated another novel clinical 
grade pDC activation stimulus, CpG-P. CpG ODNs are short single-stranded DNA 
molecules containing unmethylated CpG dinucleotides and can be divided in different 
classes depending on their effects. CpG-C and CpG-P combine both effects of CpG-A and 
CpG-B, namely strong IFN-α release and strong maturation marker upregulation [31, 32].
In our study we obtained and analyzed RNA sequencing data of the two DC subsets using 
these new clinical grade adjuvants conditions to obtain a comprehensive and unbiased 
overview of the effect of each stimulus on the phenotype of the activated DCs. Focusing 
only on specific maturation markers and cytokine may lead to a loss of relevant findings. 
Recently, the relevance of implementing systems biology in vaccine research has been 
demonstrated by studying the effect of human adjuvants in animal models with 
transcriptome profiling [33-35]. Because of its unbiased nature, system vaccinology may 
help to understand which immunological processes are detrimental for vaccine success 
[36-38]. In the present study, we applied principal coordinate analysis (PCoA) and gene 
ontology (GO) analysis to evaluate the effect of each adjuvant on the whole cell rather than 
selected maturation markers and cytokines only. Using these approaches, we compared the 
previously used DC activation stimuli, GM-CSF for CD1c+mDCs and FSME for pDCs, 
with the novel stimuli, pRNA and CpG-P, and validated several of our findings with 
functional assays. Our data indicate that both pRNA and CpG-P are suitable clinical grade 
adjuvants for the activation of either both DC subsets together or pDCs alone.
RESULTS
RNA-seq gene expression levels are comparable with protein levels
To evaluate the transcriptome of the two DC subsets upon activation with different stimuli, 
we performed whole-cell RNA sequencing of magnetic bead isolated CD1c+ mDCs and 
pDCs of the same donors. To this aim, DC transcriptomes were analyzed directly after 
isolation or following 6 hours of stimulation with either IL-3 alone, FSME and IL-3 or 
pRNA and IL-3 (pDCs) or GM-CSF, pRNA (CD1c+ mDCs). First, we were interested in 
whether this approach would give comparable results as targeted flow cytometry evaluation 
of established DC maturation markers. Here we chose the markers CD80, PDL-1, and CD40 
(Figure 1A-C) as representatives for the maturation state of these DC subsets. CD80 is a 
co-stimulatory maturation marker also used in our clinical set up to determine the 
maturation state of the DCs [8, 39]. PD-L1 as a co-inhibitory and CD40 as an additional 
co-stimulatory marker were considered suitable candidates to complete the set, because 
both maturation markers are known to be expressed on both cell subsets [40]. Comparing 
the different conditions of pDCs with each other, we found that the overall pattern of RNA 
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and protein expression was similar. The survival factor IL-3 showed no or very little effect 
on the expression of the maturation markers, except on CD40 (Figure 1C). FSME and 
pRNA, showed a similar upregulation of maturation markers CD80, PDL-1 and CD40 on 
pDCs. In CD1c+ mDCs, GM-CSF or pRNA caused an upregulation of all maturation 
markers, at both RNA and protein levels. However, there were some differences in the 
strength of the two stimuli: pRNA appeared to have a stronger affect on CD80 and PD-L1 
RNA and protein expression. GM-CSF induced stronger CD40 RNA expression but this 
was not found at the protein level. In order to further delineate the relation between RNA-
seq reads and protein expression levels, we performed a Spearman nonparametric 
correlation analysis with the RNA sequencing samples of the 3 donors and compared them 
to protein expression values of 6 different donors. All three maturation markers showed 
strong correlations between RNA and protein levels (CD80: r2=0.902, p=0.00545; PD-L1: 
r2=0.814, p=0.026; CD40: r2=0.822, p=0.0232). Altogether, RNA seq data well reflected flow 
cytometry data indicating the biological relevance of changes in RNA expression values. 
Furthermore, this first analysis suggests that pRNA is equally or even more potent than 
currently used clinical grade stimuli in the activation of CD1c+ mDCs and pDCs.
Clinical grade stimuli have similar overall effects on both cell types
Having confirmed the validity of RNA-seq for evaluating DC maturation status, we were 
interested in how specific stimuli affect the entire DC transcriptome, rather than a small 
pre-defined set of maturation markers. Therefore, we applied principal coordinates analysis 
(PCoA) on the gene expression data of all DC types and conditions tested, separately per 
donor. The first two principal coordinates are shown in Figure 2A. The first coordinate (X 
axis) aligned roughly with the cell type (pDC versus CD1c+ mDC), whereas the second 
coordinate reflected maturation status. The overall picture was similar between the three 
donors, indicating good reproducibility of the RNA sequencing.
In both DC subsets the new stimulus, pRNA, showed a similar effect as the previously used 
stimuli FSME and GM-CSF. While the differences in effects between GM-CSF and pRNA, 
as measured by the first two principal coordinates, were very small for CD1c+ mDCs, the 
differences between stimuli were more pronounced on pDCs. Using the unstimulated pDCs 
as the reference point, the FSME sample and pRNA did align along the same axis, but pRNA 
was located further away from the unstimulated cells. This suggests that both stimuli affect 
the RNA expression of roughly the same genes, but that pRNA has an overall stronger effect 
on these genes. Furthermore, the data indicated that upon stimulation, the differences 
between the two DC phenotypes increased.
To directly compare the established and the novel stimuli for each of the two cell types, we 
correlated the fold-changes of each gene relative to unstimulated cells (for CD1c+ mDCS) 
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or to IL3-treated cells (for pDCs) of existing and novel activation stimuli (Figure 2B). Both 
plots confirmed the overall similar effect of the existing and novel stimuli on the 
transcriptome we already observed by PCoA. In line with PCoA, a slight skewing of the 
pDC correlation plot towards pRNA indicated that indeed pRNA had a stronger effect than 
FSME on mostly the same set of genes. Interestingly, for pDCs more genes were highly 
upregulated (>10 fold) than highly downregulated by both stimuli, whereas for CD1c+ 
mDCs this difference was less pronounced (Figure 2B). 
Figure 1. RNA-seq results represent protein levels. A) Flow cytometry histograms for three maturation markers 
(CD80, PD-L1 and CD40) on pDCs and CD1c+ mDCs. For CD1c: Light grey represents unstimulated samples, 
dark grey represents GM-CSF samples, and black represents pRNA samples. For pDC: bright transparent grey 
represents the unstimulated samples, light grey represents the IL-3 samples, grey represents FSME and black 
represents pRNA samples. B) Gene expression levels of the 3 donors of the RNA-seq. C) Correlation plot of the 
RNA-seq counts/1 million reads set out against the geometric mean fluorescence intensity as measured by flow 
cytometry (protein level). Throughout this paper, error bars represent standard error of the mean.
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To find out which biologically coherent gene groups were most affected by the different 
stimuli, a gene ontology (GO) term analysis was performed (Table 1) on all significantly 
(p<0.05 after multiple testing correction with the Benjamini-Hochberger method) up- and 
downregulated genes of each subset. This qualitative method also provided insight in 
affected pathways and gene groups not directly connected to DC maturation. Overall, all 
stimuli most strongly affected immune response-related genes. However, GM-CSF treatment 
of CD1c+ mDCs also clearly affected a number of gene clusters that are not directly linked 
to immune response. Of note, one of these clusters was “nonsense-mediated decay” [41], 
pointing to a possible deleterious effect.
Together, the whole-transcriptome analysis indicated that pRNA had similar effects on 
both cell types as the existing cell type-specific stimuli. However, pRNA appeared to have 
an overall stronger maturation effect on pDCs and a similar effect on CD1c+ mDCs 
compared to the previously used stimuli. Importantly, unlike GM-CSF, pRNA did not have 
any obvious negative effects on CD1c+ mDCs. 
Figure	2	
Figure 2. RNA-seq-based global assessment of DC responses to clinical stimuli. A) Principal coordinates 
analysis (PCoA) of pDCs and CD1c+ mDCs was performed for each of the stimuli to compare their similarities 
in gene expression. Each point represents the transcriptome of the respective condition and the analysis was based 
on the first and second coordinate. On the x-axis the principle coordinate one (PCO1) is displayed, on the y-axis 
the principle coordinate two (PCO2). B) Correlation plots depicting the gene expression changes upon each 
stimulus for each subset. Each point represents a gene.
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Table 1 Clinical stimuli have similar effect on gene clusters in pDCs, but less in CD1c+ mDCs. 
Changes in gene expression clusters were detected by performing a GO term analysis. Of each 
stimulus the top 10 most differential expressed gene clusters were selected. The description for each 
gene cluster is mentioned in the columns. Th  ontology defines the sub-ontology: molecular function 
(MF), cellular component (CC) and biological process (BP). N genes stands for the total amount of 
genes for this gene cluster and N up/down the ones, which changed their expression values upon the 
stimulus. The table is sorted on the –log10 p-value, which can be found in the column on the very right.  
Table 1. Clinical stimuli affect similar gene clusters in pDCs but less so in CD1c+ mDCs. Changes in gene 
expression clusters were detected by performing a GO term analysis. Of each stimulus the top 10 most differential 
expressed gene clusters were selected. The description for each gene cluster is mentioned in the columns. The 
ontology defines the sub-ontology: molecular function (MF), cellular component (CC) and biological process 
(BP). N genes stands for the total amount of genes for this gene cluster and N up/down for the number of genes 
that changed their expression values upon the stimulus. The table is sorted on the –log10 p-value, which can be 
found in the column on the very right.
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Discrepancies between pRNA stimulated pDCs and CD1c+ mDCs
Besides the overall similarities among used stimuli, we also observed differences between 
the effects of the existing and novel stimuli on each cell subset. A limitation of the GO term 
analysis is that it does not take into account the magnitude of the expression changes and 
therefore no conclusions on these can be drawn. Therefore, as a complementary approach, 
we generated Volcano plots of the overall fold-changes and p-values for each gene based 
on the combined data from all 3 donors. These plots show that pRNA in CD1c+ mDCs 
caused a strong upregulation of cytokines and migration-related genes (Figure 3). In CD1c+ 
mDCs stimulated with GM-CSF, several chemokines (CXCL5, CCL1 CSF1, CCL24 and 
CCL22) were upregulated 12-13 fold. Upon activation with pRNA, chemokines were once 
again found among the most upregulated genes. Except for CXCL5 and CCL17, these genes 
were upregulated to a very similar extent as upon GM-CSF stimulation. Comparing the 
chemokines with each other, the fold changes were almost on the same level between the 
two stimuli (Figure 3A and B). 
In pDCs, multiple genes related to type I and III interferons (IFN-α and IFN-λ) were found 
among the most strongly and significantly upregulated genes. While pRNA lead to a 
significant increase of the transcription of various subtypes of IFN-α and IFN-λ (IL28/ 
IL29), FSME upregulated the chemokines CXCL9, CXCL10 and CXCL11 when compared 
to unstimulated pDCs. As already indicated by PCoA and correlation plots (Figure 2), the 
overall extent of gene expression increase upon FSME was less than upon pRNA stimulation. 
For instance, whereas FSME caused a >10-fold increase for only 3 genes, pRNA did so for 
26 genes. Several IFN-α subtypes showed 13-fold increases when stimulated with pRNA, 
compared to 9- to 10-fold for FSME (Figure 3C and 3D). As expected the difference between 
DC subtypes was most prominent for type I IFN, pRNA induced no IFN-α production in 
CD1c+ mDCs in contrast to high levels in pDCs. In pDCs, all 13 type I IFN genes were 
upregulated upon pRNA stimulation in all 3 donors (Figure 4A). We confirmed this 
observation at the protein level in 7 donors and detected a significantly higher (10-fold, 
p<0.001) release of IFN-α upon pRNA compared to FSME stimulation (Figure 4B).
To assess the effect of pRNA on CD1c+ mDC, we assessed additional immunostimulatory 
cytokines that are known to be relevant for this subset. Based on the RNA-seq data, the 
gene expression of the immunostimulatory cytokines IL-12p40, IL-23 and IL-6 increased 
significantly upon pRNA stimulation (Figure 5A). TNF-α, another immunostimulatory 
cytokine, was increased on both pDCs and (less strongly) on CD1c+ mDCs. Additionally, 
the transcription of the immunoinhibitory cytokine IL-10 increased by pRNA stimulation 
compared to the unstimulated and GM-CSF-stimulated samples. We chose IL12p70 and 
TNF-α as representing cytokines to confirm the RNA-seq results on the protein level (Figure 
5B). IL-12p70 release showed the same pattern as the RNA-seq counts, whereas for TNF-α 
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release the results differed slightly from the RNA-seq data: On protein level, pRNA was the 
most effective stimulus for TNF-α production on both cell types, whereas the RNA-seq 
counts suggested GM-CSF as a slightly more potent TNF-α stimulus. 
Taken together, our results suggest pRNA to be a potent activation stimulus for pDCs as 
well as CD1c+ mDCs, reflected by a strong upregulation of type I IFN and chemokines.Figure	3	
Figure 3. Stimuli effects on individual genes. A-D) Volcano plots representing the gene expression changes 
(x-axis: log fold) together with the statistical significance (y-axis: -10log p-value). Each condition was compared 
to the respective unstimulated cell type. Genes with a log fold change of more than 10 were labeled with the gene 
name. A) GM-CSF stimulated CD1c+ mDC; B) pRNA stimulated CD1c+ mDCs; C) FSME stimulated pDCs; D) 
pRNA stimulated pDCs.
201751 proefschrift_Till Mathan_titel_kleur.indd   101 23-02-18   19:49
CHAPTE R 5
102
CpG-P as a clinical grade stimulus for pDCs
Finally, we investigated CpG-P, a novel clinical grade TLR9 agonist, as a pDC-specific 
activator. These synthetic oligonucleotides mimic the effect of bacterial DNA and therefore 
may support Th1 responses. We used RNA-seq on pDCs from two donors to evaluate the 
effect of CpG-P on pDCs and validated our findings with additional functional assays on 
protein level. For that purpose, we incorporated the CpG-P stimulated pDC samples into 
the PCoA analysis and evaluated their positions. The CpG-P samples appeared to be similar 
to pRNA in Donor 2 and close to both pRNA and FSME in Donor 3 regarding overall gene 
expression levels (Figure 6A). These results suggested that CpG-P is a strong activation 
stimulus for pDCs. To get a more detailed view of the changes in gene expression of DC-
specific genes, we focused on the DC maturation markers shown in Figure 1. CpG-P 
induced a stronger upregulation of transcripts and proteins of all 3 maturation markers 
than FSME and pRNA (Figure 6B & C). In addition to the maturation markers, the release 
of type I IFN was strongly upregulated by CpG-P (Supplementary Figure 1). Altogether, 
our RNA-seq method suggests CpG-P as a strong adjuvant for pDCs.
Figure	4	
Figure 4. High type I/III interferon production of pDCs upon pRNA stimulation. A) Heat map of the type I/
III interferon genes. Red colour represents high expression and blue low expression. B) Type I interferon levels 
on protein level measured in the supernatant of the stimulated cells after an overnight incubation (n=7).
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Figure	5	
Figure 5. Pro-and anti-inflammatory cytokine release by CD1c+ mDCs and pDCs. A) RNA expression values 
of several pro-inflammatory (IL-12p70, TNF-α, IL-23 and IL6) and anti-inflammatory cytokines (IL-10 and 
TGF-β) of pDCs and CD1c+ mDCs. B) IL-12p70 and TNF-α levels on protein level were measured in the 
supernatant of the stimulated cells after overnight incubation (n=3).
201751 proefschrift_Till Mathan_titel_kleur.indd   103 23-02-18   19:49
CHAPTE R 5
104
DISCUSSION
In this study, we aimed to evaluate the efficiency of two novel clinical grade adjuvants in a 
comprehensive and unbiased manner. We therefore used RNA-seq to evaluate the effects 
of each stimulus on total gene expression in two DC subsets of interest for immunotherapy. 
This approach allowed us to directly and extensively compare the effects of different 
adjuvants on DC phenotypes, beyond conventional maturation markers [40]. With our 
approach we translated changes on the whole-transcriptome level to possibly functionally 
Figure	6	
Figure 6. Assessment of CpG-P as a clinical-grade stimulus. A) PCoA of pDCs of donor 2 and 3 with CpG-P 
data included in the figure. Each point represents the transcriptome of the respective condition and the analysis 
was based on the first and second coordinate. B) Upregulation of the maturation markers on pDCs at RNA-seq 
level upon indicated stimuli (n=2). Upregulation of the maturation markers on pDCs at protein level upon the 
indicated stimuli (n=7).
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relevant effects. Firstly, the results revealed the effect of different stimuli in each donor and 
allowed us to draw conclusions based on these patterns. Secondly, the similarity of the 
results in all three donors indicated good reproducibility of this method. Importantly, we 
were able to confirm RNA-seq expression changes regarding maturation marker expression 
and cytokine release on protein level and therefore validate the expression differences we 
observed in the transcriptome. This allowed us to draw conclusions about the efficacy of 
the tested clinical grade stimuli. 
The PCoA analysis generated a useful initial summary of the whole-transcriptome data 
into a simplified representation that nevertheless revealed striking relations between the 
individual datasets. Importantly, this approach allowed for an overall assessment of the 
“strength” of each stimulus. This analysis suggested that pRNA is potentially a stronger 
pDC stimulus than FSME, with qualitatively similar effects as indicated by the GO analysis 
(Table 1). We demonstrated in a previous study that pRNA–induced activation of CD1c+ 
mDCs leads to significantly higher IL12p70 release and a similar TNF-α production as 
R848 and Poly IC, combined with lower immunosuppressive IL-10 production [30]. The 
robustness of these findings was corroborated by our functional assays on protein level. 
Additionally, based on PCoA, CpG-P was identified as a potentially strong stimulus for 
pDCs. Our functional assays confirmed this finding by showing that CpG-P not only 
upregulated the maturation markers significantly more than the other stimuli, it also led 
to a very high release of immunostimulatory cytokines such as IFN-α. Since type I IFNs 
are known to play important roles in T cell activation, these findings suggest that CpG-P 
could prove to be a potent pDC stimulus in immune therapies [42]. Interestingly, the 
transcriptome changes by CpG-P stimulation are very similar to the ones induced by pRNA, 
even though they stimulate different TLRs.
GM-CSF is widely used to differentiate in vitro monocytes into DCs and its high levels are 
connected to higher numbers of moDCs in vivo [43-47]. However, GM-CSF has been shown 
to inhibit pDC development via IRF8 [48]. GO-analysis of the effect of GM-CSF on CD1c+ 
mDC indicated that upon GM-CSF stimulation, a significant number of genes belonging 
to the GO term “nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 
(NMD)” were differentially expressed. This NMD pathway activates the destruction of 
mRNAs containing premature stop codons, which has negative side effects [49, 50]. How 
this pathway affects the maturation process of CD1c+ mDCs and their functionality has 
not been reported yet, but it may be involved in inflammatory processes [51]. An unexpected 
side-effect like this would not have been found by using FACS analysis on an a priori 
defined, limited set of genes. This should be considered when GM-CSF is clinically applied, 
as inducing this gene cluster may have a negative impact on CD1c+ mDC function.
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Other studies have already applied RNA-seq to characterize DCs upon stimulation with 
antigen. For example, two recent studies have applied single cell RNA-seq in a non-clinical 
context to identify differences between DC subsets and the effect of pathogenic stimuli on 
these cells [52, 53]. Furthermore, there is considerable interest to apply RNA-seq in the 
clinic for diagnostic purposes, with several applications already underway [54]. 
Complementing these efforts, our study highlights the usefulness of RNA-seq based 
approaches for the design of clinical therapies, as it allows to determine the effects of certain 
stimuli on the target cells. In addition to RNA-seq, proteomics is another powerful unbiased 
approach that can be used to study the differences between DC subsets [55].
Taken together, a whole-transcriptome approach was used to analyze the effect of clinical 
grade stimuli on human DCs. This method provides a global, unbiased overview of how 
cells react to certain stimuli. In our case, we could confirm pRNA as a potent stimulus for 
both pDCs and CD1c+ mDCs and introduce CpG-P as a new clinical grade stimulus for 
pDCs. In vitro, both new stimuli outperformed or had clear advantages over the existing 
stimuli. 
MATERIAL AND METHODS
Cell isolation and culture. For functional assays, DCs were isolated from buffy coats of 
healthy volunteers (Sanquin, Nijmegen, the Netherlands) after obtaining written informed 
consent per the Declaration of Helsinki and according to institutional guidelines. For RNA-
seq measurements, cells were obtained from aphaeresis of 3 different donors. Peripheral 
blood mononuclear cells (PBMCs) were isolated by using Ficoll density centrifugation 
(Lymphoprep; Axis-Shield PoC AS, Oslo, Norway). CD1c isolation kit of Miltenyi Biotec 
(Bergisch-Gladbach, Germany) was used to obtain CD1c+ mDCs, by following 
manufacturer’s instructions. Subsequently, monocytes were depleted by either plastic 
adhesion, or by the use of CD14 microbeads (Miltenyi Biotec). Next, pDCs were purified 
by positive selection using anti–BDCA-4–conjugated magnetic microbeads (Miltenyi 
Biotec). DCs were cultured in X-VIVO-15 medium (Lonza, Basel, Switzerland) 
supplemented with 2% human serum (Sanquin). DCs were stimulated with: FSME (5%; 
Baxter AG, Vienna), pRNA (15µg/ml), CpG-P (5µg/ml; Miltenyi Biotech, Germany), GM-
CSF (800 U/ml; (Cellgenix, Freiburg, Germany). pRNA complexes were prepared fresh 
5-10 minutes before adding to the cell culture. pDCs were cultured with 10 ng/mL IL-3 
(Cellgenix, Freiburg, Germany) as a survival factor in addition to the stimuli.
Protamine-RNA complexes. pRNA complexes were made freshly before adding to the cells. 
Protamine (protaminehydrochloride MPH 5000 IE/ml; Meda Pharma BV Amstelveen, the 
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Netherlands) was diluted to 0.5 mg/ml in RNase free water and mixed with 2-kbp-long 
single-stranded mRNA (coding for gp100). It was extensively mixed and incubated for 5-10 
minutes at room temperature, before added to the cells.
FACS phenotyping. The phenotype of pDC and CD1c+ mDC populations was determined 
by flow cytometry. DC purity was assessed by double staining CD11c+/CD1c+ for 
CD1c+mDCs (above 95%) and BDCA2/CD123 for pDCs (above 95%; all Miltenyi Biotec) 
[56]. The following primary monoclonal antibodies (mAbs) were used to determine the 
maturation state of the DCs: anti–CD80-APC, anti–PD-L1-APC (all BD Bioscience 
Pharmingen, San Jose, CA); and anti–CD40-PE (Beckman Coulter, Marseille, France). 
Measurements were performed on FACSCalibur and FACSVerse flowcytometers (BD).
 
Cytokine detection. Supernatant was taken from each sample after 6 hours of incubation 
and analyzed with standard sandwich ELISAs detecting IFN-α (Bender Medsystems, 
Vienna, Austria).
RNA sequencing. CD1c+ mDCs and pDCs were isolated as described above and total RNA 
was extracted using Trizol (Invitrogen, MA, USA), following the standard protocol. The 
quality control of the isolated RNA (concentration, RIN, 28S/18S and size) was performed 
with Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA). RNA sequencing 
and read alignment were performed by BGI TECH SOLUTIONS (Hong Kong). Reads were 
aligned to human genome version 19. RNA sequencing data is deposited at the Gene 
Expression Omnibus (GEO; accession number: GSE89442).
Hierachical clustering. Data was transformed to log values for performing hierarchical 
clustering analysis using the standard settings of the GENE-E software (Broad institute, 
Cambrige, MA; http://www.broadinstitute.org/cancer/software/GENE-E/index.html).
Statistical analysis. Data was analyzed using the R platform for statistical computing. 
Specifically, the package “edgeR”, version 3.12, was used for whole-transcriptome principal 
coordinates analysis (using the “plotMDS” command), differential expression analysis, and 
GO term analysis [57]. Differential expression was determined by fitting a generalized linear 
model using the “glmFit” command, and significance was determined using the likelihood 
ratio test provided by the “glmLRT” command [58]. The R scripts used to perform the data 
analysis are available as Supporting Information for this manuscript.
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SUPPLEMENTARY
Supplemntary	Figure	
Supplementary Figure 1. High type I interferon production of pDCs upon CpG-P stimulation. A) Type I 
interferon release on protein level as measured in the supernatant of DCs after overnight incubation with the 
indicated stimuli (n=7).
201751 proefschrift_Till Mathan_titel_kleur.indd   112 23-02-18   19:49
Unbiased evaluat ion of  adjuvants  for  cancer  immunotherapy
113
5
201751 proefschrift_Till Mathan_titel_kleur.indd   113 23-02-18   19:49
201751 proefschrift_Till Mathan_titel_kleur.indd   114 23-02-18   19:49
CHAPTER
Submitted
Department of Tumor Immonology, Radboud Institute for Molecular Life Sciences, Radboudumc, 
Nijmegen, the Netherlands
Cancer Center Karolinska, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 
Sweden
Department of Medical Oncology, Radboud Institute for Molecular Life Sciences, Radboudumc, 
Nijmegen, the Netherlands
Current address: Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm 
University, Stockholm, Sweden
Current address: Allergic Inflammation DPU, R&D Respiratory TAU, GSK Medicines Research 
Centre, Stevenage, Hertfordshire, UK
Annette E. Sköld1,2,*, Till S. M. Mathan1, Jasper J. P. van Beek1, Michelle 
D. van den Beukelen1, Simone P. Sittig1, Florian Wimmers1, Ghaith 
Bakdash1,#, Gerty Schreibelt1, I. Jolanda M. de Vries1,3,§
Naturally Produced Type I IFNs Enhance 
Myeloid Dendritic Cell Maturation and 
IL-12p70 Production and Mediate Elevated 
Effector Functions in Innate and Adaptive 
Immune cells
6
201751 proefschrift_Till Mathan_titel_kleur.indd   115 23-02-18   19:49
CHAPTE R 6
116
ABSTRACT
There has recently been a paradigm shift in the field of dendritic cell (DC)-based 
immunotherapy, where several clinical studies have confirmed the feasibility and 
advantageousness of using directly isolated human blood-derived DCs over in vitro 
differentiated subsets. There are two major DC subsets found in blood; plasmacytoid DCs 
(pDCs) and myeloid DCs (mDCs), and both have been tested clinically. CD1c+ mDCs are 
highly efficient antigen-presenting cells that have the ability to secrete IL-12p70, while 
pDCs are professional IFN-a-secreting cells that are shown to induce innate immune 
responses in melanoma patients. Hence, combining mDCs and pDCs poses as an attractive, 
multi-functional vaccine approach. However, type I IFNs have been reported to inhibit 
IL-12p70 production and mDC-induced T cell activation. In this study, we investigate the 
effect of IFN-a on mDC maturation and function. We demonstrate that both recombinant 
IFN-a and activated pDCs strongly enhance mDC maturation and increase IL-12p70 
production. Co-cultured mDCs and pDCs additionally have beneficial effect on NK and 
NKT cell activation and also enhances IFN-g production by allogeneic T cells. In contrast, 
the presence of type I IFNs reduces the proliferative T cell response. The mere presence of 
a small fraction of activated pDCs is sufficient for these effects and the required ratio 
between the subsets is non-stringent. Taken together, these results support the usage of 
mDCs and pDCs combined into one immunotherapeutic vaccine with broad 
immunostimulatory features.
Précis
In this manuscript, a stimulatory effect of IFN-a producing pDCs on mDC function and IL-12p70 secretion 
is described. Combining these two blood-derived DC subsets hence poses as an interesting concept for cell-based 
anti-cancer immunotherapy.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen presenting cells, best known for their ability 
to activate and polarize naïve T cells against specific antigens [1]. These characteristics have 
made DCs an interesting target in vaccine development, and several different protocols have 
been tested clinically [2]. A classical source of DCs used in clinical studies are monocyte-
derived DCs (moDCs), which are differentiated from monocytes ex vivo [3]. However, recent 
progress within the field has made it feasible to use naturally circulating blood DCs as the 
source of cells in therapeutic vaccination against cancer. Both pDCs and CD1c+ mDCs have 
been tested clinically in cancer patients and antigen-specific T cell responses and prolonged 
overall survival have been achieved [4, 5]. Using natural blood DCs in cell-based 
immunotherapy is more beneficial as compared to moDCs in many aspects, such as reduced 
ex vivo culture time, less exhaustion, and high migratory capacity [6]. 
In general, mDCs are displaying “classical” DC features, such as efficient antigen uptake 
and presentation, and have the ability to initiate T helper (Th) 1 responses by production 
of the Th1-polerizing cytokine interleukin (IL)-12p70 [7]. Stimulated pDCs release high 
quantities of IFN-α, a group of type I IFNs important in responses towards viral infections 
[8] and an important feed-back loop to enhance cellular responses towards the detection 
of nucleic acids [9].  Type I IFNs also have a stimulating effect on innate immune cells, such 
as NK cells and NKT cells, and these responses are in turn important to identify and 
eliminate mutated autologous tumor cells [10]. Hence, a vaccine based on the combination 
of mDCs and pDCs would have the ability to initiate both an adaptive and innate anti-tumor 
immune response. In addition, at the time of their discovery, DCs were referred to as 
“natures adjuvant” [11], and the two subsets might even have additive effects on each other 
when matured together. Indeed, the responsiveness to TLR ligands has been shown to 
increase for both subsets when cultured together [12], and IFN-α has been shown to 
upregulate additional TLRs on both mDCs and pDCs [13]. During viral infection, pDCs 
are important stimulators of mDCs, which in turn enhances anti-viral responses [14]. Also, 
in a murine tumor vaccination model, antigen-specific T cell responses were increased 
when mDCs and pDCs were activated together rather than separately [15]. 
On the other hand, there is also a risk that mDC-pDC crosstalk would have a negative 
impact as a combined vaccine product. Type I IFNs have been reported to have dampening 
effects on both immune and non-immune cells [8, 16]. Although IFN-a is needed in low 
levels to induce IL-12 production [17], some studies have indicated a negative effect on 
human mDCs and moDCs. The release of IL-12 has e.g. been reported to be inhibited by 
high doses of type I IFNs [18–20]. However, the literature is conflicting regarding the matter, 
and several studies have shown an increase of IL-12 production from human [21–23] and 
murine [13, 17, 24] DCs in the presence of IFN-α.
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In present study, we investigate the responses of human blood-derived DC subsets either 
treated with recombinant IFN-α or IL-12p70 or co-cultured at various ratios. The production 
of cell type-specific cytokines and the expression of maturation markers is evaluated. 
Additionally, we investigate how these cultures affect both innate and adaptive immune 
cells. As a stimulus, we use protamine-RNA complexes (pR), a previously described TLR7/8 
agonist that induces high levels of both IL-12p70 and IFN-α in mDCs and pDCs, respectively 
[25–28]. This will prevent possible artifact effects previously detected upon combination 
of different TLR ligands [29] and better resemble the clinical studies on mDCs and pDCs 
that are being performed with this stimulus (NCT02574377). We demonstrate that IFN-α 
matures mDCs and that low doses increases mDC-produced IL-12p70. In addition, we 
show that pR-induced mDC maturation is dependent on type I IFN signaling. The presence 
of IL-12 does not have any significant effects on pDC maturation or IFN-α production, and 
in co-cultures, pDCs have a stronger beneficial effect on mDCs than vice versa. We 
additionally demonstrate that co-cultured DCs increase both innate immune cell and T 
cell activation, but dampen the proliferative response of T cells. Our study contributes 
important information on the effect of crosstalk between different subsets of human blood-
derived DC subsets and clarifies why contradictory effects of type I IFNs previously have 
been reported in literature. This study also supports the combined usage of CD1c+ mDCs 
and pDCs as a cellular anti-cancer immunotherapy, combining the beneficial effects of both 
subsets into one potent treatment modality.
MATERIAL AND METHODS
Reagents
Isolated DCs were activated with TLR7/8 ligand imidazoquinoline  (R848, 4 µg/ml; Axxora, 
San Diego, CA) or protamine-RNA complexes (pR, 15 mg/ml) formed in water as previously 
described [25] by mixing protamine (Protaminehydrochloride MPH 5000 IE/ml, 0.5 mg/
ml; Meda Pharma BV, Amstelveen, the Netherlands) and gp100 mRNA (0.5 mg/ml) in a 
2:1 ratio. Recombinant IFN-a2a (Roferon®-A, 1; 10; and 100 ng/ml, corresponding to ca 
1.35*102-1.35*104 UI/ml; Roche, Basel, Switzerland) and IL-12p70 (0.2-2 ng/ml; BD 
Biosciences, San Jose, CA) was used to stimulate mDCs and pDCs, respectively, and 
recombinant IL-3 (10 ng/ml; Cellgenix, Freiburg, Germany) was used as a survival factor 
for unstimulated pDCs.
To capture intracellular cytokines for flow cytometry, Brefeldin A (10 mg/ml; Sigma-
Aldrich, St Louis, MO) was added to the cultured cells 4 or 12h before analysis.
Isolated PBLs or T cells were activated with Dynabeads human T-activator CD3/CD28 
(anti-CD3/anti-CD28 beads, 0.25*106 beads/ml; Life Technologies, Carlsbad, CA)
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Cell isolation and culture
PBMCs were isolated from buffy coats (Sanquin, Nijmegen, The Netherlands) donated by 
healthy human blood donors given informed consent by ficoll density centrifugation 
(Lymphoprep; Axis-Shield PoC AS, Oslo, Norway). Microbead isolation kits (BDCA1+ DC 
and BDCA4+ DC isolation kits; Miltenyi Biotec, Bergisch-Gladbach, Germany) were used 
to isolate CD1c+ mDCs and pDCs from PBMCs. For mDCs, CD14+ cells were depleted 
using CD14 microbeads (Miltenyi Biotec) and prior pDCs isolation, PBLs were prepared 
from PBMCs by plastic adherence for 1h in RPMI (Life Technologies) supplemented with 
2% human serum (Sanquin, Nijmegen, The Netherlands) and 0.5% antibiotic antimycotic 
(PAA laboratories, Pasching, Austria). Pan-T cells were negatively selected from PBLs using 
microbead isolation (Miltenyi Biotec).
Purified cells were cultured at 0.5*106 cells/ml in X-VIVO-15 medium (Lonza, Basel, 
Switzerland) supplemented with 2% human serum. For the DC co-cultures, autologous 
mDCs and pDCs were mixed in ratios of 1:1 and 5:1, with the total cell concentration kept 
constant between the co-culture conditions and single-cultured cells.
Type I IFN block
Cells were cultured in combination with a cocktail of three blocking antibodies (all from 
PBL Biomedical Laboratories, Piscataway, NJ, USA) was used to abrogate type I IFN 
signaling: anti-IFN-α (5000 NU/ml, anti-IFN-β (5000 NU/ml), and anti-IFNAR1 (20 mg/
ml). Samples were pre-treated with the IFN blocking cocktail for 1h at 37°C.  Respective 
stimuli were added to the samples and incubated o/n. Cells were harvested and analyzed 
by flow cytometry after 16h.
ELISA
The presence of secreted cytokines was measured in cell culture supernatants taken at 
indicated time-points and the levels of IL-12p70, IFN-γ (both from Thermo Scientific, 
Waltham, MA), IFN-α (Bender Medsystems, Vienna, Austria), and TNF-α (BD Biosciencess) 
was assessed with sandwich ELISA.
Flow cytometry
Freshly isolated CD1c+ DC and pDC were stained with the following primary mAbs to 
evaluate phenotype: anti-CD14-FITC (Dako, Glostrup, Denmark), anti-BDCA1-PE 
(Miltenyi Biotec), anti-BDCA-2-Pe-Cy7 (Biolegend, San Diego, CA) and anti-CD20-APC 
(eBioscience). The purity of freshly isolated T cells was determined with mAbs anti-CD20-
FITC, anti-CD3-PE, and anti-CD56-APC (all BD Biosciences). DC maturation was 
evaluated with mAbs anti-CD80-PE, anti-CD86-APC, anti-PDL-1-APC (all BD 
Biosciences), and anti-CD40-PE (Immunotech, Marseille, France). In DC co-cultures, 
mDCs and pDCs were identified by mAbs anti-CD11c-FITC (BD Biosciences) and anti-
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BDCA2-PE-Cy7 (Biolegend). The cell subsets in PBLs were identified with mAbs anti-
CD56-APC and anti-CD3-PE-Cy7 (eBiosciences) and their activation was determined with 
mAbs anti-CD69-FITC and anti-IFN-g-BV421 (both from BD Biosciences). For the IFN-g 
stainings, fluorescence minus one controls were made on positive controls using either a 
concentration matched anti-mouse IgG1-BV421 isotype control (eBioscience) or no mAb 
at all and used to determine the IFN-g+ gate.
For all cultured cells, viability was assessed with Fixable Viability Dye eFluor 780 
(eBioscience). In the proliferation assays, PBLs or T cells were labeled with carboxyfluorescein 
diacetate succinimidyl ester (CFSE, 5mM; Life Technologies) for 10 minutes, where after 
the reaction was stopped by protein blocking using FCS. To perform intracellular cytokine 
staining (ICS), the cells were fixed and permeabilized using a cytofix/cytoperm kit (BD 
Biosciences).
The cells were acquired on a FACSVerse (BD Biosciences) and the data was analyzed with 
FlowJo Software (TreeStar Inc., Ashland, OR). For all cultured cells, duplicate events were 
excluded by FCS-A-FCS-H gating and only viable cells were used in the analyses. 
Lymphocytes or DCs were identified by FCS-SSC and subsequently by phenotypic markers. 
In the proliferation assays, proliferating cells were identified as CFSElow. The CFSElow gate 
was set based on cultured, but unstimulated, donor-specific CFSE-labeled PBLs or T cells, 
which were considered non-proliferating. Donors where a proliferating subset was detected 
in the negative control was excluded from total data analyses.
Mixed lymphocyte reaction
The ability of stimulated DCs to induce T cell proliferation or innate cell activation was 
determined in a mixed lymphocyte reaction (MLR). DCs were activated overnight with 
indicated stimuli in round-bottomed 96-well plates. In some assays, fresh medium was 
added to the cultures and the cells were pelleted by centrifugation. The medium was 
discarded and the procedure was repeated two more times before resuspending the cells 
in the initial volume. Allogeneic PBLs or T cells were added to overnight-stimulated DCs 
in a 10:1 or 5:1 ratio, respectively. PBL activation was evaluated after overnight co-culture 
and T cell proliferation after 5 days of co-culture.
Statistical analyses
Statistical relevance was calculated in GraphPad Prism (v5.0; San Diego, CA). To perform 
multiple variance analyses, ANOVA with Bonferroni’s multiple comparison test was applied. 
Wilcoxon matched-pairs signed rank tests were performed for paired analyses.
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RESULTS
Recombinant IFN-α increase the production of IL-12p70 by mDCs and increases pR-
induced maturation
Detection of nucleic acids by endosomal TLRs induces low levels of type I IFN, which in 
an autocrine manner enhances the response to the ligand [13, 30], and RNA-based adjuvants 
have clinically been shown to induce type I IFN-mediated anti-tumor responses [9, 31]. 
We have previously shown that the TLR7/8 ligand protamine-RNA (pR) induces maturation 
and release of high levels IL-12p70 and IFN-α by mDCs and pDCs, respectively [25]. We 
therefore first investigated the involvement of type I IFN signaling in pR-mediated DC 
maturation. DCs were pre-treated with a cocktail of type I IFN blocking antibodies before 
addition of pR-complexes and upregulation of the maturation marker CD80 was investigated 
after over-night culture. Type I IFN signaling was required for pR-mediated mDC 
maturation, but not for pDCs (Figure 1a-b).
Next, we investigated how the DC-specific cytokine production was affected upon addition 
of recombinant cytokines. To represent both low and high producing donors as well as 
varying DC concentrations, a range between 0.2-2 ng/ml of recombinant IL-12p70 (rIL-12) 
and 1-100 ng/ml rIFN-α (corresponding to ca 1.35*102-1.35*104 UI/ml) was used in 
subsequent experiments. A significant increase of IL-12p70 was detected from pR-
stimulated mDCs in the presence of the lowest dose rIFN-α tested, as compared to untreated 
pR-stimulated cells (Figure 1c). This is in line with previous observations in moDCs [17]. 
Higher concentrations of IFN-α could not further increase the IL-12p70 production, 
indicating that only minute amounts of IFN-a are necessary to drive this effect. For rIL-
12-treated pDCs, no changes in IFN- production were detected, as compared to untreated 
cells (Figure 1d). 
The expression of maturation marker CD80 and production of the pro-inflammatory 
cytokine TNF-α was thereafter investigated on cytokine-treated DCs. The presence of rIFN-α 
had a dose-dependent effect on both pR-stimulated and untreated mDCs (Figure 1e). Already 
the lowest dose of rIFN-α significantly elevated the expression of CD80 on pR-stimulated 
cells, while the highest concentrations was required to mature unstimulated mDCs. TNF-α 
levels were on the contrary not elevated by rIFN-α (Suppl. Figure 1a). For pDCs, rIL-12 had 
no maturing effect, neither on IL-3-treated nor pR-stimulated cells (Figure 1f), and no 
significant difference in TNF-α production was detected (Suppl. Figure 1b). 
Co-culture of mDCs and pDCs increases the maturation of mDCs, but not pDCs 
Next, the direct impact on co-cultured DC subsets was investigated. Autologous mDCs and 
pDCs were cultured either alone or in combination in a 5:1 or 1:1 ratio. The total number 
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of cells was kept constant between the different conditions and the cells were either left 
untreated or stimulated with pR complexes overnight. An increase in expression of 
maturation markers CD80 and CD86 was detected for the co-cultured pR-stimulated mDCs, 
as compared to mDCs cultured alone (Figure 2a and Suppl. Figure 2). A slight increase was 
also observed in the untreated control, which could be due to the presence of IL-3 in the 
pDC culture medium. Similar to previous results, no obvious effect was detected for the 
pDCs (Figure 2b). There were also no significant changes in TNF-α levels between the 
different conditions (Figure 2c). When investigating the secretion of subset-specific cytokines, 
the ratios of IFN-α corresponded well with the ratio of pDCs, while the IL-12p70 levels were 
high also in the co-cultured conditions where the ratio of mDCs was less (Figure 2d-e). This 
supports the positive effect of IFN-α on IL-12p70 production noted in figure 1c.
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Figure 1. mDCs and pDCs upregulate CD80 and secrete high levels of subset specific cytokines IL-12p70 and 
IFN-a, respectively, upon pR-treatment. Purified mDCs and pDCs were stimulated overnight with medium alone/
IL-3, or pR complexes in the presence or absence of an IFN blocking cocktail (a-b) or recombinant cytokines (e-f). 
Average expression levels of the CD80 maturation marker ± SEM were measured on (a) mDCs and (b) pDCs from 
5 donors. Cytokine release into supernatant was analyzed with ELISA (c-d). Average secreted levels of (c) IL-12p70 
± SEM from 7 pR-activated mDC donors in the presence or absence of increasing levels (1; 10; and 100 ng/ml) of 
rIFN- and (d) IFN-a ± SEM from 9 pR-activated pDC donors in the presence or absence of increasing levels (0.2 
and 2 ng/ml) of rIL-12p70. (e) Average MFI expression levels of CD80 ± SEM from 7 mDC donors in the presence 
or absence of increasing levels (1; 10; and 100 ng/ml) of rIFN-a. (f) Average MFI expression levels of CD80 ± SEM 
from 6 pDC donors in the presence or absence of increasing levels (0.2 and 2 ng/ml) of rIL-12p70. Statistical 
differences compared to untreated controls (c-f) were analyzed by paired one-way ANOVA with Bonferroni’s multiple 
comparison test and significance is indicated by * (p<0.05), ** (p<0.01), *** (p<0.001), or ns (non-significant).
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The presence of rIFN-α reduces mDC-induced T cell proliferation, but increases IFN-γ 
production in innate immune cells
To evaluate the functional effect of the increased mDC maturation in the presence of rIFN-α, 
the proliferative T cell response was investigated in a MLR setting. First, the effect of rIFN-α 
on PBLs alone was evaluated (Figure 3a). Anti-CD3/anti-CD28 stimulated T cells displayed 
a small, but significant, decrease in proliferation for the higher concentrations. rIFN-α did 
not significantly affect IFN-γ secretion, but a dose-dependent increase could be detected for 
most donors (Figure 3b). When the PBLs were instead stimulated with mDCs activated 
overnight in the presence or absence of increasing concentration rIFN-α, the dose-dependent 
decrease in T cell proliferation was again observed (Figure 3c). Also when investigating the 
IFN-γ secretion, a prominent increase was observed in rIFN-α cultures for the majority of 
pR-stimulated donors, indicating that rIFN-α promotes cytokine secretion over T cell 
proliferation (Figure 3d).
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Figure 2. Stimulation of co-cultured autologous mDCs and pDCs enhance pR-mediated mDC, but not pDC, 
maturation. Purified autologous mDCs and pDCs were cultured overnight either alone or together in a 5:1 or 
1:1 ratio in the presence of medium alone/IL-3 or pR complexes. The total number of cells was kept constant 
between the cultures. Upregulation of maturation marker CD80 was evaluated by flow cytometry (a-b) on viable 
DCs gated on CD11c (mDCs) or BDCA2 (pDCs) expression. Cytokine release was analyzed with ELISA (c-d). 
(a) mDCs or (b) pDCs from 11 donors cultured either alone or combined at a 5:1 or 1:1 ratio in the presence or 
absence of stimuli. Average secreted levels of (c) TNF-a ± SEM from 8 donors, (d) IL-12p70 ± SEM from 7 donors, 
and (e) IFN-a ± SEM from 10 donors. Statistical differences within the treatment groups were analyzed by paired 
one-way ANOVA with Bonferroni’s multiple comparison test and significance is indicated by ** (p<0.01), *** 
(p<0.001), or ns (non-significant).
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IFN-γ is an important Th1 cytokine that is secreted by activated lymphocytes and acts in 
a feedback loop to further stimulate Th1 polarization and effector functions [32]. Since 
IFN-α is known to activate innate immune cells such as Natural Killer (NK) cells and NKT 
cells [10, 33], these cells might be important sources of the elevated levels of IFN-γ detected 
in figure 3b and 3d. The activation status of innate immune cells in the presence of rIFN-α 
was therefore investigated. Unstimulated PBLs were cultured overnight in the presence or 
absence of increasing concentrations of rIFN-α, and the upregulation of activation marker 
CD69 and the cell-type specific production of IFN-γ was evaluated for T cells, NK cells, 
and NKT cells (Figure 3e-f and Suppl. Figure 3). Strikingly, rIFN-α alone significantly 
induced dose-dependent upregulation of CD69 in all cell types investigated (Figure 3f). 
Furthermore, it induced IFN-γ production by NK cells (Figure 3g). Hence, the presence of 
IFN-α-activated innate immune cells in the MLR of figure 3c might affect the observed T 
cell responses. 
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Figure 3. IFN-a reduces T cell proliferation but activates innate immune cells and increases the production 
of IFN-g. PBLs were activated either by anti-CD3/anti-CD28 beads (a-b) or overnight-activated allogeneic mDCs 
(c-d) in the presence or absence of increasing levels (1; 10; and 100 ng/ml) rIFN-a and the proliferative responses 
of T cells, characterized as live, CFSElow CD3+ lymphocytes, or activation of NK, NKT, and T cells (e-g) were 
measured by flow cytometry (a, c, and e-g). The release of IFN-g was measured with ELISA (b and d). (a) Mean 
percentage ± SEM proliferating T cells from 9 PBL donors at day 5 of culture. (b) Mean levels of secreted IFN-g 
± SEM from 9 PBL donors at day 4 of culture. (c) Mean percentage ± SEM of proliferating T cells at day 5 induced 
by 9 mDC donors. (d) Mean levels of secreted IFN-g ± SEM at day 4 of co-culture induced by 5 mDC donors. 
Mean percentage ± SEM NK, NKT, or T cells expressing (e) the activation marker CD69 or (f) intracellular IFN-g 
after overnight treatment in the presence or absence of increasing levels (1; 10; and 100 ng/ml) rIFN-a from 9 
PBL donors. The ICS gate is set based on isotype control. Statistical differences compared to untreated controls 
within each treatment group or for each investigated cell type were analyzed by paired one-way ANOVA with 
Bonferroni’s multiple comparison test and significance is indicated by * (p<0.05), ** (p<0.01), *** (p<0.001), or 
ns (non-significant).
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Innate immune cells are activated in the presence of pR-stimulated pDCs
To investigate if innate immune cells also can be activated by pR-stimulated DCs, their 
activation status was examined upon co-culture with mDC and/or pDCs (Figure 4). 
Autologous mDCs and pDCs were cultured in the same ratios as in figure 2 and allogeneic 
PBLs were added after overnight stimulation for another 24 hours. The cell type specific 
expression of CD69 and IFN-γ was thereafter investigated. Both NK cells and NKT cells 
upregulated the activation marker CD69 after overnight co-culture with pDCs or pDCs 
co-cultured with mDCs (Figure 4a). However, in the presence of mDCs alone, only a minor 
fraction of cells expressed this activation marker. The same trend was observed for the T 
cell fraction in the PBLs. Stimulated pDCs were also able to induce IFN-γ production in 
innate immune cells, with the highest levels being expressed in cells from the 1:1 ratio 
mDC-pDC co-culture, while only background levels were detected in cells stimulated with 
only with mDCs (Figure 4b). 
Soluble factors produced by pR-stimulated pDCs reduces the proliferative response of 
T cells
To explore the effect of IFN-α and IL-12 on T cell activation in more detail and considering 
the prominent effect of pDCs on innate immune cells, subsequent studies of adaptive 
responses were instead performed with isolated total T cells. mDCs and pDCs were pR-
activated alone or together overnight, whereafter allogeneic T cells were added. Stimulated 
mDCs induced a robust proliferative T cell response, which was greatly reduced when pDCs 
were added (Figure 5a). Oppositely, the levels of IFN-g were elevated in the co-cultured 
groups (Figure 5b). 
Since rIFN-α in figure 3c was shown to inhibit mDC-induced T cell proliferation, the impact 
of released factors from pR-treated pDCs was therefore investigated on stimulated T cells. 
Conditioned medium (CM) was made by stimulating pDCs overnight with either pR 
complexes (pR-CM) or IL-3 (IL-3-CM), and the supernatant from several donors was 
collected and pooled. Indeed, in the presence of pR-CM, anti-CD3/anti-CD28-stimulated 
T cells displayed a reduced proliferative response compared to untreated activated cells 
(Figure 5c). This was less prominent for cells cultured with IL-3-CM or pR complexes. In 
a similar manner, the mDC-induced T cell proliferation was markedly less in the presence 
of pR-CM than of IL-3-CM or untreated pR-stimulated mDCs (Figure 5d), despite that 
pR-CM-treated pR-stimulated mDCs expressed higher levels of maturation markers than 
pR treatment alone (Suppl. Figure 4a). The involvement of IFN-a in the reduced proliferative 
response was confirmed by adding the cytokine to pR-stimulated mDCs together with the 
allogentic T cells (Figure 5e).
201751 proefschrift_Till Mathan_titel_kleur.indd   125 23-02-18   19:49
CHAPTE R 6
126
To circumvent the observed inhibitory effect of IFN-α on T cell proliferation, the DC 
cultures were thoroughly washed after overnight activation and just before the addition of 
allogeneic T cells. This indeed increased the proliferative response of T cells activated by 
mDCs co-cultured with pDCs, but reduced IFN-g secretion (Figure 5f-g). However, it did 
not fully restore the T cell proliferation. This could be due to a reduced number of mDCs 
present in the co-cultures, since pDCs only induced minor T cell proliferation, but another 
possibility is that IFN-α induces expression of inhibitory molecules on mDCs.
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Figure 4 
Figure 4. pR-activated pDCs, but not mDCs, are able to activate innate immune cells. mDCs and pDCs were 
pR-activated overnight, either alone or in 5:1 or 1:1 ratios where the total number of cells/sample was kept constant, 
and thereafter co-cultured another 24h with allogeneic PBLs, whereafter the upregulation of activation marker 
CD69 and cell type-specific IFN-g production in viable lymphocytic CD56+CD3- NK cells, CD56+CD3+ NKT 
cells, and CD56-CD3+ T cells was determined by flow cytometry. Mean expression ± SEM of (a) CD69 and (b) 
IFN-g from 6 PBL donors was determined. Statistical differences compared within cell type were analyzed by 
paired one-way ANOVA with Bonferroni’s multiple comparison test and significance is indicated by * (p<0.05), 
** (p<0.01), *** (p<0.001). All unlabeled comparisons were statistically non-significant.
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PD-L1 signaling is not specifically induced in T cells stimulated by co-cultured pR-
stimulated DCs
A potent inhibitory receptor expressed on activated T cells is the programmed cell death 
(PD)-1 molecule [34]. It interacts with its ligand PD-L1, which is upregulated on activated 
DCs as a feedback mechanism to prevent autoimmune or immunopathological responses 
[35]. To evaluate the importance of PD-1 in IFN-α-reduced T cell proliferation, the 
expression of PD-L1 on mDCs was assessed upon treatment with pR-complexes, increasing 
concentrations of rIFN-α, or pR-CM (Figure 6a). pR-treatment upregulated PD-L1 on 
mDCs, while pR-CM and the highest dose of rIFN-α induced even higher levels of the 
ligand, which was similarly detected for the expression of CD80 and CD40 (Suppl. Figure 
4a). In addition, co-culturing the mDCs with pDCs also displayed a strong induction of 
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Figure 5. Secreted factors from pR-activated pDCs reduce the proliferation of stimulated T cells, but increase 
their ability to produce IFN-g. Isolated, CFSE-labeled T cells were stimulated with overnight-activated mDCs 
and pDCs, cultured either alone or in 5:1 or 1:1 ratios, or anti-CD3/anti-CD28 beads in the presence of indicated 
stimuli and the proliferative responses, characterized as live, CFSElow CD3+ lymphocytes, were investigated after 
5 days by flow cytometry (a, c-e). Secretion of IFN-g at day 4 was measured by ELISA (b and f). (a) Mean 
percentage ± SEM proliferating T cells induced by 6 DC donors. (b) Mean levels of secreted IFN-g ± SEM from 
7 DC donors at day 4 of culture. (c) Mean percentage ± SEM proliferating anti-CD3/anti-CD28-activated T cells 
treated with medium alone, pR-CM, IL-3-CM, or freshly made pR complexes from 6 donors. (d) Mean percentage 
± SEM proliferating T cells induced by 3-7 mDC donors in the presence of medium alone, pR-CM, or IL-3-CM. 
(e) Mean percentage ± SEM proliferating T cells induced by 6 DC donors that were washed 3 timed before addition 
of T cells. (f) Mean levels of secreted IFN-g ± SEM at day 4 from 7 washed DC donors. Statistical differences were 
analyzed by paired one-way ANOVA or, for (d), ordinary ANOVA with Bonferroni’s multiple comparison test 
and significance is indicated by * (p<0.05), ** (p<0.01), *** (p<0.001), or ns (non-significant). All unlabeled 
comparisons in figure a, b, e, and f were statistically non-significant.
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PD-L1 (Figure 6b-c). To investigate the importance of the observed PD-L1 upregulation, 
activated DCs were washed and thereafter treated with a PD-L1 blocking antibody 1h before 
the addition of T cells. Blocking PD-L1 induced a minor increase in T cell proliferation in 
all groups for a majority of the donors (Figure 6d). This indicates that PD-1 signaling indeed 
does reduce the proliferative response of T cells, but it is not specifically induced in the 
pDC cultures but is rather a general response. 
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Figure 6 
Figure 6. IFN-a induces PD-L1 expression in mDCs, but this upregulation is not responsible for the reduced 
proliferation induced by co-cultured DCs. Purified DCs were cultured either alone or in 5:1 or 1:1 ratios and 
activated overnight with medium alone/IL-3, pR complexes, increasing levels (1; 10; and 100 ng/ml) rIFN-a, or 
pR-CM. The expression of PD-L1 was investigated with flow cytometry (a-c). Isolated, CFSE-labeled T cells were 
co-cultured with allogeneic pR-activated DCs and proliferative responses, characterized as viable CD3+ CFSElow 
lymphocytes, were measured after 5 days (d). Average MFI expression levels of PD-L1 ± SEM on (a) 7 mDC 
donors or on co-cultured (b) mDCs and (c) pDCs from 8 donors. (d) Mean percentage ± SEM proliferating T 
cells induced by 9 pR-activated DC donors pre-treated with PD-L1 blocking Ab 1h before addition of T cells. 
Statistical differences compared to untreated control (a) or within each treatment group (b and c) were analyzed 
by paired one-way ANOVA with Bonferroni’s multiple comparison test or Wilcoxon matched-pair signed rank 
test (c) and significance is indicated by * (p<0.05), *** (p<0.001), or ns (non-significant).
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DISCUSSION
In this study, we have investigated the effect of type I IFNs on human blood-derived mDC 
maturation and function. This is an important question in light of clinical treatment 
modalities involving type I IFNs and agents stimulating high levels of it. However, the 
answers found in literature are partly contradictory, where the addition of type I IFNs to 
myeloid DCs has been shown to both inhibit [18–20] and promote [17, 21, 22] IL-12p70 
production, and mostly does not investigate the effect of naturally produced type I IFNs 
but fully rely on selected recombinant proteins.
We here demonstrate that IFN-a has a beneficial impact on mDC maturation and IL-12p70 
production, but impair T cell proliferation. Type I IFN-signaling is required for pR-mediated 
mDC maturation, since blocking experiments abolished the upregulation of maturation 
markers. Adding low doses of rIFN-α to mDCs significantly enhanced pR-induced IL-12p70 
release, corresponding to previous observations in murine bone marrow-derived DCs [17]. 
Beneficial effect of type I IFNs has also been reported in human moDCs [17, 21, 22]. With 
increasing doses of both IFN-a and IFN-b, Heystek et. al could further enhance LPS- or 
CD40L-induced IL-12p70 production, while no effect on maturation marker expression 
was observed [21]. When increasing the rIFN-a dose, we observed that some donors 
reverted back to basal levels of IL-12p70 secretion, while an increase still could be detected 
in the remaining donors. In the highest dose, a minority of donors still displayed an elevated 
level of IL-12p70 production, compared to untreated pR-stimulated mDCs. These donor- 
and dose-dependent responses towards IFN-a might explain why a lack of IL-12p70 
secretion has been reported in other studies. In addition, type I IFNs alone do not provoke 
IL-12 production, but need to be combined with an IL-12p70 inducing stimulus [21, 36]. 
This, on the other hand, does not hold true for DC maturation. When treating unstimulated 
mDCs with increasing doses of rIFN-a, we observed that the highest dose used results in 
an even higher expression of maturation markers than for pR-stimulated DCs. The ability 
of type I IFNs to mature DCs is also strongly supported by literature [23, 36–38].
The mDC secreted cytokine IL-12p70, on the other hand, has no effect on pDC maturation 
or cytokine production. The observed one-sided effect on mDCs was therefore not 
surprising when studying the responses of mDCs and pDCs cultured and activated together. 
The presence of pDCs strongly enhanced the maturation response of mDCs in pR-activated 
co-cultures. In addition, despite reduced total numbers of mDCs, the IL-12p70 secretion 
remained high in the co-cultures, indicating an increased capacity of the co-cultured mDCs 
to produce IL-12p70. For the pDCs, the production of IFN-a correlated much stricter with 
the total number of cells in the culture and no alteration in maturation was detected in the 
co-cultures, again pointing towards a lesser impact of pR-stimulated mDCs on pDCs. 
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Indeed, several studies on mDC-pDC crosstalk have highlighted the importance of pDCs 
to fully potentiate the mDCs in various infection models [14]. Both cell-cell interaction 
and secreted factors have been described as mediators of this crosstalk, but type I IFNs 
emerge as a key factor [15, 39, 40]. Confirming the stimulatory ability of pDC-secreted 
factors, we could induce a strong maturation response in mDCs treated with conditioned 
medium from pR-activated pDCs. However, since pR complexes mature both pDCs and 
mDCs, we cannot fully exclude that this effect is not partly due to remaining complexes in 
the supernatant, although pR complexes incubated overnight are strongly reduced in their 
stimulatory ability (data not shown) and their half-time are reportedly a few hours [27].
Type I IFNs have been shown to polarize a Th1 response in naïve T cells [41], although it 
is questioned whether they fully can substitute the effect of IL-12p70 or if additional 
cytokine signaling is needed [42, 43]. An elegant study by Ramos et al. suggested that IFN-a 
and IL-12p70 induce varied effector functions in stimulated CD8+ T cells, where IL-12p70 
signaling promoted fast dividing T cells with an effector-memory phenotype. IFN-a, on 
the other hand, reduced proliferation in responding cells and rather stimulated a central-
memory phenotype [44]. Importantly, the strength of the T cell receptor signaling determine 
which phenotype predominantly develops [44–46], possibly explaining the distinct 
reduction in T cell proliferation we observe in MLRs with IFN-a- or pR-CM-treated mDCs, 
but much less when T cells are stimulated with high dose anti-CD3/anti-CD28 beads. One 
could speculate that reducing the dose of the highly stimulatory activation beads would 
make the T cells more sensitive to the polarizing effect of type I IFNs and hence render a 
similar dose-response pattern as in the MLRs. Further support of the IFN-a-mediated 
polarization is found in a recent study by Willemen et al., where moDCs engineered to 
secrete high levels of IFN-a had a reducing effect on both CD4+ and CD8+ T cell proliferation 
in an IFN-a-dependent manner. Interestingly, antigen-specific T cell activation and IFN-g 
production was markedly increased in the presence of IFN-a, despite their reduced 
proliferative response [33]. This correlates well with our observations of a reduced 
proliferative T cell response but increased IFN-g secretion in MLRs with co-cultured DCs. 
In addition, thorough washing of co-cultured DCs before addition of allogeneic T cells 
markedly increased the T cell proliferation, but reduced IFN-g production, further 
supporting the direct effect of type I IFNs on T cells.
Although washing the DC cultures increases T cell proliferation, removing the secreted 
factors does not fully restore the proliferative response induced by mDCs alone. This could 
be explained by a reduced total number of mDCs, since pR-stimulated pDCs are modest 
inducers of T cell proliferation, but it might also be due to the crosstalk effect between the 
two subsets. Upon strong activation, matured DCs additionally start upregulating inhibitory 
ligands to prevent the development of immunopathological responses [35]. A pathway that 
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recently has been shown to be important in the immune escape of several types of cancers 
is PD-1/PD-L1 signaling [47]. Treating unstimulated mDCs with high doses of IFN-a or 
pR-CM or co-activating them with pDCs strongly upregulate the expression of PD-L1 on 
mDCs. However, blocking PD-L1 on DCs before addition of T cells does not further 
increase the proliferative response in the co-cultured groups, independent on pre-washing 
the DC cultures or not (data not shown). A small general increase in proliferation is detected 
though, both for single-cultured and co-cultured mDCs, which indicates that a natural 
PD-L1-mediated inhibition exists in the MLR set up, but it is not enhanced by the presence 
of pDCs. Instead, the retained reduction of T cell proliferation in washed co-cultures might 
actually be a symptom of the enhanced maturation response detected for the mDCs, where 
the elevated levels of pro-inflammatory cytokines and IL-12p70 simply is washed away and, 
due to the late kinetics of 24h activation, is not replaced. Several studies supporting the 
IFN-a-mediated enhancement of IL-12-production also indicate a time-dependence for 
this effect, where addition of type I IFNs at a later point in mDC maturation actually inhibits 
further production of IL-12p70 [20, 21]. Hence, an earlier wash of the DC cultures and 
addition of isolated T cells would likely be more beneficial.
In this study, we have investigated two different ratios of mDC-pDC co-culture. However, 
surprisingly few differences between the groups are detected. Even a low number of pDCs 
have the ability to significantly enhance mDC maturation and affect T cell proliferation 
and activation. Indeed, the only set-up where an equal ratio between mDC and pDCs was 
beneficial was when studying the innate immune cell activation. IFN-a alone had the ability 
to activate NK cells in a dose-dependent manner, and stimulated pDCs induced an even 
greater effect. Stimulated mDCs alone, however, were poor inducers of innate immune cell 
activation, despite the fact that IL-12p70 is a known activator of both NK and NKT cells 
[48, 49], and the presence of pDCs was needed to upregulate the activation marker CD69. 
However, despite producing the highest levels of IFN-a, pDCs alone were not sufficient to 
significantly increase IFN-g production in innate immune cells. Instead, the 1:1 combination 
with mDCs was necessary to induce peak activation of both NK and NKT cells. In this 
culture, the IFN-a levels are still high, while IL-12p70 is also present, which implies that 
synergistic effects on innate immune activation can be achieved by combining the two DC 
subsets and thereby supplying both IFN-a and IL-12p70. Nevertheless, innate immune cells 
have been shown to respond to several other factors provided by activated DCs [10], and 
we have not excluded the involvement of additional factors in this crosstalk.
To conclude our study, we here confirm previous studies describing beneficial effects of 
type I IFNs on mDC maturation and IL-12p70 production [17, 21, 22]. We additionally 
show that activated type I IFN-producing pDCs also have this effect on mDCs and are 
highly beneficial for activation of innate immune cells. The observed reduced proliferative 
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response of T cells stimulated by co-cultured DCs is mostly dependent on the inhibitory 
effect of secreted factors, rather than a reduced stimulatory effect of co-cultured mDCs. 
This might explain why some studies have ascribed type I IFNs a negative effect on the 
functionality of mDCs [18, 20, 21]. It also indicates that ex vivo stimulated DCs will still 
be functional in vivo if the cells are stimulated for a shorter time and washed before 
administration to the patient. The ratio between the co-cultured DC subsets is less important 
for the functional effects, and even a minor fraction of activated pDCs have a positive effect 
on both innate immune cell and T cell activation. Indeed, melanoma patients treated with 
a pDC-based cellular vaccine displayed an IFN signature, which even was detected in 
patients receiving the lowest dose cells, indicating that stimulated human pDCs are highly 
potent also in vivo [4]. Since pDCs are less prevalent than mDCs in human blood, we 
conclude that cellular immunotherapies based on both primary DC subsets can utilize all 
cells isolated, despite a lower ratio of pDCs, and still be predicted highly functional.
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Supplementary Figure 1 
Purified mDCs and pDCs were stimulated overnight with medium alone/IL-3 or 
pR complexes in the presence or absence of increasing concentration 
recombinant IFN-α or IL-12p70, respectively. TNF-α release into supernatant 
was analyzed with ELISA. (A) Average secreted levels of TNF-α ± SEM from 9 
mDC donors in the presence or absence of increasing levels (1; 10; and 100 ng/
ml) of rIFN-α. and (B) Average secreted levels of TNF-α ± SEM from 6 pDC 
donors in the presence or absence of increasing levels (200 and 2000 pg/ml) of 
rIL-12p70. Statistical differences compared to untreated medium/IL-3 or pR-
activated controls were analyzed by paired one-way ANOVA with Bonferroni’s 
multiple comparison test.  
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Supplementary Figure 2 
Purified autologous mDCs and pDCs were cultured overnight either alone or 
together in a 5:1 or 1:1 ratio in the presence of medium alone/IL-3 or pR 
complexes. The total number of cells was kept constant between the cultures. 
Upregulation of maturation marker CD86 was evaluated by flow cytometry. (A) 
Representative figure of gating strategy for identification of CD11c+ mDCs and 
BDCA2+ pDCs. Average MFI expression levels of CD86 ± SEM on (B) mDCs or 
(C) pDCs from 5 donors cultured either alone or combined at a 5:1 or 1:1 ratio in 
the presence or absence of stimuli.  
Supplementary Figure 3 
Representative figure of gating strategy for identification of CD56+CD3- NK 
cells, CD56+CD3+ NKT cells, and CD56-CD3+ T cells in co-cultures of activated 
DCs and allogenic PBLs 
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(A) Purified mDCs were activated overnight with medium alone, pR complexes, 
increasing levels (1; 10; and 100 ng/ml) rIFN-α, or pR-CM. The mean expression 
± SEM of CD40 and CD80 was investigated with flow cytometry. (B) Purified 
mDCs were activated overnight with pR complexes. Mean percentage ± SEM 
proliferating T cells induced by 6 DC donors that were washed 3 timed before 
addition of T cells and increasing levels (1; 10; and 100 ng/ml) of rIFN-α. 
Statistical differences were analyzed by paired one-way ANOVA with 
Bonferroni’s multiple comparison test and significance is indicated by ** 
(p<0.05).  
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ABSTRACT
Many immunotherapies rely on ex vivo stimulation of immune cells, which requires stimuli 
that are both safe and effective. Here, we evaluate two clinical grade stimuli for BDCA3+ 
myeloid dendritic cells (mDCs), a rare DC subset that is currently being explored for use 
in DC-based immunotherapy. In contrast to routine evaluation methods, which focus on 
predefined maturation markers on the surface or factors released from the activated cells, 
we applied an unbiased transcriptome-based method based on both RNA-sequencing 
(RNA-seq) and microarrays. Specifically, we analyzed the RNA of BDCA3+ myeloid 
dendritic cells (mDCs) from five human donors upon activation with two clinical-grade 
adjuvants, Hiltonol (TLR3 ligand) and pRNA (TLR7/8 ligand), and compared these samples 
to unstimulated cells. Both methods, RNA-seq and microarray, gave very similar results 
and showed that Hiltonol and pRNA lead to very similar changes to the transcriptome of 
BDCA3+ mDCs. A gene ontology (GO) term analysis suggested that these changes were 
mainly related to activation and maturation pathways, while we did not find pathways 
related to adverse effects or cell damage among the most strongly affected pathways. The 
combination of both stimuli gave a very similar result as compared to either stimulus alone 
suggesting no synergistic effect. Together, our results indicate that both stimuli potentially 
are potent and safe clinical grade adjuvants with comparable effects to mature BDCA3+ 
mDCs in an immunotherapy setting. Moreover, our analysis shows that microarray analysis 
and RNA-seq lead to similar conclusions about the activation state of BDCA3+ mDCs. 
Because they require much less RNA, microarray analyses may thus remain suitable for 
studying the activation of rare cell types such as BDCA3+ mDCs, despite the advantages of 
RNA-seq.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen presenting cells (APCs) and are found in 
most tissues of the human body [1]. Upon activation, DCs migrate to the lymph nodes and 
activate T cells [2]. Among the primary circulating blood DCs, there are two main subsets, 
the myeloid DCs (mDCs) and the plasmacytoid DCs (pDCs). The mDC subset can be 
further subdivided into CD1c+ (BDCA1) mDCs and CD141+ (BDCA3+) mDCs. Each subset 
has been shown to have specific functions. Whereas pDCs are known to produce high 
amounts of type I interferons (IFNs) upon sensing viral pathogens via TLR7 or TLR9, 
CD1c+ mDCs are able to sense bacterial pathogens via TLR3, TLR4 or TLR8 and release 
IL12p70 and IL-1β. BDCA3+ mDCs show a high expression of TLR3, have been 
characterized as high IFN-λ producers and are highly efficient cross-presenters, which 
qualifies them as a very interesting target for DC-based immunotherapies [3-10]. Yet, due 
to their low frequencies in the human blood, BDCA3+ mDCs have not been included in 
clinical trial settings so far and have not been studied as extensively as the more abundant 
CD1c+ mDCs and pDCs.
Efficient maturation is a crucial step for DC-based cancer immunotherapy [11-17]. DC 
maturity can be measured based on different parameters. Firstly, surface expression of 
maturation markers like CD40, CD80, CD86, or PD-L1 as well as chemokine receptors like 
C-C chemokine receptor type 7 (CCR7) can be measured using flow cytometry [18]. Co-
stimulatory molecules like CD80 or CD40, but also co-inhibitory molecules like PD-L1, 
do not only represent the maturation stage of DCs but also play an important role in 
regulating T cell stimulation. Secondly, cytokines and chemokines released by the cells give 
an indication of their viability, functionality and maturation state. Furthermore, as indicators 
of the DC activation state, their ability to stimulate T cells or other immune cells can be 
measured by co-culture experiments in which T cell proliferation or phenotypic changes 
are used as a read-out. All these methods are based on a pre-defined set of markers and 
targets. On the one hand, this means that those experiments are focused and comparable. 
On the other hand, however, important effects that are not known or expected a priori, or 
do not belong to the most obvious targets, can be missed.
In clinical trials we used CD1c+ mDCs and pDCs for therapeutic vaccination to treat cancer 
and demonstrated positive clinical responses [13, 17]. We evaluated several clinical-grade 
adjuvants and chose pRNA as the most suitable stimulus [14, 19]. Since BDCA3+ mDCs 
appear promising for future immunotherapies, we here aimed to identify an optimal 
adjuvant for this DC subset. Because BDCA3+ mDCs express TLR8 and TLR3 to a high 
extent, we chose the TLR8 ligand pRNA and Hiltonol, a commercially available clinical 
grade Poly I:C form that can trigger TLR3. Hiltonol appeared like a promising option 
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because of the characteristic high expression of the TLR3 receptor by BDCA3+ mDCs. 
To compare the effects of these two adjuvants in an unbiased and global manner, we applied 
transcriptome analysis. This approach not only provides a general overview of the induced 
effects, but also allows us to investigate which specific cellular pathways are affected by each 
stimulus. In this study, we employed both RNA-seq and microarray measurements to 
interrogate the DC transcriptome and asked whether these techniques would lead to similar 
conclusions. Whereas RNA-seq is known to have a higher sensitivity and therefore increases 
the chance to observe changes in low-abundant genes, while the microarray approach has 
the advantage of requiring substantially less starting material, which can be a limiting factor 
for rare cell populations like BDCA3+ mDCs [20]. 
RESULTS
Microarray and RNA-seq measurements lead to similar results
We obtained BDCA3+ mDCs from five different donors, isolating between 0.7 and 1.5x106 
cells per donor. In an overnight stimulation assay, we tested the two different stimuli 
separately and in combination. We used both RNA-seq and microarray-based mRNA 
analysis on the exact same sample. For 4 out of 5 donors, we obtained sufficient material to 
perform both RNA-seq and microarray analysis (though in one case, we omitted the 
combined stimulation); for the remaining donor, we only performed microarray analysis. 
As a first data exploration step, we applied Principle Coordinate analysis (PCoA) to the 
combined data of all conditions and all donors for both the RNA-seq (Figure 1A) and the 
microarray data (Figure 1B). In these plots, the first principle coordinate separated stimulated 
from unstimulated cells, whereas the second coordinate appeared to be related to donor 
differences and no clustering of the different stimuli was observed. Separate MDS-plots per 
donor (Figure 1C, RNA-seq, and Figure 1D, microarray) also showed the first coordinate to 
align in each case with stimulation. The combined stimulation was located in between the 
two individual stimuli in all cases, except for donor 3. For this donor, in both the RNA-seq 
and the microarray data, the pRNA-stimulated sample clustered together with the 
unstimulated samples (highlighted with an arrow in Figures 1A and 1B).  As this outlier was 
present in both datasets, this indicates that the cells in this sample were not stimulated as 
expected, perhaps due to a mistake in the experiment or genuine variability in how well 
BDCA3+ mDCs respond to pRNA. To prevent biased conclusions, the best course of action 
appeared to be to exclude this outlier from the rest of the analysis presented in this paper.
Next, we directly compared the RNA-seq and microarray results for single genes, to see if the 
conclusions from both analyses would be similar. Focusing on the set of genes that show 
significant up-or downregulation upon stimulation (Figure 2A, B), we observe that the 
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direction of the change was the same in all cases (i.e., they were either up- or downregulated 
in both datasets) with the single exception being the E2F3P1 pseudogene (Figure 2A). The 
correlation between the estimated fold changes in the RNA-seq versus microarray data for 
the selected gene set was 0.9 and 0.91, respectively (Figure 2), largely due to the consistency 
in the direction of the effect. The fold-change estimated from the RNA-seq datasets was in 
fact often several orders of magnitude larger than that obtained from the microarray datasets, 
which is expected due to the higher dynamic range of RNA-seq (cite [20] here!). However, 
this analysis does show that both datasets are expected to yield similar qualitative conclusions, 
especially in downstream analyses that focus more on the direction of a change (i.e. after 
applying a fold-change cutoff) than on its magnitude, such as gene ontology (GO) analyses. 
Figure 1 Stimulation has strong effects on the transcriptomes of BDCA3+ mDCs. Principal coordinates analysis 
(PCoA) was performed to globally assess the differences between transcriptomes. Each point represents the 
transcriptome of one sample and the first and second principle coordinates are plotted. For both the pooled (A) 
RNA-seq and (B) microarray datasets, as well as for separated PCoA for each donor and for (C) RNA-seq and 
(D) microarray datasets, the first principle coordinate aligned roughly with stimulation. The arrows in (A) and 
(B) highlight an outlier sample (donor 3) in which the stimulation appears to have failed. This sample was removed 
from subsequent analysis. S1 represents the sample stimulated with Hiltonol, S2 represents the sample stimulated 
with pRNA and S1+S2 represents the combination of both stimuli.
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Both stimuli affect most genes similarly
Aiming to identify similarities and differences between the two stimuli, we next correlated 
the transcript fold-change values upon each stimulus (pRNA or Hiltonol) to each other for 
the RNA-seq (Figure 3A) versus the microarray (Figure 3B) data. This showed that (a) both 
stimuli upregulated more genes than they downregulated and (b) both had a similar effect; 
indeed, a differential gene expression analysis based on both datatypes showed no 
significantly different genes (below a p-value of 0.05 after multiple testing correction) 
between the two different stimuli (not shown). Focusing on highly upregulated genes (log 
fold changes >5 for RNA-seq, >2 for microarray) showed, again for both methods, that 
both stimuli strongly upregulated more transcripts than they downregulated. In summary, 
both stimuli appear to have very similar effects on the transcriptome; as expected, RNA-seq 
and microarray data both led to this conclusion. For reasons of simplicity, we therefore 
focus on the RNA-seq data only in the rest of this paper.
Next, to zoom in on the most dominant changes upon each stimulus, we generated volcano 
plots in which the genes with a log fold change of higher than 8 were labeled with the gene 
names (Figure 3C and 3D). Upon both TLR stimuli, genes for IFN-λ, IL-27 or CCL19 were 
among the most strongly upregulated and DLL4, GBGT and ZBTB32 belong to the group of 
genes that behaved most consistently. As expected, due to the omission of the outlier sample, 
the p-values of the pRNA were much higher, but the overall log fold changes were very similar. 
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Figure 2 RNA-seq and microarray analysis strongly agree on the effects of each stimulus. Microarray and 
RNA-seq fold change estimates for significantly up- or downregulated genes (applying a p-value cut-off of 0.05 
after multiple testing correction) upon (A) Hiltonol and (B) pRNA were plotted against each other. The overall 
correlation was quantified using Spearman’s rho. 
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To identify specific pathways that changed in BDCA3+ mDCs upon stimulation with 
Hiltonol or pRNA, we performed a GO term analysis. The more genes belonging to a certain 
gene cluster (i.e. GO term) change their expression upon stimulation, the higher this gene 
cluster is ranked. Comparing both stimuli based on the GO term analysis, we see three 
overlapping gene clusters among the ten most significant gene clusters of each stimulus. 
The top differentially expressed GO term upon Hiltonol stimulation was “response to stress”, 
whereas for pRNA it was “response to virus”. But overall, both stimuli lead to an upregulation 
Figure 3 Hiltonol and pRNA stimulation have similar effects on the transcriptome of BDCA3+ mDCs. (A+B) 
Scatterplots depicting gene expression changes upon both stimuli as measured by RNA-seq (A) and microarrays 
(B). Each point represents a gene. (C+D) Volcano plots showing the magnitude of transcript abundance changes 
(x-axis: log fold) together with the statistical significance (y-axis: -log10 p-value). Both stimuli, (C) Hiltonol and 
(D) pRNA, were compared to the unstimulated sample. Genes with a log fold change of more than 8 were labeled 
with the gene name. Fold changes and p-values were determined using edgeR (see Methods). P-values were 
corrected for multiplicity using the Benjamini-Hochberg method.
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of similar GO terms, with most terms relating to immune responses or antiviral responses. 
Importantly, the top 100 affected GO terms contained no pathways related to cell damage 
or apoptosis (Supplementary Table 1-3).
Table 1. Both stimuli affect similar regulatory pathways. 
Hiltonol 
term ontology N genes N up/down -log10 p-value
response to stress BP 3557 1028 28.7
cytoplasm CC 10548 2601 28.2
immune system process BP 2348 717 26.1
viral process BP 942 344 25.8
regulation of response to stimulus BP 3503 1000 25.6
multi-organism cellular process BP 947 344 25.4
symbiosis, encompassing mutualism through parasitism BP 973 351 25.3
interspecies interaction between organisms BP 973 351 25.3
response to virus BP 304 147 24.3
binding MF 13201 3127 24.1
pRNA
term ontology N genes N up/down -log10 p-value
response to virus BP 304 70 23.5
defense response to virus BP 226 59 22.9
defense response BP 1461 169 18.8
defense response to other organism BP 475 80 17.8
immune response BP 1509 170 17.7
response to biotic stimulus BP 839 114 17.6
immune system process BP 2348 232 17.3
response to stress BP 3557 315 16.9
response to external biotic stimulus BP 801 109 16.9
response to other organism BP 801 109 16.9
Hiltonol + pRNA 
term ontology N genes N up/down -log10 p-value
immune system process BP 2348 694 30.4
response to stress BP 3557 975 30.2
cytoplasm CC 10548 2428 27.3
regulation of response to stimulus BP 3503 943 26
cytoplasmic part CC 7919 1890 25.8
regulation of immune system process BP 1302 416 24.6
cell surface receptor signaling pathway BP 2595 727 24.3
intracellular signal transduction BP 2588 719 22.9
immune response BP 1509 461 22.7
response to cytokine BP 782 275 22.7
Changes in clusters of transcripts were detected using a GO term analysis. The top 10 most differential expressed 
gene clusters upon each stimulus and the combination were selected. The description for each gene cluster is 
shown in the columns. The GO contains three sub-ontologies: molecular function (MF), cellular component (CC) 
and biological process (BP). N genes stands for the total amount of genes contained in a cluster and N up/down 
denotes the number of genes that changed their expression values upon the stimulus. The table is sorted on the 
–log10 p-value shown in the rightmost column.
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Type I/III IFN upregulation upon stimulation
Chemokines, chemokine receptors and interferons are among the most relevant groups of 
genes for the T cell activating function of DCs. Therefore, we subsequently investigated 
these gene groups directly (Figure 4). Hierarchical clustering of samples based on a selected 
set of these genes mirrored the results of our earlier PCoA analysis: unstimulated conditions 
and stimulated conditions formed clear separate clusters. This confirms the clear effect of 
the stimuli on the phenotype and the function of the BDCA3+ mDCs with respect to 
chemokines, their receptors and interferons. Furthermore, consistent with the lack of a 
major difference between the different TLR stimuli or combinations thereof, the stimuli 
did not cluster separately. One big cluster of genes that are predominantly upregulated upon 
stimulation included chemokines like CCL3, CCL4 and CCL5 (Figure 4A). Additionally, 
NK cell attracting chemokines like CXCL9, 10, and 11 appeared strongly upregulated upon 
both stimuli. By contrast, CXCL16, CXCL1 and CXCL6 were more highly expressed in the 
unstimulated samples than upon stimulation. 
Comparing the chemokine receptor genes, again unstimulated samples cluster together 
whereas the samples of the different stimuli form a second, mixed cluster (Figure 4B). This 
analysis shows a cluster of 3 chemokine receptors (CCR6, CXCR4 and CXCR6) that are all 
downregulated upon stimulation. Another cluster (shown near the bottom of Figure 4) 
contains genes that are upregulated upon stimulation, including the gene for the migration-
related chemokine receptor CCR7, but also for CXCR3, CXCR5and CCR4. Type I/III 
interferons are mainly found upon pRNA stimulation (Figure 4C). Finally, comparing the 
cytokine genes reveals one big cluster containing IL-27, IL-36γ and IL-12p40, which are 
all upregulated upon stimulation and several smaller clusters with less clear patterns.
Finally, we were interested in the transcript levels of established BDCA3+ mDC maturation 
markers and therefore investigated the CD80, CD40 and CD86 transcripts (Figure 5). Here, 
pRNA leads to the strongest upregulation of CD80 and CD40, while CD86 is upregulated 
the highest upon the combination of both stimuli. However, these differences are very small 
and not statistically significant. Upon stimulation with Hiltonol and pRNA, the cells 
upregulate the C-C chemokine receptor type 7 (CCR7). However, the expression of the 
MHC class II receptor, HLA-DR, is lower in all stimulated conditions. The combination of 
the two stimuli has no additional effect on the transcript levels of the maturation markers 
and the chemokine receptor CCR7.
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Figure 5 Both stimuli upregulate maturation markers on BDCA3+ mDCs. Normalized transcript abundance 
values, computed with the edgeR package (Methods), are shown for the surface receptors (A) CD80, (B) CCR7, 
(C) HLA-DR, (D) CD40 and (E) CD86. 
To investigate the similarities and differences of BDCA3+ mDCs to CD1c+ mDCs and pDCs, we pooled our RNA-
seq data with the datasets of our previous study on the effects of different clinical stimuli on those more common 
DC subsets [21]. Performing a PCoA of all three stimulated and unstimulated DC subsets (Figure 6), the three 
DC subsets clustered separately. Interestingly, the distance between the stimulated pDCs and CD1c+ mDCs 
increases compared to the unstimulated samples, while pDCs and BDCA3+ mDCs keep similar distances upon 
stimulation. No clear correspondence was visible between the CD1c+ mDCs and BDCA3+ mDCs. The CD1c+ 
mDCs and pDCs were most related to each other (at least in the unstimulated case), which could be interpreted 
as meaning that that they biologically most similar. However, it is more likely that this was caused by the fact that 
these two populations were measured at the same time. Furthermore, among the three clusters the BDCA3+ mDC 
shows the highest homogeneity suggesting once again a high similarity of the two stimuli tested in this study.
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DISCUSSION
We compared two clinical grade TLR stimuli and their effect on BDCA3+ mDCs and 
demonstrated that both adjuvants had similar effects on this subset despite the fact that 
different TLRs were targeted. Furthermore, we used two independent methods to analyze 
the transcriptome and similar conclusions were drawn. Overall, our analysis suggests that 
both stimuli are potent adjuvants for BDCA3+ mDC immunotherapeutic applications.
To evaluate a new clinical grade adjuvant for the BDCA3+ DC subset, we used RNA-seq to 
obtain unbiased and global overviews of the transcriptome, as we did previously for CD1c+ 
mDCs and pDCs [21]. Previously, we studied the effect of pRNA and other adjuvants on 
CD1c+ mDCs and pDCs and pointed out the stronger adjuvant potential of pRNA compared 
to FSME or GM-CSF. Those results were in line with an initial study by Skold et al. to 
characterize the effect of pRNA on DC subsets [14]. Additionally, we here used a microarray 
based approach, which requires 20 times less material compared to the RNA-seq approach 
and may be better suited for cells from which only few cells are available. Importantly, the 
results of both methods were very similar and the most significant changes were overlapping 
indicating microarray is still a good alternative for rare cell types. Due its larger dynamic 
Figure 6 Comparing BDCA3+ mDCs with pDCs and CD1c+ mDCs. Principal coordinates analysis (PCoA) was 
performed for all stimuli, all donors and all three DC subsets to compare their transcriptomes. Each point 
represents the transcriptome of the respective sample. On the x-axis, the principle coordinate one (PCO1) is 
shown, on the y-axis the principle coordinate three (PCO3). Coordinate 2 is not depicted since it appeared to be 
related mostly to differences between the donors.
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range when measuring transcript abundance, RNA-seq can distinguish more specifically 
among the low expressed genes, which explains why the fold changes estimated from 
microarray data are often lower [20].
Despite the fact that pRNA binds most likely TLR7/8 and Hiltonol is a ligand for TLR3, 
their general effects on BDCA3+ mDCs were strikingly similar, as shown by the strong 
agreement between the fold changes for most genes. Furthermore, our initial analysis did 
not indicate that the combination of both stimuli would lead to an improved or adverse 
effect on the maturation of BDCA3+ mDCs compared to either stimulus alone. Furthermore, 
our analyses revealed no strong signs of toxic effects of either stimulus on this DC subset, 
since no GO terms and genes related to adverse responses, e.g. the activation of pathways 
related to nonsense-mediated decay (as we found previously for GM-CSF stimulation of 
mDCs) were upregulated or changed upon stimulation [21].
A minor difference between pRNA and Hiltonol could be observed by comparing the 
upregulation of type I/III IFN related genes (Figure 4), which indicated that the combination 
and predominantly more samples with a pRNA stimulation upregulated type I/III IFN 
genes. However, these results do not reach statistical significance in the whole-transcriptome 
analysis. Further functional assays measuring released interferons on the protein level 
should be performed to investigate this issue.
Since the cost of RNA-seq has decreased, the technique has become commercially available 
and the required amount of RNA has diminished, it has become a standard technique for 
measuring gene expression, including for some clinical applications [22-25].  A major 
advantage of RNA-seq is its ability to quantify and detect novel transcripts, unlike 
microarray techniques [26, 27]; further, it directly yields RNA sequences, which simplifies 
data analysis. The usefulness of RNA-seq for immunotherapy was recently demonstrated 
by the use of this technique to detect mutations or to search for neo-antigens [28-30]. 
Another study performed by van Allen et al., investigated transcriptomic changes of 
melanoma cells upon treatment with ipilimumab, a CTLA-4 inhibitor  [31]. Such studies 
point to the potential for RNA-seq to become an integral component of personalized 
medicine.
In summary, we provide extensive and unbiased data regarding how BDCA3+ mDCs react 
upon stimulation with clinical grade stimuli. Until now, studies including this rare DC 
subsets have been limited to their low numbers, but we anticipate that the improved 
isolation methods and also techniques to increase BDCA3+ mDCs in vivo will draw more 
attention of this subset. We do not claim that RNA-seq will replace other commonly used 
protein-level methods like flow cytometry or western blotting. Instead, we would suggest 
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to combine both approaches once interesting targets have been detected by unbiased RNA-
seq. Additionally, with both methods we observed similar results, which points out the 
efficacy of the micro-array approach, since it requires a significant lesser amount of data. 
However, RNA-seq does have established advantages such as being more sensitive and 
precise, and being able to deliver additional information about differential splicing, detect 
new gene variants and new genes, which are highly relevant from the research-related point 
of view. Nonetheless, for diagnostics and clinical applications, our data suggest that 
microarrays are still a suitable alternative.
MATERIAL AND METHODS
Cell isolation and culture 
For functional assays, DCs were isolated from buffy coats of healthy volunteers (Sanquin, 
Nijmegen, the Netherlands) after obtaining written informed consent per the Declaration 
of Helsinki and according to institutional guidelines. For RNA-seq and microarray 
measurements, cells were obtained from aphaeresis of 5 different donors. Due to the limited 
cell numbers of donor 1, only 4 donors could be used for RNA-seq. Peripheral blood 
mononuclear cells (PBMCs) were isolated by using Ficoll density centrifugation 
(Lymphoprep; Axis-Shield PoC AS, Oslo, Norway). Anti-Human Lineage Cocktail 1 in 
FITC (LIN1) (BD Bioscience Pharmingen, San Jose, CA) containing antibodies for CD3, 
CD14, CD16, CD19, CD20, CD56 receptors, together with the anti-FITC conjugated 
magnetic microbeads of Miltenyi Biotec (Bergisch-Gladbach, Germany) were used to 
deplete the LIN1+ cell fraction, by following manufacturer’s instructions. Next, BDCA3+ 
mDCs were further purified by sorting (flowcytometry) using anti–BDCA-3–APC 
combined with anti-HLA-DR-PE-Vio770 (Miltenyi Biotec) to a purity of 99.9%. DCs were 
cultured in X-VIVO-15 medium (Lonza, Basel, Switzerland) supplemented with 2% human 
serum (Sanquin). DCs were stimulated with: pRNA (15µg/ ml) and Hiltonol (10 µg/ml) 
for 16 hours. pRNA complexes were prepared fresh 5-10 minutes before adding to the cell 
culture. 
Protamine-RNA (pRNA) complexes 
pRNA complexes were made freshly before adding to the cells. Protamine 
(protaminehydrochloride MPH 5000 IE/ml; Meda Pharma BV Amstelveen, the Netherlands) 
was diluted to 0.5 mg/ml in RNase free water and mixed with 2-kbp-long single-stranded 
mRNA (coding for human gp100 protein). It was extensively mixed and incubated for 5-10 
minutes at room temperature, before being added to the cells.
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RNA sequencing and Microarray analysis
BDCA3+ mDCs were isolated as described above and total RNA was extracted using Trizol 
(Invitrogen, MA, USA), following the standard protocol. The quality control of the isolated 
RNA (concentration, RIN, 28S/18S and size) was performed with Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, USA). RNA sequencing and read alignment were 
performed by BGI TECH SOLUTIONS (Hong Kong). Reads were aligned to human 
genome version 19. The microarray analysis of the RNA was performed by using the 
Clariom D assay (Thermo Fisher Scientific).
Hierarchical clustering
Data was transformed to log2 values for performing hierarchical clustering analysis (One 
minus Pearson correlation) using the standard settings of the MORPHEUS - Versatile 
matrix visualization and analysis software (Broad institute, Cambridge, MA; https://
software.broadinstitute.org/morpheus/index.html).
Statistical analysis
Data was analyzed using the R platform for statistical computing. Specifically, the package 
“edgeR”, version 3.16.5, in Bioconductor version 3.4 was used for whole-transcriptome 
principal coordinates analysis (using the “plotMDS” command), differential gene expression 
analysis, and GO term analysis [57]. Differential expression was determined by fitting a 
generalized linear model using the “glmFit” command, and significance was determined 
using the likelihood ratio test provided by the “glmLRT” command [58]. Data from the 
Clariom D assays were imported into R using the Bioconductor packages “affycoretools” 
[32] and “oligo” [33] and were analyzed using the empirical Bayes procedure implemented 
in the “limma” package, version 3.30.13 [34]. Throughout, p-values were corrected for 
multiplicity using the Benjamini-Hochberg method. For GO term analyses, a significance 
cutoff of 0.05 was used. All data analysis scripts are available as Supporting Information 
for this article.
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SUPPLEMENTARY TABLES
Supplementary Table 1. Pathways affected by Hiltonol stimulation. Changes in clusters of transcripts were detected 
using a GO term analysis. The top 100 most differential expressed gene clusters upon Hiltonol were selected. The 
description for each gene cluster is shown in the columns. The GO contains three sub-ontologies: molecular 
function (MF), cellular component (CC) and biological process (BP). N genes stands for the total amount of genes 
contained in a cluster and N up/down denotes the number of genes that changed their expression values upon 
the stimulus. The table is sorted on the –log10 p-value shown in the rightmost column.
Hiltonol 
term ontology N genes N up/
down
-log10 
p-value
response to stress BP 3557 1028 28.7
cytoplasm CC 10548 2601 28.2
immune system process BP 2348 717 26.1
viral process BP 942 344 25.8
regulation of response to stimulus BP 3503 1000 25.6
multi-organism cellular process BP 947 344 25.4
symbiosis, encompassing mutualism through parasitism BP 973 351 25.3
interspecies interaction between organisms BP 973 351 25.3
response to virus BP 304 147 24.3
binding MF 13201 3127 24.1
immune response BP 1509 491 23.7
cytoplasmic part CC 7919 2003 23.4
intracellular CC 13930 3267 23
regulation of immune system process BP 1302 433 22.8
intracellular signal transduction BP 2588 760 22.3
cell surface receptor signaling pathway BP 2595 759 21.7
cytosol CC 3327 933 20.9
response to cytokine BP 782 284 20.9
response to organic substance BP 2741 790 20.8
intracellular part CC 13592 3186 20.6
protein binding MF 8879 2195 20.6
cellular response to chemical stimulus BP 2586 751 20.6
cellular response to organic substance BP 2134 638 20.4
cellular process BP 14950 3454 20.3
defense response to virus BP 226 112 19.7
regulation of signal transduction BP 2646 759 19.2
response to type I interferon BP 84 57 18.8
cellular response to cytokine stimulus BP 688 251 18.8
response to stimulus BP 8081 2002 18
regulation of immune response BP 860 296 17.9
cell activation BP 884 302 17.7
regulation of signaling BP 2984 832 17.6
defense response BP 1461 453 17.3
regulation of cell communication BP 2933 818 17.3
cytokine-mediated signaling pathway BP 543 205 17.3
immune effector process BP 682 244 17.1
cellular metabolic process BP 9977 2406 16.9
type I interferon signaling pathway BP 80 53 16.8
cellular response to type I interferon BP 80 53 16.8
cellular response to stimulus BP 6756 1699 16.8
positive regulation of biological process BP 5094 1319 16.3
leukocyte activation BP 723 253 16.3
viral life cycle BP 444 173 16.2
positive regulation of immune system process BP 903 301 16
positive regulation of cellular process BP 4580 1197 15.8
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Supplementary Table 1. Continued
regulation of response to stress BP 1241 388 15.4
response to external biotic stimulus BP 801 271 15.3
response to other organism BP 801 271 15.3
response to biotic stimulus BP 839 281 15.2
phosphorus metabolic process BP 3008 822 14.9
regulation of intracellular signal transduction BP 1662 493 14.9
phosphate-containing compound metabolic process BP 3002 820 14.8
negative regulation of cellular process BP 4169 1094 14.7
cellular macromolecule metabolic process BP 8215 2005 14.5
negative regulation of biological process BP 4486 1166 14.5
response to external stimulus BP 1996 574 14.5
metabolic process BP 10817 2566 14.3
biological_process BP 16672 3753 14.3
hemopoiesis BP 705 241 14.2
regulation of defense response BP 647 225 14.2
organelle CC 12881 2998 14.1
primary metabolic process BP 9990 2387 14.1
regulation of cellular process BP 10130 2416 14
molecular_function MF 16309 3683 13.9
macromolecule metabolic process BP 8903 2150 13.9
regulation of innate immune response BP 350 139 13.9
single organismal cell-cell adhesion BP 710 241 13.8
organic substance metabolic process BP 10448 2483 13.8
signal transduction BP 5623 1421 13.8
intracellular membrane-bounded organelle CC 10794 2556 13.7
positive regulation of response to stimulus BP 1928 553 13.7
leukocyte differentiation BP 454 169 13.7
membrane-bounded organelle CC 11961 2802 13.6
single organism cell adhesion BP 762 254 13.5
regulation of biological process BP 10652 2524 13.5
cell-cell adhesion BP 1147 355 13.4
immune system development BP 786 260 13.4
signaling BP 6071 1518 13.3
biological adhesion BP 1689 491 13.2
anchoring junction CC 704 237 13.2
hematopoietic or lymphoid organ development BP 745 248 13.1
single organism signaling BP 6064 1515 13.1
cell communication BP 6089 1520 13
innate immune response BP 811 265 12.9
single-organism cellular process BP 11664 2734 12.9
cell adhesion BP 1683 488 12.9
intracellular organelle CC 11832 2769 12.9
lymphocyte activation BP 621 213 12.8
adherens junction CC 687 231 12.8
biological regulation BP 11279 2651 12.7
multi-organism process BP 2262 628 12.5
regulation of molecular function BP 2796 755 12.3
phosphorylation BP 2176 606 12.3
cellular protein metabolic process BP 4779 1217 12.3
inflammatory response BP 645 218 12.3
cell-substrate adherens junction CC 391 146 12
focal adhesion CC 388 145 12
cell-substrate junction CC 395 147 12
negative regulation of viral life cycle BP 84 48 11.8
cell motility BP 1309 388 11.6
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Supplementary Table 2. Pathways affected by pRNA stimulation. Changes in clusters of transcripts were detected 
using a GO term analysis. The top 100 most differential expressed gene clusters upon pRNA stimulation were 
selected. The description for each gene cluster is shown in the columns. The GO contains three sub-ontologies: 
molecular function (MF), cellular component (CC) and biological process (BP). N genes stands for the total 
amount of genes contained in a cluster and N up/down denotes the number of genes that changed their expression 
values upon the stimulus. The table is sorted on the –log10 p-value shown in the rightmost column.
pRNA
term ontology N genes N up/
down
-log10 
p-value
response to virus BP 304 70 23.5
defense response to virus BP 226 59 22.9
defense response BP 1461 169 18.8
defense response to other organism BP 475 80 17.8
immune response BP 1509 170 17.7
response to biotic stimulus BP 839 114 17.6
immune system process BP 2348 232 17.3
response to stress BP 3557 315 16.9
response to external biotic stimulus BP 801 109 16.9
response to other organism BP 801 109 16.9
innate immune response BP 811 108 16.1
positive regulation of peptidyl-serine phosphorylation of STAT protein BP 21 16 15.7
immune effector process BP 682 95 15.4
biological adhesion BP 1689 177 15.3
regulation of immune system process BP 1302 147 15.3
regulation of peptidyl-serine phosphorylation of STAT protein BP 22 16 15.2
cell adhesion BP 1683 175 14.8
type I interferon signaling pathway BP 80 28 14.7
cellular response to type I interferon BP 80 28 14.7
response to external stimulus BP 1996 196 14.1
response to type I interferon BP 84 28 14.1
cytokine activity MF 220 46 14
response to cytokine BP 782 100 13.7
cell surface receptor signaling pathway BP 2595 237 13.7
single organism cell adhesion BP 762 98 13.6
hemopoiesis BP 705 93 13.6
single organismal cell-cell adhesion BP 710 93 13.4
hematopoietic or lymphoid organ development BP 745 96 13.4
cytokine production BP 613 84 13.2
serine phosphorylation of STAT protein BP 27 16 13.1
type I interferon receptor binding MF 17 13 12.9
positive regulation of immune system process BP 903 108 12.9
regulation of defense response BP 647 86 12.8
immune system development BP 786 98 12.8
regulation of innate immune response BP 350 58 12.7
leukocyte differentiation BP 454 68 12.6
symbiosis, encompassing mutualism through parasitism BP 973 113 12.6
interspecies interaction between organisms BP 973 113 12.6
mononuclear cell proliferation BP 248 47 12.6
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Supplementary Table 2. Continued
cellular response to cytokine stimulus BP 688 89 12.5
leukocyte proliferation BP 263 48 12.2
lymphocyte proliferation BP 246 46 12.1
viral process BP 942 109 12
multi-organism cellular process BP 947 109 11.9
positive regulation of biological process BP 5094 393 11.8
leukocyte activation BP 723 90 11.7
cytokine-mediated signaling pathway BP 543 74 11.6
response to stimulus BP 8081 571 11.6
cell activation BP 884 103 11.6
regulation of cytokine production BP 557 75 11.5
regulation of immune response BP 860 100 11.2
cellular response to organic substance BP 2134 195 11.1
cell proliferation BP 1899 178 11
natural killer cell activation involved in immune response BP 30 15 10.8
T cell activation involved in immune response BP 89 25 10.8
leukocyte cell-cell adhesion BP 476 66 10.7
cell-cell adhesion BP 1147 121 10.6
lymphocyte differentiation BP 306 49 10.3
regulation of response to stimulus BP 3503 284 10.3
negative regulation of multi-organism process BP 150 32 10.1
T cell activation BP 436 61 10.1
T cell aggregation BP 436 61 10.1
lymphocyte aggregation BP 437 61 10.1
response to exogenous dsRNA BP 44 17 10
regulation of multicellular organismal process BP 2576 221 10
regulation of type I interferon-mediated signaling pathway BP 39 16 9.9
regulation of symbiosis, encompassing mutualism through parasitism BP 274 45 9.9
leukocyte aggregation BP 444 61 9.8
cell communication BP 6089 443 9.7
positive regulation of cellular process BP 4580 350 9.7
regulation of multi-organism process BP 363 53 9.5
cellular response to stimulus BP 6756 482 9.5
response to organic substance BP 2741 230 9.5
single-multicellular organism process BP 5802 424 9.4
signaling BP 6071 440 9.4
positive regulation of peptidyl-serine phosphorylation BP 88 23 9.3
natural killer cell activation BP 74 21 9.3
single organism signaling BP 6064 439 9.3
cellular response to chemical stimulus BP 2586 218 9.1
cytokine receptor binding MF 268 43 9.1
positive regulation of response to stimulus BP 1928 172 8.9
regulation of viral process BP 252 41 8.9
leukocyte activation involved in immune response BP 214 37 8.9
lymphocyte activation BP 621 74 8.8
regulation of cell adhesion BP 623 74 8.8
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Supplementary Table 2. Continued
positive regulation of mononuclear cell proliferation BP 125 27 8.8
single-organism cellular process BP 11664 756 8.8
regulation of response to stress BP 1241 122 8.7
cell activation involved in immune response BP 216 37 8.7
regulation of peptidyl-serine phosphorylation BP 118 26 8.7
intracellular signal transduction BP 2588 216 8.7
extracellular space CC 1381 132 8.7
regulation of immune effector process BP 310 46 8.6
signal transduction BP 5623 408 8.5
JAK-STAT cascade BP 164 31 8.5
STAT cascade BP 164 31 8.5
adaptive immune response BP 369 51 8.4
positive regulation of leukocyte proliferation BP 131 27 8.3
positive regulation of immune response BP 641 74 8.2
positive regulation of lymphocyte proliferation BP 124 26 8.2
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Supplementary Table 3. The pathways affected by the combination stimulus (Hiltonol + pRNA). Changes in 
clusters of transcripts were detected using a GO term analysis. The top 100 most differential expressed gene clusters 
upon the combination stimulus were selected. The description for each gene cluster is shown in the columns. The 
GO contains three sub-ontologies: molecular function (MF), cellular component (CC) and biological process 
(BP). N genes stands for the total amount of genes contained in a cluster and N up/down denotes the number of 
genes that changed their expression values upon the stimulus. The table is sorted on the –log10 p-value shown 
in the rightmost column.
Hiltonol + pRNA 
term ontology N genes N up/
down
-log10 
p-value
immune system process BP 2348 694 30.4
response to stress BP 3557 975 30.2
cytoplasm CC 10548 2428 27.3
regulation of response to stimulus BP 3503 943 26
cytoplasmic part CC 7919 1890 25.8
regulation of immune system process BP 1302 416 24.6
cell surface receptor signaling pathway BP 2595 727 24.3
intracellular signal transduction BP 2588 719 22.9
immune response BP 1509 461 22.7
response to cytokine BP 782 275 22.7
cellular response to chemical stimulus BP 2586 713 21.7
cellular response to organic substance BP 2134 606 21.4
response to organic substance BP 2741 746 21.2
cellular response to cytokine stimulus BP 688 244 20.7
cell activation BP 884 294 20.1
regulation of signal transduction BP 2646 718 19.9
protein binding MF 8879 2047 19.6
cellular process BP 14950 3216 19.2
intracellular CC 13930 3027 18.9
cytokine-mediated signaling pathway BP 543 199 18.7
defense response BP 1461 432 18.3
response to stimulus BP 8081 1875 18.2
regulation of immune response BP 860 280 17.7
leukocyte activation BP 723 244 17.6
regulation of cell communication BP 2933 770 17.4
positive regulation of biological process BP 5094 1241 17
positive regulation of cellular process BP 4580 1130 16.9
response to virus BP 304 126 16.8
regulation of signaling BP 2984 777 16.6
hemopoiesis BP 705 236 16.5
cellular response to stimulus BP 6756 1588 16.4
cytosol CC 3327 852 16.4
binding MF 13201 2874 16.3
positive regulation of immune system process BP 903 286 16.2
intracellular part CC 13592 2947 16.1
leukocyte differentiation BP 454 167 16
single-organism cellular process BP 11664 2575 15.9
immune system development BP 786 255 15.9
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Supplementary Table 3. Continued
phosphorus metabolic process BP 3008 777 15.7
response to external stimulus BP 1996 546 15.5
inflammatory response BP 645 217 15.5
hematopoietic or lymphoid organ development BP 745 243 15.5
negative regulation of cellular process BP 4169 1031 15.4
phosphate-containing compound metabolic process BP 3002 774 15.4
regulation of response to stress BP 1241 366 15.3
negative regulation of biological process BP 4486 1098 15.2
regulation of multicellular organismal process BP 2576 676 15
signal transduction BP 5623 1339 14.9
positive regulation of response to stimulus BP 1928 525 14.5
regulation of defense response BP 647 214 14.4
single organismal cell-cell adhesion BP 710 230 14.3
defense response to virus BP 226 97 14.2
single organism cell adhesion BP 762 243 14.2
response to biotic stimulus BP 839 262 14.1
regulation of molecular function BP 2796 719 13.9
cell communication BP 6089 1429 13.8
cell motility BP 1309 376 13.8
localization of cell BP 1309 376 13.8
organelle CC 12881 2795 13.8
single-organism process BP 12914 2801 13.7
response to external biotic stimulus BP 801 251 13.7
response to other organism BP 801 251 13.7
system development BP 4167 1018 13.6
animal organ development BP 3035 770 13.6
signaling BP 6071 1423 13.5
regulation of intracellular signal transduction BP 1662 458 13.5
immune effector process BP 682 220 13.5
biological_process BP 16672 3493 13.4
cytokine production BP 613 202 13.4
lymphocyte activation BP 621 204 13.4
single organism signaling BP 6064 1420 13.3
cell migration BP 1190 345 13.3
phosphorylation BP 2176 575 13.2
single-multicellular organism process BP 5802 1364 13.2
locomotion BP 1494 417 13.2
regulation of cellular component movement BP 770 241 13.1
regulation of cytokine production BP 557 186 13
membrane-bounded organelle CC 11961 2610 12.9
intracellular organelle CC 11832 2584 12.8
multicellular organism development BP 4736 1134 12.7
lymphocyte differentiation BP 306 117 12.7
negative regulation of response to stimulus BP 1331 376 12.7
viral process BP 942 282 12.6
programmed cell death BP 1785 482 12.6
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intracellular membrane-bounded organelle CC 10794 2378 12.6
symbiosis, encompassing mutualism through parasitism BP 973 289 12.5
interspecies interaction between organisms BP 973 289 12.5
movement of cell or subcellular component BP 1741 471 12.5
apoptotic process BP 1765 476 12.4
multi-organism cellular process BP 947 282 12.3
localization BP 5684 1332 12.3
cell death BP 1892 505 12.3
regulation of developmental process BP 2227 581 12.3
regulation of innate immune response BP 350 128 12.2
biological regulation BP 11279 2470 12.1
regulation of multicellular organismal development BP 1671 453 12.1
biological adhesion BP 1689 456 11.9
positive regulation of molecular function BP 1803 482 11.9
regulation of locomotion BP 742 229 11.8
regulation of biological process BP 10652 2342 11.7
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Many aspects play important roles in developing an effective dendritic cell (DC)-based 
immunotherapy for cancer patients, including the choice of DC subset, identification of a 
suitable stimulus, and identification of specific and effective tumor antigens. Through use 
of more advanced techniques [1] and improvement of subject knowledge, the DC subset 
of choice changed from ex vivo cultured monocyte-derived DCs to human circulating blood 
DCs, reviewed in [2-4].
DC TA XONOMY
The goal of my PhD project was to unravel new characteristics and functions of human 
circulating blood DC subsets and to make recommendations for translation into the clinic. 
Therefore, I performed studies to observe changes and differences among the different 
subsets but also between different stimuli on a protein and RNA level. Both proteomic 
studies (Chapter 3) on steady state DCs and comparison between different DC subsets 
delivered interesting insights, highlighting unique characteristics of each cell type and 
permitting the identification of uniquely expressed receptors on several subsets [5]. 
Furthermore, combining the analysis with pre-existing mRNA data supported the 
conclusions related to the presence or absence of genes.
Discriminating between different cellular subsets and characterizing functional and 
phenotypical differences among them is a highly studied field. As single cell analysis is being 
further developed using RNA-seq, the potential for analyzing single cells in depth has 
increased dramatically. Very recently, two high impact papers were published demonstrating 
analysis of DC and monocyte subsets which proposes a revised taxonomy [6, 7]. Villiani et 
al. identified a previously-undefined DC subset which shows similarities with pDCs and 
which potently activates T cells. Furthermore, they redefine the mDC subsets and present 
a new monocyte subset, which may be more suitable for in vitro generation of DCs [7]. See 
et al. highlighted the existence of a DC precursor, which shares many similarities with pDCs. 
Both studies point out their relevance fur future therapeutic applications. In line with this, 
our department identified CD14+/CD1c+ mDCs subsets to be present in melanoma patients 
and could link these to inhibitory effects in immunotherapy [8]. Based on this study this 
subset is now depleted prior to isolation and stimulation of DCs from melanoma patients 
for DC-based immunotherapy, demonstrating the importance of further defining subsets 
of the DC population in improving clinical trials both now and in the future. In line with 
this, our proteomics (Chapter 3) [5] and the transcriptomics (Chapter 5 and Chapter 7) 
[9] studies will deliver insights into up- or downregulated genes, gene clusters or entire 
pathways. We have also provided an extensive overview of the expressed genes and proteins, 
and we focused specifically on receptors expression within the subsets. 
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In Chapter 3, we demonstrated that pDCs lack Caspase-1 and are therefore unable to 
produce the inflammatory cytokine IL-1β. So far, we can only speculate what the absence 
of the inflammatory pathways in pDCs means for their functionality. A possible explanation 
could be a protective mechanism, since pDCs are less sensitive to inflammasome activation, 
which can result in apoptosis. Based on this theory, pDCs with a downregulated or lack of 
Caspase-1 expression have a survival advantage. Since pDCs play an important role in the 
early immune response, this impaired inflammatory pathway might prevent an extensive 
inflammatory reaction. To add to this initial finding, we performed a follow up study by 
investigating the effect of IL-1β on the DC subsets (Chapter 4). Since IL-1β is a highly 
potent inflammatory cytokine, it plays an important role in the behavior and the phenotype 
of DCs [10, 11]. Our results pointed out the clear difference between pDCs and CD1c+ 
mDCs regarding their sensitivity to IL-1β. Next to the effect on maturation markers, IL-1β 
leads to a more migratory phenotype of CD1c+ mDCs by upregulation of CCR7. The IL-1β 
producing and sensing ability of CD1c+ mDCs underscores their closer proximity of CD1c+ 
mDCs to monocytes, the latter being highly sensitive to and able to release high amounts 
of IL-1β. On the other hand, it reinforces the pDC’s position, not sharing too many 
similarities with monocytes, but rather sharing certain similarities with lymphocytes [6, 7, 
12]. Furthermore, it shows that pDCs function completely independent of IL-1β, by not 
sensing and not releasing this cytokine.
Plasmacytoid DCs in an immature state or with limited IFNα-production potential are 
observed in various tumors [13, 14]. Those pDCs do not exert immunostimulatory 
functions and have tolerogenic characteristics. This highlights the importance of efficient 
and potent stimuli for DCs. In our studies, we used RNA-seq techniques to evaluate clinical 
grade stimuli (Chapter 5 and Chapter 7). Through this unbiased and global, yet in-depth 
analysis of the whole transcriptome of the steady state and stimulated cells, we could 
appreciate the full consequences of stimulation instead of being restricted to the commonly 
used maturation markers. The aim for the upcoming studies and experiments will be, to 
use these improved techniques for obtaining data and apply this knowledge to identify new 
stimuli, target cells and new protocols. Not only the understanding of how DCs responding 
to a cytokine, TLR ligand or a pathogen, but also their communication with other immune 
cells will help us to better understand the complexity of the immune system and this 
knowledge could help to improve the efficacy of immunotherapies.
Until now, there is no general agreement on the optimal methods for an effective DC-based 
immunotherapy. Numerous factors are changing throughout the time due to new knowledge 
about the DC subsets, but also about new stimuli. Next to in vitro studies, it is important 
to know how strong the cytokine release of DCs is after injection and how long this cytokine 
release last in this environment. Furthermore, this raises the question on which cytokine 
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levels are sufficient enough for an effective T cell activation. In our in vitro studies, we 
compared the level of IFN-α, IL-12p70 and TNF-α as a readout of the suitable stimulus. In 
that context, we interpreted the higher the release, the better the outcome. Without any 
doubts, do type I IFNs have an immense high potential in anti-tumor responses, but it 
remains still unclear which concentration of IFN-α or IL12p70 is sufficient or on the other 
hand too much and therefore could lead to an adverse effect [15, 16].
DC CROSS TALK 
A crucial point is to understand potential cross talk between DC subsets and between DCs 
and other immune cells. Due to their complementary characteristics, the coculture of pDCs 
and mDCs was thought to have a synergistic effect on the immunostimulatory outcome. A 
synergistic effect of DC subsets on NK cell function could be confirmed, but not on T cell 
function [17]. Additionally, we studied the cross talk between mDCs and pDCs regarding 
their release of IL-12p70 and type I IFN, respectively (Chapter 6). Here, we could demonstrate 
cross-activation of both subsets. The high release of type I IFNs by pDCs led to a more potent 
activation of mDCs when coculturing these two subsets. In a clinical trial setting, which 
includes coculturing and simultaneous stimulation of both subsets with pRNA, these findings 
suggest coculturing DC subsets ex vivo as part of the vaccine preparation process could 
positively affect clinical outcome. Next to the increased activating effect on innate immune 
cells, like NK and NKT cells, we could demonstrate increased production of IFN-γ by T 
cells upon co-culture with the combined DC subsets. An additional advantage of using the 
same stimulus is to avoid any potential off-target effects, which have been observed in a 
previous study which demonstrated that CpG (TLR9 ligand) stimulation has an inhibitory 
effect on the stimulation by poly I:C (TLR3 ligand) when added to the cells at the same time 
[18]. This suggests that the stimulation of different TLRs could have a negative effect on the 
overall efficacy of each individual stimulus. Our results highlight that for future 
immunotherapies, combined stimulation of DC subsets has a strong potential to optimize 
the immune activation and thereby increase specificity of the immune response.
PRIMARY DC S IN IMMUNOTHERAPY
Throughout this thesis, our publications and our clinical trials we discuss the potency and 
advantages of primary human blood DCs in the context of DC immunotherapy as an 
alternative to ex vivo generated monocyte derived DCs. Both DC subsets, mDCs and pDCs, 
have strong potential for use in treating cancer patients [19, 20]. We and others have 
demonstrated that both mDCs and pDCs have strong cross-presenting capabilities [21-24]. 
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Whereas pDCs produce high levels of the immunostimulatory cytokine IFN-α upon viral 
stimulation, activated mDCs are known for the release of IL-12 [25-27]. The release of type 
I IFNs has been shown to affect the survival and activation of CD4+ and CD8+ T cells, but 
also to activate NK cells and induce the upregulation of MHC class I on various cells [28-
30]. These characteristics, together with the ability to infiltrate tumors, point out the 
important role of pDCs in anti-cancer immune responses [13, 14]. Myeloid DCs, which 
respond more to bacterial and fungal stimuli, are able to induce TH1 responses via the 
release of IL-12[31]. Due to complementary functions of mDCs and pDCs regarding their 
TLR expression, cytokine release and stimuli sensitivity, a therapy to combine both subsets 
could be very promising [32]. This hypothesis is supported by the study in Chapter 6, which 
illustrates this beneficial effect of DC cross-talk. After completing the first clinical trials 
with both DC subsets separately, the next step will now be the combination of both subsets. 
The data and results of Chapter 5 and the study by Skold et al. provided important 
information to improve our understanding of the new stimulus, pRNA, which is suitable 
for both DC subsets [27]. The results of this study were therefore immediately translated 
into clinical practice. As described in Chapter 7, there are also good reasons to include 
BDCA3+ mDCs in DC immunotherapy, since this subset has been shown to have a very 
high cross-presenting ability [33]. The reason why they have not been included so far was 
mostly because of practical reasons. The isolation of BDCA3+ mDCs is very difficult due 
to extremely low numbers of circulating cells. To date, the isolation methods are improved 
and strategies have been published to increase the circulating numbers of DC subsets in 
human and mice [34, 35]. This paves the way to harvest sufficient numbers of cells. For 
further studies on BDCA3+ mDCs, our study in Chapter 7 will be a helpful source of data 
regarding their characteristics upon TLR stimulation.
RNA-SEQUENCING IN CLINIC AL SET TINGS
So far, RNA-seq has been predominantly used to sequence tumor material and to detect 
mutations. In 2008, Marioni et al. demonstrated the high reproducibility of RNA-seq 
approaches in order to detect gene expression changes, which is in line with what we 
observed in our studies in Chapter 5 and Chapter 7 comparing the different samples among 
different donors [36]. Furthermore, they claimed that RNA-seq detected 30% more 
differentially expressed genes than a comparable microarray studies did [36].  To include 
RNA-seq in clinical settings, it needs to fulfill the strict rules of analytical validity, clinical 
validity and, eventually, clinical utility (reviewed by Byron et al. [37]. 
In 2009 single cell RNA-sequencing was been described for the first time [38]. Since then, 
the field has developed rapidly, highlights the importance of this tool in the potential 
provided to study cell interactions and effects of cells on a single cell level using very little 
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starting material [39-41]. Especially in the context of working with rare cell subsets like 
the BDCA3+ mDCs, these new technologies may facilitate significant research advancements. 
Those single cell RNA-seq techniques can be applied in basic research to identify new 
subsets as described earlier here in the discussion [6, 7] or to decipher the interactions 
between different immune cells on a single cell level. However, a more translational 
application of these new possibilities could favor the clinical related research and clinical 
settings. We pointed out the high potential of evaluating clinical adjuvants using RNA-seq. 
Single cell RNA-seq is particular interesting when working with primary patient material. 
However, the low amount of material could also be a big challenge to detect differences in 
genes expressed at low levels and therefore some limitations may exist regarding the 
unbiased and global overview.
A different application of RNA-seq is to use it to detect patient specific neoantigens in a 
DC immunotherapy setting as was done recently by several research groups [42, 43]. Sahin 
et al. and Ott et al.  recently published exemplary clinical data which highlighted the strong 
potential of such personalized immunotherapy [44, 45]. Compared to our ex vivo 
stimulation and loading of DC with known tumor antigens, this approach has the advantage 
of using patient specific neoantigens of the tumor. Tumor antigens could be also expressed 
elsewhere in low densities and therefore could lead to off-target effect in contrast to the 
uniquely in tumor expressed neoantigens. This data suggests an increased chance that tumor 
specific T cells will detect the tumor cells in the patient [44]. Related to the occurrence of 
neoantigens within the tumors, van Allen et al. used RNA-seq to demonstrate that the 
treatment with cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors affects 
the expression of tumor specific neoantigens [46, 47].
To conclude, RNA-seq has been demonstrated to be a powerful tool due to its high 
sensitivity, reproducibility and high specificity to analyze tumor samples, but also to evaluate 
clinical adjuvants by analyzing gene expression changes of immune cells. However, a big 
challenge will be to standardize RNA-seq based studies and to establish technical and 
analytical benchmarks. Those steps will help to increase the power of validation of the 
observed changes and conclusions.
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COMBINATION THERAPIES
Since tumors are very efficient in immune evasion and have various mechanisms to trick 
the immune system, the potential of monotherapies to cure a patient from cancer have 
their limitations. Therefore, the combination of several approaches could overcome each 
monotherapy’s limitation and combine their impact to achieve greater anti-tumor effect. 
DC vaccination aims to master the bottleneck of DCs detecting and ingesting the tumor 
cells in the body and their subsequent migration to the lymph nodes to present tumor 
derived antigens and to activate tumor reactive T cells. Other immunotherapies instead 
focus on the interaction of T cells with tumor cells, like immune checkpoint inhibitors that 
lift suppressive T cell interactions. Recently, a study that combed electroporated DCs, 
constitutively presenting melanoma associated antigens on their surface, and of the 
checkpoint inhibitor ipilimumab showed a promising overall response rate [48]. 
Furthermore, several other clinical trials combining DC therapies and checkpoint inhibitor 
therapies are ongoing to test the beneficial effect on the anti-tumor response (clinical trial 
reference: NCT02677155, NCT01067287, and NCT01441765). 
To further increase the efficiency of DC vaccines, also modulation of the tumor micro 
environment (TME) could help. As an immune evasion mechanism, tumors create an 
immunosuppressive environment and decrease the infiltration of immune cells or reduce 
the immune cells’ immunostimulatory potential for example by expressing co-inhibitory 
molecules as PD-L1. To combine the modulation of the TME and the efficiency of T cell 
stimulation and priming may be a powerful approach.
CONCLUSION
In summary, this thesis illustrates the importance of an unbiased and global approach to 
compare different DC subsets. We detected significant differences between but also 
similarities among the DC subsets and could link those to functional characteristics of each 
individual subset. We showed for the first time that pDCs lack the expression of Caspase-1, 
and do not release IL-1β or express the receptor for this cytokine (Chapter 3 and Chapter 
4). Furthermore, we demonstrated how the cross-talk of the DC subsets affects each other’s 
functions and how this can influence other immune cells (Chapter 6). The evaluation of 
clinical adjuvants using RNA-seq introduces a new approach to compare efficacies of 
potential new stimuli in a clinical context but also helps our understanding of the 
characteristics of DCs upon stimulation (Chapter 5 and Chapter 7). We believe that these 
findings will provide important information for the DC research community. Chapter 3, 
5 and 7 provide three large datasets which can be used by the research community to focus 
on the genes and pathways of interest and could serve as the basis of further studies.
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FUTURE PERSPECTIVES
The DC immunotherapy field is progressing rapidly and is now well established due to a 
multitude of successful studies. In 2016, the Dutch health care system approved the DC 
immunotherapy performed in our department to be covered by the national health 
insurance. This gives us the opportunity to show the strong potential and the beneficial 
effect this therapy might have. Most importantly, DC vaccines have shown a very mild 
toxicity profile with fever, fatigue and injection side reactions only. Taken together, in the 
coming years DC vaccination will be tested for clinical benefit as well as the consequences 
for patient’s daily life.
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Mijn proefschrift beschrijft het onderzoek naar dendritische cellen in de context van kanker 
immuuntherapie. Dendritische cellen zijn antigeen-presenterende cellen (APC) en behoren 
bij het adaptieve immuunsysteem. Zij zijn in staat pathogenen op te nemen en aan andere 
cellen te presenteren. Vervolgens kunnen zij in lymfklieren de zogenaamde effector cellen 
activeren, T cellen en NK cellen.
Binnen de dendritische cellen bestaan er verschillende deelgroepen (subsets), die allemaal 
specifieke karakteristieke functies hebben. Sommige zijn in staat virale pathogenen 
(plasmacytoïde dendritische cellen) op te sporen en andere reageren op bacteriële 
pathogenen (myeloïde dendritische cellen). Onze afdeling, tumor immunologie, is 
gespecialiseerd in onderzoek naar dendritische cellen en het gebruik van deze cellen voor 
kanker immuuntherapieën. Wij maken gebruik van deze eigenschappen van dendritische 
cellen en ondersteunen hun strijd om tumor cellen te vinden en aan te vallen. Dit gebeurt 
door middel van het isoleren van dendritische cellen van kankerpatiënten. De cellen worden 
vervolgens buiten het lichaam geactiveerd door tumorspecifieke antigenen aan te bieden, 
waardoor de dendritische cellen denken een tumorcel tegengekomen te zijn. Vervolgens 
worden de cellen weer aan de patiënt teruggegeven door injectie in de lymfklier. Hier 
activeren de dendritische cellen T cellen door middel van hun geactiveerde toestand en het 
presenteren van de tumorspecifieke antigenen op hun oppervlakte. Hoe de T cellen 
geactiveerd worden hangt af van verschillende factoren. Ten eerste spelen de zogenaamde 
co-stimulatoire moleculen op de oppervlakte van dendritische cellen een belangrijke rol. 
Deze directe cel-cel interactie bepaalt of een T cel geactiveerd of geïnhibeerd wordt. Bekende 
co-stimulatoire moleculen zijn CD80, CD86 en CD40. PD-L1 is daarentegen een heel 
belangrijk en veel bestudeerd co-inhiberend molecuul. Om deze reden is het uitschakelen 
of blokkeren van PD-L1 expressie ook een bekend doel binnen het kankeronderzoek.
Bovendien spelen cytokinen een belangrijke rol bij T cel stimulatie. Cytokinen zijn 
signaalstoffen die in staat zijn cellen te activeren, reguleren of informeren.
In Hoofdstuk 1 wordt een inleiding in het onderwerp gegeven. Er wordt kort uitgelegd wat 
dendritische cellen zijn, hoe belangrijk een effectieve maturatie is en er wordt een overzicht 
van immuuntherapieën in het verleden en heden gegeven.
Hoofdstuk 2 is een overzicht van de plasmacytoïde dendritische cel. In dit hoofdstuk wordt 
de interactie van deze dendritische cel subset met andere immuuncellen, en hun belangrijke 
rol daar in, uitgelegd. 
In Hoofdstuk 3 worden ongestimuleerde dendritische cel subsets en een monocyt subset 
onderling vergeleken op basis van hun eiwitexpressie. Hierbij is gebruik gemaakt van 
massaspectrometrie, waardoor we een globaal overzicht hebben gegenereerd zonder daarbij 
verdere aannames te doen. Hier zijn plasmacytoïde dendritische cellen en twee myeloide 
dendritische cel subsets, BDCA3+ mDCs and CD1c+ mDCs, meegenomen. De CD16+ 
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monocyten zijn meegenomen op basis van hun overlappende eigenschappen en functies. 
De gegenereerde data is gecombineerd met bestaande mRNA data om een robuuster cel-
specifiek overzicht te creëren. Met behulp van deze dataset zijn subset-specifieke receptoren 
geïdentificeerd en is aangetoond dat pDCs geen Caspase-1 bezitten en hierdoor ook geen 
IL-1β kunnen afscheiden.
Als voortzetting van de resultaten met betrekking tot de verschillen in IL-1β uitstoot tussen 
de DC subsets, hebben wij in Hoofdstuk 4 naar de gevoeligheid voor IL-1β gekeken. Hier 
zijn pDCs en CD1c+ mDCs met IL-1β geïncubeerd. Hier kwam uit dat pDCs IL-1β niet als 
activatiestimulus waarnemen en dus geen dus geen verandering in de expressie van de 
maturatie markers plaatsvindt. Bovendien is aangetoond dat de expressie van de receptor 
voor IL-1β, en een aantal moleculen downstream van de receptor minder tot expressie 
komen in pDCs. Daarmee laten we zien dat pDCs niet alleen geen IL-1β produceren, maar 
hier ook niet op reageren. 
In Hoofdstuk 5 is gekeken naar de effectiviteit van klinische adjuvanten op CD1c+ mDCs 
en pDCs met behulp van RNA-sequencing (RNA-seq). Hierbij wordt het effect van oude, 
in de kliniek gebruikte stimuli vergeleken met huidige of toekomstige klinische stimuli. 
Deze resultaten en datasets geven een uitstekend inzicht in hoe de subsets zich gedragen 
als zij in een klinisch relevante toestand gebracht worden. Door middel van deze resultaten 
is meer kennis over deze subsets verzameld, wat zal bijdragen aan het verder verbeteren 
van de DC immuuntherapie. 
Hoofdstuk 6 gaat over de communicatie (crosstalk) van in Hoofdstuk 5 beschreven DC 
subsets: CD1c+ mDCs en pDCs. Bij deze studie hebben wij onderzocht hoe deze twee subsets 
elkaar beïnvloeden op basis van twee belangrijke cytokinen. Wij hebben ons gericht op de 
type I cytokinen, welke door pDCs geproduceerd worden, en op IL12p70, dat in hoge mate 
vrijkomt bij gestimuleerde CD1c+ mDCs. Op basis van onze resultaten is aangetoond dat 
een verhoogd type I productie een activerend effect op CD1c+ mDCs en andere 
immuuncellen heeft.
In Hoofdstuk 7 wordt de in kleine percentages voorkomende DC subset BDCA3+ mDCs 
bestudeerd. Net als in Hoofdstuk 5 wordt gebruik gemaakt van RNA-seq en aanvullend een 
microarray methode. Wij vergelijken de potentie van twee verschillende klinische adjuvants. 
Deze resultaten dragen bij aan een keuze tussen deze twee adjuvants voor een toekomstige 
BDCA3+ mDC immuuntherapie. Op basis van onze resultaten lijken beide adjuvants even 
sterk en laten ze geen grote verschillen op basis van hun effect op dit celtype zien. 
Tot slot wordt het proefschrift in Hoofdstuk 8 samengevat en worden conclusies met 
betrekking tot toekomstige ontwikkelingen getrokken. De opgedane resultaten worden in 
context geplaatst en de meerwaarde voor wetenschappelijk onderzoek wordt benadrukt.
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Die vorliegende Doktorarbeit gibt einen Überblick über die Erforschung von dendritischen 
Zellen, bezogen auf die Krebs-Immuntherapie. Dendritische Zellen (DCs) sind Antigen-
präsentierende Zellen (APC) und sind mit dem adaptiven Immunsystem verbunden. Sie 
sind in der Lage, Pathogene zu absorbieren und sie auf ihrer Oberfläche anderen Zellen zu 
präsentieren. Die aktivierten DCs wandern daraufhin zu den Lymphknoten und aktivieren 
ihrerseits die sogenannten Effektor-Zellen, T-Zellen und NK-Zellen. Innerhalb der DCs 
gibt es verschiedene Untergruppen, die jeweils mit spezifischen Eigenschaften und 
Funktionen ausgestattet sind. Einige sind in der Lage, virale pathogene (plasmazytoide 
DCs) zu erfassen, Andere wiederum sind spezialisiert, bakterielle Pathogene (myeloide 
DC) aufzuspüren. Unsere Abteilung, Tumorimmunologie, hat außergewöhnlich große 
Erfahrungen mit dendritischen Zellen und ihre Verwendung für Krebsimmuntherapien. 
Bei dieser Art von Therapie nutzen wir die antigen-aufnehmende Eigenschaften der  DCs 
und unterstützen ihre Fähigkeit, Tumorzellen zu finden. Dafür werden die DCs von 
Krebspatienten isoliert und außerhalb des Körpers (ex vivo) aktiviert. Daraufhin werden 
sie mit tumorspezifischen Antigenen „gefüttert“, in dem Glauben, Tumorzellen aufgespürt 
zu haben. Anschließend werden die Zellen dem Patienten wieder zurückgeführt, indem 
sie in den Lymphknoten injiziert werden. Hier aktivieren die dendritischen Zellen die 
T-Zellen durch ihren aktivierten Zustand und die präsentieren die tumorspezifischen 
Antigene auf ihrer Oberfläche. Auf welche Weise die T-Zellen aktiviert werden, hängt von 
mehreren Faktoren ab.
Hier spielen die kostimulatorischen Moleküle auf der Oberfläche der dendritischen Zellen 
eine wichtige Rolle. Diese direkte Zell-Zell-Wechselwirkung gibt den Ausschlag, ob eine 
T-Zelle aktiviert oder gehemmt wird. Bekannte kostimulatorische Moleküle sind CD80, 
CD86 oder CD40. Im Gegensatz dazu ist PD-L1 ein sehr intensiv untersuchtes und sehr 
wichtiges koinhibitorischen Molekül. Aus diesem Grunde stellt das Inhibieren oder 
Ausschalten der PD-L1-Expression auch ein bekanntes Ziel innerhalb der Krebsforschung 
dar. Desweiteren spielen Zytokine eine wichtige Rolle bei der T-Zell-Stimulation. Zytokine 
sind Signalmoleküle, die von Zellen abgegeben werden und in der Lage sind, andere Zellen 
zu regulieren oder auch Informationen weiterzugeben. 
Kapitel 1 ist eine Einleitung in das Thema der Promotionsarbeit. Hier erkläre ich in einer 
kurzen Zusammenfassung, was dendritische Zellen sind, welche Bedeutung die effektive 
Stimulation einnimmt und gebe einen Überblick über DC-Immuntherapie. 
Kapitel 2 ist eine wissenschaftliche Literaturstudie über plasmazytoide dendritische Zellen 
(pDCs). In diesem Kapitel wird die Wechselwirkung der pDCs mit anderen Immunzellen 
beschrieben und ihre bedeutende und weitreichende Rolle herausgehoben.
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In Kapitel 3 werden unstimulierte DC-Subsets und ein DC-ähnliches Monozyten-Subset, 
welches dendritischen Zellen sehr ähnlich ist, auf der Grundlage ihrer Proteinexpression 
miteinander verglichen. Durch den Gebrauch von Massenspektrometrie war es möglich 
eine unvoreingenommene Übersicht der Proteine in diesen Zellen darzulegen. Zusätzlich 
zu den pDCs, wurden auch myeloide dendritische Zellen (mDCs), die BDCA3+ mDC und 
CD1c+ mDC Subsets untersucht. Aufgrund ihrer Ähnlichkeiten mit DCs befinden sich 
ausserdem CD16+-Monozyten unter den untersuchten Subsets. Die gewonnenen Daten 
wurden mit vorhandenen mRNA-Daten kombiniert, um ein robustes zellspezifisches 
Expressionsmuster zu erstellen. Mithilfe  von zahlreichen Analysen des Datensatzes haben 
wir subset-spezifische Rezeptoren identifiziert und waren in der Lage zu beweisen, dass in 
pDCs das Protein Caspase-1 nicht vorhanden ist und daher pDCs kein IL-1β ausschütten 
können.
Hinzufügend zu den Unterschieden von IL-1β-Ausschüttung zwischen den DC-Subsets 
im vorigen Kapitel, wird in Kapitel 4 die Sensitiviät der DC-subsets auf IL-1β untersucht. 
Dabei wurden pDCs und CD1c+ mDCs mit IL-1β inkubiert und die Effekte gemessen. 
Hierbei hat sich gezeigt, dass pDCs IL-1ß nicht als aktivierenden Reiz wahrnehmen und 
daher keine Reifungsmarker auf der Zelloberfläche repräsentieren. Außerdem konnten wir 
mithilfe dieser Studie beweisen, dass die Expression des IL-1β-receptors, IL1R1, und 
mehreren nachgeschlalteten Proteinen des IL1R1-Signalwegs in pDCs schwächer 
ausgebildet sind. Somit demonstrieren wir, dass pDCs sowohl kein IL-1β produzieren 
können, als auch IL-1β nicht als Reifungstimulus wahrnehmen.
In Kapitel 5 bewerten wir die Wirksamkeit der klinischen Adjuvanten in CD1c+ mDCs 
und pDCs unter Verwendung von RNA-Sequenzierung (RNA-Seq). Hier vergleichen wir 
die Wirkung bisheriger Stimuli mit den jetzigen, beziehungsweise zukünftigen, klinischen 
Adjuvanten. Die erfassten Ergebnisse und Datensätze bieten einen Einblick, wie 
unterschiedlich sich die Subsets verhalten, wenn sie in einen aktivierten und klinischen 
Zustand versetzt werden. Diese Ergebnisse helfen uns, unser Wissen über DCs zu erweitern 
und werden dazu beitragen, die DC-Immuntherapie kurzfristig und langfristig zu 
verbessern.
In Kapitel 6 werden die Wechselwirkungen (cross-talk) zwischen den in Kapitel 5 
beschribenen DC-Subsets pDCs und CD1c+ mDCs studiert. In dieser Studie wird 
untersucht, welche Rolle Zytokine bei dieser Wechselwirkung spielen. Einfachheitshalber 
haben wir uns auf Typ-I-IFNs, welche von pDCs produziert werden, und IL12p70, welches 
in großen Mengen von CD1c+ mDCs ausgeschüttet wird, konzentriert. Unsere Ergebnisse 
zeigen, dass eine erhöhte Typ-I-interferon (IFN)-Produktion der pDCs eine aktivierende 
Wirkung auf CD1c+ mDCs und andere Immunzellen hat. 
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In Kapitel 7 widmen wir uns einem eher seltener vorkommenenden  DC-Subset, den 
BDCA3+ mDCs. Wie bereits in Kapitel 5 untersuchen wir auch hier den Effekt von 
klinischen Stimuli in diesem Falle dann bei BDCA3+ mDCs. Diesmal  verwenden wir neben 
der bereits erwähnten RNA-Seq-Methode zusätzlich ein Mikroarray-Verfahren. Wir 
vergleichen das Potenzial von zwei verschiedenen klinischen Stumuli, pRNA und Hiltonol 
(TLR3-Ligand). Diese Ergebnisse helfen uns bei der Wahl zwischen diesen beiden 
Adjutanten für zukünftige BDCA3+ mDC Immuntherapie-Studien. Unsere Ergebnisse 
zeigten auf, dass beide Adjuvanten zu einem Reifungsprozess der BDCA3+ mDCs führte 
und wiesen sehr große Gemeinsamkeiten bezüglich ihrer Wirkung auf diesen Zelltypen 
auf.
Abschließend fasse ich die These in Kapitel 8 zusammen und ziehen Schlussfolgerungen 
in Bezug auf die zukünftige Entwicklung. Darüberhinaus setzen wir hier die erzielten 
Resultate in den Kontext der heutigen Forschung und heben den Mehrwert dieser 
Ergebnisse für die Forschungsgemeinschaft hervor.
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